Psoriatic Arthritis

On this page

Quick Reference

RxDrug of choiceMethotrexate 15-25 mg/week orally or subcutaneously as first-line csDMARD; for biologic-naïve patients with active peripheral arthritis, adalimumab 40 mg every other week or secukinumab 150-300 mg every 4 weeks are first-line bDMARDs.

AltAlternativesLeflunomide 20 mg/day, sulfasalazine 2-3 g/day, apremilast 30 mg twice daily; IL-17 inhibitors (ixekizumab, bimekizumab), IL-23 inhibitors (guselkumab, risankizumab), IL-12/23 inhibitor (ustekinumab), TNF inhibitors (etanercept, golimumab, certolizumab, infliximab), JAK inhibitors (tofacitinib, upadacitinib).

⊘AvoidIL-17 inhibitors in active inflammatory bowel disease; non-dihydropyridine CCBs (diltiazem, verapamil) exacerbate heart failure if present; avoid prolonged systemic glucocorticoids (>3 months) without steroid-sparing DMARD; JAK inhibitors in patients aged ≥65 with cardiovascular risk factors or history of MACE.

DxTest of choiceCASPAR criteria (≥3 points) for diagnosis; radiographs of hands and feet for structural damage; ultrasound with power Doppler for synovitis and enthesitis; MRI with STIR sequences for axial disease if radiographs are normal.

ScKey scoreMinimal Disease Activity (MDA) criteria: 5 of 7 met (tender joint count ≤1, swollen joint count ≤1, PASI ≤1 or BSA ≤3%, pain VAS ≤15 mm, patient global VAS ≤20 mm, HAQ ≤0.5, enthesitis count ≤1). DAPSA score: remission ≤4, low activity >4-14, moderate >14-28, high >28.

→When to referAll patients with suspected or confirmed PsA to rheumatology; acute red painful eye with photophobia to ophthalmology; new-onset diarrhea or abdominal pain to gastroenterology; high cardiovascular risk or established CVD to cardiology; severe psoriasis to dermatology; inadequate response to two bDMARDs with different mechanisms to a specialist centre for difficult-to-treat PsA.

PsA is a treatable but progressive disease; early diagnosis using CASPAR criteria and a treat-to-target strategy aiming for MDA or DAPSA remission with stepwise escalation from csDMARDs to bDMARDs (TNFi, IL-17i, IL-23i) or JAK inhibitors can achieve sustained remission in 30-50% of patients and prevent irreversible joint damage; cardiovascular risk management is essential due to excess mortality.

Psoriatic arthritis (PsA) is a chronic, systemic inflammatory arthritis within the spondyloarthritis family, affecting approximately 0.1-0.5% of the general population and up to 30% of patients with psoriasis. It is driven by an IL-23/IL-17 axis targeting the enthesis, leading to peripheral arthritis, enthesitis, dactylitis, axial disease, and characteristic skin/nail involvement. Early diagnosis using the validated CASPAR criteria (≥3 points) and a treat-to-target strategy aiming for minimal disease activity (MDA) are critical, as untreated disease causes irreversible joint damage (erosions in 24.6% within 5 years) and excess cardiovascular mortality (HR 1.36). Management follows a stepwise DMARD ladder: conventional synthetic DMARDs (methotrexate 15-25 mg/week) first-line, then biologic DMARDs (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors) or JAK inhibitors for inadequate response, with tapering considered after ≥6 months of sustained remission.

Overview and Recommendations

Background

•Psoriatic arthritis (PsA) is a chronic, systemic inflammatory arthritis belonging to the spondyloarthritis (SpA) family, affecting approximately 0.1-0.5% of the general population and 30% of patients with psoriasis. It carries a substantial disease burden: untreated 5-year mortality is increased by 36% (HR 1.36, 95% CI 1.12-1.66), primarily driven by cardiovascular disease, and radiographic erosions develop in 24.6% within the first 5 years of symptom onset.
•The disease is fundamentally an entheseal disorder, the insertion site of tendon or ligament into bone is the primary anatomical locus of inflammation. The IL-23/IL-17 cytokine axis is the central effector pathway; genetic variants in IL23R, IL12B, and ERAP1, along with HLA-C*06:02 and HLA-B27, confer susceptibility. Biomechanical microtrauma triggers local IL-23 release from myeloid cells, activating entheseal-resident γδ T cells and innate lymphoid cells to produce IL-17A, TNF, and IL-22, orchestrating both bone erosion and new bone formation.
•The classic Moll and Wright classification defines five clinical subtypes: oligoarticular (≤4 joints, asymmetric, 30-40%), polyarticular (≥5 joints, 30-40%), distal interphalangeal (DIP) predominant (5-10%), arthritis mutilans (<5%), and axial (spondylitis, 20-30%). These subtypes are not mutually exclusive; axial involvement frequently coexists with peripheral arthritis, and patients may transition between patterns over time.
•The CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria, developed in 2006, provide a validated classification tool requiring ≥3 points from: current psoriasis (2 points), personal/family history of psoriasis (1), nail dystrophy (1), dactylitis (1), negative rheumatoid factor (1), and juxta-articular new bone formation on radiographs (1). Sensitivity is 91.4% and specificity 98.7% for distinguishing PsA from other inflammatory arthritides.
•PsA is the second most common inflammatory arthritis after rheumatoid arthritis. Incidence has risen 2.4-fold over 5 decades in the US (3.6 to 8.5 per 100,000 person-years), driven by rising obesity, aging populations, and improved recognition. Modifiable risk factors for PsA in psoriasis patients include obesity (BMI ≥30: OR 2.0-3.0), smoking (OR 1.5-2.0), severe psoriasis (BSA >10%: HR 2.5), nail psoriasis, and physical trauma (deep Koebner phenomenon).
•The disease is associated with significant extra-articular comorbidities: metabolic syndrome (40-50% prevalence), inflammatory bowel disease (6-8%), acute anterior uveitis (25% lifetime risk, especially in HLA-B27+ patients), and interstitial lung disease (5-10%). These comorbidities influence treatment selection, for example, IL-17 inhibitors are avoided in active IBD, while TNF inhibitors and IL-23 inhibitors are preferred.

Evaluation

•Suspect PsA in any patient with psoriasis (or family history) who presents with inflammatory joint pain, morning stiffness >30 minutes, improvement with activity, swelling of entire digits (dactylitis, or 'sausage digit'), or pain at tendon/ligament insertions (enthesitis, most commonly Achilles tendon or plantar fascia).
•Ask about skin and nail changes: plaque psoriasis (scalp, extensor surfaces, umbilicus, intergluteal cleft) and nail changes (pitting, onycholysis, subungual hyperkeratosis). Nail psoriasis is present in 50-70% of PsA patients and is a strong predictor of arthritis.
•Examine with the patient in a gown, palpating for synovitis in hands (especially DIP joints, which are characteristic), wrists, knees, ankles, and MTPs. Assess for dactylitis by comparing digit circumference. Test for enthesitis by applying firm pressure to the Achilles insertion, plantar fascia origin, medial femoral condyles, and lateral epicondyles using the Leeds Enthesitis Index (LEI).
•Assess axial involvement: check for inflammatory back pain (insidious onset, morning stiffness >30 min, improvement with exercise but not rest, nocturnal pain), measure spinal mobility (Schober test <5 cm indicates reduced lumbar flexion), and chest expansion (<2.5 cm suggests costovertebral involvement).
•Perform a full skin examination to quantify psoriasis severity (Psoriasis Area and Severity Index [PASI] or body surface area [BSA]). The CASPAR criteria can be applied at bedside: current psoriasis = 2 points; any one of nail dystrophy, dactylitis, negative RF, or family history of psoriasis = 1 point each; score ≥3 supports diagnosis.
•Order laboratory studies: rheumatoid factor (RF) and anti-CCP (both negative in PsA; if positive, consider rheumatoid arthritis), C-reactive protein (CRP) and ESR (may be elevated but CRP is normal in ~40% of patients), and uric acid (to exclude gout in monoarticular presentation). Consider HLA-B27 testing if axial disease is suspected (positive in ~25% of axial PsA vs 90% in ankylosing spondylitis).
•Obtain radiographs of hands and feet as first-line imaging. Look for erosions with adjacent new bone formation (pencil-in-cup deformity), juxta-articular periostitis, and ankylosis. A modified Sharp/van der Heijde score quantifies damage. For axial disease, consider radiographs of the sacroiliac joints and spine; look for asymmetric sacroiliitis and chunky, non-marginal syndesmophytes.
•If radiographs are normal but clinical suspicion remains high, order ultrasound with power Doppler of symptomatic joints and entheses. Ultrasound has high sensitivity for synovitis and enthesitis; power Doppler signal at entheses has 92% specificity for PsA. Ultrasound can detect subclinical enthesitis in up to 40% of psoriasis patients without arthritis, and its presence predicts progression to PsA.
•Consider magnetic resonance imaging (MRI) with STIR sequences if axial involvement is suspected and radiographs are normal, or if peripheral ultrasound is inconclusive. Whole-body MRI can assess both peripheral and axial inflammation simultaneously and is useful for complex cases.
•Also consider alternative diagnoses: rheumatoid arthritis (symmetric small joint disease, positive RF/anti-CCP), gout (monoarticular, elevated uric acid, urate crystals on arthrocentesis), reactive arthritis (recent infection, conjunctivitis, urethritis), osteoarthritis (Heberden's/Bouchard's nodes, morning stiffness <30 min, no inflammatory markers), and fibromyalgia (widespread pain, tender points, fatigue, no synovitis). Fibromyalgia affects 10-30% of PsA patients and complicates disease activity assessment.
•Apply the CASPAR criteria as a diagnostic aid. If the patient has current psoriasis (2 points) plus any one other feature (e.g., dactylitis or nail dystrophy), the threshold of ≥3 points is met. In patients without psoriasis (PsA sine psoriasis), sensitivity drops to ~80%, so imaging and close follow-up are essential.
•Refer to rheumatology for confirmation and management. Early diagnosis and referral within the first year reduce radiographic progression and improve outcomes. A treat-to-target strategy initiated early produces superior outcomes compared to standard care.
•Assess disease activity using validated composite measures: DAPSA (sum of 66 swollen joints, 68 tender joints, patient global VAS, pain VAS, and CRP) or MDA criteria (5 of 7: tender joint count ≤1, swollen joint count ≤1, PASI ≤1 or BSA ≤3%, pain VAS ≤15 mm, patient global VAS ≤20 mm, HAQ ≤0.5, enthesitis count ≤1). MDA is the recommended target in EULAR and ACR guidelines. Perform monitoring every 1-3 months during dose escalation and every 3-6 months once target is achieved.
•Red flags that mandate urgent evaluation: acute monoarthritis with fever (septic arthritis), rapidly progressive symmetric polyarthritis with positive RF (rheumatoid arthritis), acute anterior uveitis (red, painful eye with photophobia, urgent ophthalmology referral), new-onset inflammatory bowel disease symptoms (diarrhea, abdominal pain, may worsen with IL-17 inhibitors), and rapidly progressive joint destruction with telescoping digits (arthritis mutilans).

Management

•Initiate conventional synthetic DMARD (csDMARD) therapy as first-line for active peripheral arthritis with no poor prognostic features. Start methotrexate (MTX) 15-25 mg orally or subcutaneously once weekly, with folic acid 5 mg weekly to reduce gastrointestinal and hepatic toxicity. Target dose is 20-25 mg/week; assess response at 12 weeks. Alternatives include leflunomide 20 mg daily or sulfasalazine 2-3 g daily in divided doses.
•If the treat-to-target target (MDA or DAPSA low disease activity) is not reached after 3-6 months of adequate csDMARD therapy, add a biologic DMARD (bDMARD). The choice depends on the dominant clinical domain: for peripheral arthritis, any TNF inhibitor, IL-17 inhibitor, IL-12/23 inhibitor, or IL-23 inhibitor is acceptable. For axial disease, prefer IL-17 inhibitors (secukinumab 150-300 mg every 4 weeks) or TNF inhibitors. For prominent skin psoriasis, IL-17 or IL-23 inhibitors are preferred.
•For TNF inhibitors: adalimumab 40 mg subcutaneously every other week, etanercept 50 mg weekly, golimumab 50 mg monthly, certolizumab pegol 200 mg every 2 weeks (or 400 mg monthly), or infliximab 5 mg/kg intravenously at weeks 0, 2, 6, then every 8 weeks. TNF inhibitors remain the most extensively studied class with an NNT of 4 for ACR20; they also inhibit radiographic progression (mean Δ modified Sharp/van der Heijde score -0.53).
•For IL-17 inhibitors: secukinumab 150-300 mg subcutaneously weekly for 4 weeks, then every 4 weeks; ixekizumab 160 mg initially, then 80 mg every 2-4 weeks; bimekizumab 160 mg every 4 weeks. IL-17 inhibitors are particularly effective for axial disease (MAXIMISE trial: BASDAI50 63% vs 31% for placebo at week 12, NNT=4) and provide rapid skin clearance. Avoid IL-17 inhibitors in patients with active inflammatory bowel disease, as they can cause paradoxical disease exacerbation.
•For IL-23 inhibitors (p19-targeted): guselkumab 100 mg subcutaneously at weeks 0, 4, then every 8 weeks; risankizumab 150 mg at weeks 0, 4, then every 12 weeks. These are effective for peripheral arthritis and skin disease (DISCOVER-2: ACR20 64% vs 33% at week 24, NNT=4). Do not use IL-23 inhibitors as first-line for axial PsA; the evidence for axial efficacy is less robust than for IL-17 inhibitors.
•For IL-12/23 inhibitor (p40-targeted): ustekinumab 45-90 mg subcutaneously based on weight, at weeks 0, 4, then every 12 weeks. ACR20 42% vs 20% at week 24 (NNT=5). Adding methotrexate to ustekinumab does not improve efficacy (MUST trial).
•If the first bDMARD fails (inadequate response after 3-6 months), switch to a bDMARD with a different mechanism of action. For TNF inhibitor failure, options include IL-17 inhibitors (ixekizumab: ACR20 48% in TNFi-IR patients, NNT=4) or IL-23 inhibitors. For IL-17 inhibitor failure, consider TNF inhibitors or IL-23 inhibitors.
•JAK inhibitors (tofacitinib 5 mg twice daily, upadacitinib 15 mg once daily) are positioned as second-line after bDMARD failure, or as first-line in patients with contraindications to bDMARDs. Efficacy: upadacitinib 15 mg achieved ACR20 57% vs 24% in bDMARD-IR patients (NNT=4). However, JAK inhibitors carry a boxed warning for serious infections, malignancy, and major adverse cardiovascular events (MACE), especially in patients aged ≥50 years with cardiovascular risk factors. Screen for cardiovascular risk before starting; avoid in patients with history of MACE or age >65 per EULAR recommendations.
•Tapering can be considered once MDA is maintained for ≥6 months. Gradually prolong the dosing interval (e.g., reduce TNF inhibitor dose by 50% or extend interval). The DRESS-PS trial showed that structured tapering is non-inferior to continuation over 12 months. Complete withdrawal is not recommended because flare rates exceed 60% within 6 months.
•Monitor for treatment response every 1-3 months during dose escalation using DAPSA or MDA criteria. Target: MDA or DAPSA remission (≤4). Once target is achieved, monitor every 3-6 months. Assess for flares using the GRAPPA-OMERACT definition (≥1 point increase in patient global, ≥1 swollen joint, ≥1 tender joint, plus decision to escalate therapy).
•Manage acute flares promptly. For mild flare (≤2 joints): NSAIDs (naproxen 500 mg twice daily) or intra-articular corticosteroids (triamcinolone acetonide 40 mg for large joints). For moderate flare (3-5 joints, enthesitis, dactylitis): short-course systemic glucocorticoids (prednisone 10-20 mg/day tapered over 2-4 weeks). For severe flare (≥6 joints, axial pain, pustular/erythrodermic psoriasis, uveitis, IBD): prednisone 0.5-1 mg/kg/day (max 60 mg/day) with rapid taper, and escalate DMARD therapy. Avoid prolonged glucocorticoid use (>3 months) due to metabolic and cardiovascular risks.
•Do not use oral glucocorticoids as monotherapy for long-term disease control. Do not combine two bDMARDs (e.g., TNFi + IL-17i) due to increased infection risk without additive efficacy. Do not use IL-23 inhibitors as first-line for axial disease. Do not abruptly discontinue biologics without bridging; flare risk increases 2-4 fold.
•Refer to rheumatology for all patients with confirmed or suspected PsA. Refer to ophthalmology urgently for acute red, painful eye with photophobia (uveitis). Refer to gastroenterology if IBD symptoms develop. Refer to cardiology for cardiovascular risk assessment and management in patients with high risk or established disease. Refer to dermatology for management of severe psoriasis.
•Discharge criteria from acute care: resolution of organ-threatening manifestations (uveitis, IBD flare, severe psoriasis), stabilization of disease activity, establishment of appropriate DMARD therapy, and arrangement of outpatient rheumatology follow-up within 2-4 weeks. For elective surgery: continue csDMARDs (methotrexate, sulfasalazine) through surgery; hold TNF inhibitors for one dosing cycle before surgery and restart when wound healing is adequate (usually 14 days post-op).

Board Review — High Yield

•CASPAR criteria, Requires ≥3 points: current psoriasis (2), personal/family history of psoriasis (1), nail dystrophy (1), dactylitis (1), negative RF (1), juxta-articular new bone formation (1). Sensitivity 91.4%, specificity 98.7%.
•Enthesitis, Pathognomonic feature of PsA; the primary site of inflammation is the enthesis, driven by IL-23/IL-17 axis. Most common sites: Achilles tendon and plantar fascia. Assess with Leeds Enthesitis Index.
•Dactylitis ('sausage digit'), Results from flexor tenosynovitis; affects 30-40% of PsA patients. Diagnostic hallmark that distinguishes PsA from rheumatoid arthritis.
•Arthritis mutilans, Severe destructive form with telescoping digits ('opera-glass hand') and pencil-in-cup deformity on radiographs. <5% of PsA patients; requires aggressive therapy.
•Moll and Wright subtypes, Five clinical patterns: oligoarticular (asymmetric, ≤4 joints), polyarticular (≥5 joints), DIP predominant, arthritis mutilans, axial. Patients may transition between subtypes.
•Treat-to-target, Aim for Minimal Disease Activity (MDA) or DAPSA remission. STAMP trial: intensive first-line secukinumab + MTX achieved MDA in 62% vs 40% with step-up at 1 year.
•IL-17 inhibitors contraindicated in IBD, Secukinumab, ixekizumab, bimekizumab can cause paradoxical exacerbation of inflammatory bowel disease. Use TNF inhibitors or IL-23 inhibitors instead.
•JAK inhibitors boxed warning, Increased risk of serious infections, malignancy, MACE, and thrombosis, especially in patients ≥50 years with CV risk factors. EULAR recommends reserving for after bDMARD failure and avoiding in patients >65 with CV risk.
•Pregnancy management, Certolizumab pegol is preferred TNF inhibitor due to minimal placental transfer (cord blood <0.032 μg/mL). Methotrexate and leflunomide contraindicated. Disease activity during pregnancy increases preterm birth risk (aOR 1.8).
•Cardiovascular risk, PsA independently increases CV mortality (RR 1.49). EULAR recommends applying a 1.5 multiplier to SCORE algorithm. All patients should have annual BP, lipids, and glucose screening.

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

▸Psoriatic arthritis is a chronic inflammatory arthritis within the spondyloarthritis family, defined by its association with psoriasis and diverse clinical phenotypes.
▸The Moll and Wright classification identifies five subtypes (oligoarticular, polyarticular, DIP-predominant, arthritis mutilans, axial), which can overlap and evolve over time.
▸CASPAR criteria are validated for classification, not diagnosis; clinical recognition of inflammatory arthritis in a psoriasis patient remains the cornerstone of diagnosis.

HY High Yield: The Moll and Wright subtypes are high-yield for board exams; remember that arthritis mutilans is rare but pathognomonic, and DIP involvement is a hallmark distinguishing PsA from rheumatoid arthritis.

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis. The classic features of psoriatic arthritis include enthesitis, synovitis, and dactylitis. It particularly affects the peripheral joints, the spine, and the — Psoriatic arthritis — Psoriatic arthritis (PsA) is a chronic inflammatory arthritis. The classic features of psoriatic arthritis include enthesitis, synovitis, and dactylit...Wikipedia ↗

Psoriatic arthritis (PsA) is a chronic, systemic inflammatory arthritis associated with psoriasis, belonging to the spondyloarthritis (SpA) family and characterized by inflammation of joints, entheses, and axial structures ^[6]^B3b^[15]^C4.

Also Called / Synonyms

Psoriatic arthropathy
Psoriatic joint disease
Psoriasis arthropathica (historical)
PsA (abbreviation)
Juvenile psoriatic arthritis (JPsA) in pediatric populations ^[23]^B2b

Classification Subtypes

The classic Moll and Wright classification (1973) defines five clinical subtypes, though patients may transition between patterns over time ^[6]^B3b.

Subtype	Key Distinguishing Feature	Approximate Frequency
Oligoarticular (asymmetric)	≤4 joints, often asymmetric, involving large joints (knee, ankle)	30-40%
Polyarticular (rheumatoid-like)	≥5 joints, symmetric or asymmetric, small joints of hands/feet	30-40%
Distal interphalangeal (DIP) predominant	Predominant DIP joint involvement, often with nail psoriasis	5-10%
Arthritis mutilans	Severe, destructive arthritis with telescoping digits ("opera-glass hand")	<5%
Axial (spondylitis)	Inflammatory back pain, sacroiliitis, syndesmophytes	20-30% (may overlap with peripheral subtypes)

These subtypes are not mutually exclusive; axial involvement frequently coexists with peripheral arthritis ^[6]^B3b. The CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria, developed in 2006, provide a validated classification tool for research and clinical trials, requiring ≥3 points from features including current psoriasis (2 points), personal or family history of psoriasis, nail dystrophy, dactylitis, negative rheumatoid factor, and juxta-articular new bone formation ^[6]^B3b. CASPAR is a classification, not a diagnostic, criterion; diagnosis remains clinical, based on the pattern of inflammatory arthritis in a patient with psoriasis.

Clinical Significance

PsA affects approximately 0.1-0.5% of the general population and is the second most common inflammatory arthritis after rheumatoid arthritis. It carries a substantial disease burden: patients have increased all-cause mortality compared to the general population (HR 1.36, 95% CI 1.12-1.66) ^[16]^B2b, higher rates of metabolic syndrome (obesity, diabetes, , dyslipidemia) ^[10]^B2b, and greater comorbidity accumulation within the first three years of diagnosis ^[20]^B2b. and widespread pain are prevalent in PsA, affecting 10-30% of patients and complicating disease activity assessment ^[11]^B2b^[22]^B3b. Early diagnosis and treatment are critical, as radiographic erosions are present in 24.6% of patients within the first 5 years of symptom onset, even in treatment-naïve individuals ^[21]^B2b.

Pearl: Psoriatic arthritis is a heterogeneous disease with five classic clinical subtypes; the CASPAR criteria facilitate classification for research, but diagnosis relies on recognizing inflammatory arthritis in a patient with psoriasis, and early detection is essential to prevent irreversible joint damage ^[6]^B3b^[21]^B2b.

Pathophysiology & Mechanism

▸Psoriatic arthritis originates at the enthesis, where biomechanical stress triggers IL-23 release and activation of resident innate immune cells (γδ T cells, MAIT cells) to produce IL-17, bypassing adaptive immunity.
▸The IL-23/IL-17 axis is the central effector pathway, supported by genetic associations with IL23R, ERAP1, and HLA-C*06:02, and drives both synovial inflammation and the paradoxical combination of bone erosion and new bone formation.
▸Systemic IL-17 and TNF contribute to cardiovascular risk and metabolic syndrome, linking joint disease to comorbidities.

HY High Yield: The enthesis is the primary anatomical site of inflammation in PsA; resident IL-23R+ innate lymphoid cells and γδ T cells produce IL-17 in response to mechanical stress, independent of adaptive immunity [51, 54].

Psoriatic arthritis arises from a convergence of genetic susceptibility, biomechanical stress, and dysregulated innate and adaptive immunity that targets the , the insertion site of tendon or ligament into bone, as the primary anatomical locus of inflammation ^[37]^D5^[50]^D5^[51]^D5. The disease is driven by an / cytokine axis that orchestrates a feed-forward loop of neutrophil recruitment, synovial hyperplasia, and aberrant bone remodeling ^[34]^D5^[53]^D5.

The Enthesis as Ground Zero

The enthesis is a mechanically stressed fibrocartilaginous organ that, under normal conditions, houses resident immune cells including γδ T cells, innate lymphoid cells, and mucosal-associated invariant T (MAIT) cells ^[32]^D5^[51]^D5. These cells constitutively express the IL-23 receptor. Biomechanical microtrauma, from repetitive loading at sites such as the Achilles tendon or plantar fascia, triggers local release of IL-23 from myeloid cells, which in turn activates entheseal-resident IL-23R+ cells to produce IL-17A, IL-22, and TNF ^[34]^D5^[51]^D5. This innate immune response precedes and may bypass classical T-cell priming, explaining why PsA can develop in the absence of detectable autoantibodies ^[30]^D5^[37]^D5.

The IL-23/IL-17 Axis: Central Effector Pathway

Genetic studies have firmly linked PsA to variants in IL23R and the IL-12B gene (encoding the p40 subunit shared by IL-12 and IL-23), as well as to ERAP1, which interacts with to shape the peptide repertoire presented to CD8+ T cells ^[31]^D5^[55]^D5^[56]^D5. The strongest MHC association is with HLA-C*06:02, particularly in patients with early-onset psoriasis, though this allele is less strongly linked to PsA than to cutaneous disease alone ^[35]^D5^[36]^D5. Once IL-23 is produced by dendritic cells and macrophages in the skin, enthesis, and synovium, it drives differentiation and expansion of and sustains IL-17 production from innate sources ^[29]^D5^[53]^D5. IL-17A then acts on fibroblasts, keratinocytes, s, and neutrophils to amplify inflammation and tissue damage ^[57]^D5^[58]^D5.

Synovial Immunopathology

The synovium in PsA shows a distinct cellular landscape compared with rheumatoid arthritis. High-dimensional analyses have identified PsA-specific macrophage subsets (expressing IL-36 and IL-41), activated fibroblasts, and abundant mast cells ^[33]^D5^[18]^D5. Neutrophils are prominent, forming microabscesses analogous to Munro's microabscesses in psoriatic skin ^[34]^D5. The synovial fluid is rich in IL-17, TNF, and IL-23, and the tissue exhibits marked vascularity with tortuous, leaky vessels driven by VEGF ^[37]^D5. This environment promotes osteoclastogenesis via RANKL upregulation, leading to periarticular erosions and bone loss ^[44]^D5.

Bone Remodeling: Erosion and New Bone Formation

A hallmark of PsA is the simultaneous presence of bone erosion and new bone formation, often at the same enthesis. IL-17 and TNF drive osteoclast activation and bone resorption, while IL-22 and TGF-β promote osteoblast differentiation and entheseal new bone formation, resulting in s and ankylosis ^[44]^D5^[51]^D5. The balance between destruction and proliferation is influenced by mechanical stress and the local cytokine milieu. In axial disease, para-marginal syndesmophytes and chunky ossification of spinal ligaments are characteristic, reflecting entheseal soft tissue ossification rather than the symmetric syndesmophytes of ankylosing spondylitis ^[48]^D5^[49]^D5.

Genetic and Environmental Modifiers

Beyond HLA-Cw06 and IL23R, genome-wide studies have identified risk loci in TNFAIP3, TRAF3IP2, and REL, implicating NF-κB signaling ^[55]^D5^[56]^D5. Obesity is a strong environmental risk factor: adipose tissue secretes s (leptin, resistin) that enhance IL-17 production and reduce treatment response ^[45]^D5. The gut microbiome may also contribute; dysbiosis with reduced microbial diversity has been reported in PsA, and intestinal inflammation is common even in asymptomatic patients ^[46]^D5. Mechanical stress ( ) at the enthesis is a well-recognized trigger for both skin and joint disease ^[30]^D5^[54]^D5.

Systemic Inflammation and Comorbidities

Chronic IL-17 and TNF drive systemic effects beyond the joints. IL-17 promotes insulin resistance, endothelial dysfunction, and hepatic acute-phase responses, contributing to the increased cardiovascular risk and seen in PsA ^[57]^D5^[63]^D5. Adipokine imbalance and chronic inflammation accelerate atherogenesis, independent of traditional risk factors ^[45]^D5^[63]^D5.

Genetic Locus	Variant / Association	Implicated Pathway	Strength of Evidence
HLA-C*06:02	Strongest MHC association in psoriasis; weaker in PsA	Antigen presentation to CD8+ T cells	Established ^[35]^D5^[36]^D5
IL23R	Multiple SNPs (e.g., rs11209026)	IL-23 receptor signaling	Confirmed in GWAS ^[31]^D5^[55]^D5
ERAP1	Interacts with HLA-Cw06	Peptide trimming for MHC class I	Replicated ^[55]^D5^[56]^D5
TNFAIP3	Loss-of-function variants	NF-κB negative regulation	Associated ^[55]^D5
TRAF3IP2	Missense variant	IL-17 signal transduction	Associated ^[55]^D5

Pearl: Psoriatic arthritis is fundamentally an entheseal disease driven by the IL-23/IL-17 axis, with genetic predisposition (HLA-C*06:02, IL23R, ERAP1) and biomechanical stress as key triggers; the simultaneous bone erosion and new bone formation distinguish it from rheumatoid arthritis and explain its unique radiographic features ^[37]^D5^[50]^D5^[51]^D5.

Epidemiology, Etiology & Risk Factors

▸Worldwide PsA prevalence is 0.05-0.27% in population-based studies and incidence 3.6-8.5 per 100,000 person-years, with a clear upward temporal trend [89, 97].
▸Obesity (HR 1.28 per 5-unit BMI increase), smoking (OR 1.5-2.0), severe psoriasis (HR 2.5), and HLA-B27 (OR 5-10) are the strongest risk factors [76, 90, 52].
▸Biologic therapy for psoriasis may reduce PsA incidence by ~20-40%, but evidence is insufficient to recommend preventive use outside trials [113, 96].

HY High Yield: PsA incidence peaks in the 5th-6th decade; men and women are affected nearly equally. Obesity is the most potent modifiable risk factor, a 5-unit BMI increase raises risk by 28%.

Approximately 30% of patients with psoriasis will develop psoriatic arthritis (PsA) over their lifetime, though estimates range from 6% to 42% depending on the population studied and case ascertainment method ^[114]^D5^[96]^D5. Within the general adult population, the worldwide prevalence of PsA is 0.05% to 0.27% from population-based studies and 0.10% to 0.67% from health-administrative databases ^[89]^A1a. The global incidence is 3.6 to 8.5 per 100,000 person-years, with higher rates in North America (8.5 per 100,000) than in East Asia (1.3 per 100,000) ^[97]^B2b^[52]^D5. Temporal trends show a clear increase: US incidence rose from 3.6 per 100,000 in 1970-1979 to 8.5 per 100,000 in 2000-2017, a pattern attributed to improved recognition, aging populations, and rising obesity, not merely diagnostic drift ^[97]^B2b.

Demographic Distribution

PsA affects men and women nearly equally, though some cohorts show a slight male predominance (incidence rate ratio 1.2) ^[97]^B2b. Peak onset is between ages 40 and 50 years; incidence rises steeply from age 30, plateaus in the 5th and 6th decades, then declines after age 70 ^[95]^B2c. In a German analysis of 65 million insured individuals, the age-specific incidence in women peaked at 50-54 years (20 per 100,000) and in men at 60-64 years (25 per 100,000) ^[95]^B2c. PsA in children (juvenile psoriatic arthritis) accounts for a small fraction, with onset typically after age 6 ^[66]^A1b.

Geographic variation is driven largely by HLA-B27 prevalence. PsA is most frequent in circumpolar Indigenous communities (prevalence up to 0.3%) and lowest in East Asian populations (prevalence ~0.02%), where HLA-B27 is rare ^[52]^D5^[79]^A1a. Within Europe, prevalence is highest in Scandinavia and lowest in Mediterranean countries ^[89]^A1a.

Genetic Risk Factors

Family and twin studies confirm strong heritability. First-degree relatives of PsA probands have a 30- to 50-fold increased risk compared with the general population ^[114]^D5. The major genetic contributor is HLA-B27 (OR 5.0-10.0), which also increases the risk of axial involvement and uveitis ^[52]^D5^[69]^B2a. Other HLA alleles, HLA-Cw*0602 (the primary psoriasis-risk allele), HLA-B08, HLA-B38, and HLA-B39, confer ORs of 2.0-4.0 for PsA specifically, beyond psoriasis alone ^[52]^D5^[114]^D5. Non-MHC loci include variants near IL23R, IL12B, TRAF3IP2, and TNIP1, each with modest effect sizes (OR 1.1-1.5) ^[52]^D5. Genome-wide studies have also identified a variant near CD83 (European-prevalent) and near IL17RB (East Asian-prevalent) that increase risk during tofacitinib therapy, though these are treatment-modifying rather than disease-causing ^[70]^A1a.

Environmental and Lifestyle Risk Factors

Risk Factor	Odds Ratio / Hazard Ratio	Evidence Level
Obesity (BMI ≥30 kg/m²)	OR 2.0-3.0 for incident PsA in psoriasis	2b (prospective cohort) ^[76]^B2b
Smoking (ever vs never)	OR 1.5-2.0 for PsA in psoriasis	1a (meta-analysis) ^[90]^A1a
Trauma (physical injury)	HR 2.0-5.0 (site-specific)	3b (case-control) ^[114]^D5
Psoriasis severity (BSA >10%)	HR 2.5 (95% CI 1.5-4.2)	2b (prospective cohort) ^[76]^B2b
Nail psoriasis	HR 2.0-3.0	2b ^[76]^B2b
Scalp psoriasis	OR 2.0	2b ^[96]^D5
Family history of PsA	OR 30-50	2b ^[114]^D5
HLA-B27	OR 5.0-10.0	2a ^[52]^D5
HLA-Cw*0602	OR 2.0-4.0	2a ^[52]^D5
Infection (streptococcal pharyngitis)	OR 2.0-3.0 (within 2 months)	3b ^[114]^D5

Obesity is the strongest modifiable risk factor. In a prospective psoriasis cohort, each 5-unit increase in BMI raised PsA risk by 28% (HR 1.28, 95% CI 1.11-1.47) ^[76]^B2b. Smoking doubles the risk, with a clear dose-response: heavier smokers (>20 pack-years) have higher odds than light smokers (OR 1.9 vs 1.4) ^[90]^A1a. Physical trauma, especially to joints, tendons, or entheses, may trigger PsA through a "deep Koebner" phenomenon, with site-specific HRs of 2.0-5.0 ^[114]^D5. Infection, particularly streptococcal pharyngitis, has been linked to PsA onset within 2 months (OR 2.0-3.0), likely via molecular mimicry and T-cell cross-reactivity ^[114]^D5.

Psoriasis phenotype itself is a major determinant. Patients with severe psoriasis (body surface area >10%) have 2.5-fold higher risk of PsA than those with mild skin disease ^[76]^B2b. Nail psoriasis, scalp psoriasis, and intergluteal involvement each independently predict progression ^[96]^D5^[114]^D5.

Can Biologic Therapy Prevent PsA?

Observational data suggest that biologic treatment for psoriasis may reduce the incidence of new-onset PsA, though not eliminate it. Two meta-analyses found a 20-40% relative risk reduction with TNFi or IL-17i compared with non-biologic therapies (pooled HR 0.6-0.8) ^[113]^A1a^[84]^B3b. However, a nested case-control study reported no significant benefit after propensity-score matching (HR 0.9, 95% CI 0.6-1.3) ^[82]^B3b, and the only randomized trial (randomized to biologic or not, with arthritis endpoints) has yet to report. The EULAR task force considers the evidence insufficient to recommend biologics for PsA prevention outside clinical trials ^[96]^D5.

Summary of Incidence and Prevalence Trends

PsA incidence has increased 2.4-fold over 5 decades in the US, from 3.6 to 8.5 per 100,000 ^[97]^B2b. Parallel increases are reported in the UK and Europe, likely reflecting rising obesity, aging, and better case-finding ^[89]^A1a^[97]^B2b. Mortality in PsA is 10-20% higher than the general population, driven primarily by cardiovascular disease (standardized mortality ratio 1.3-1.5) ^[78]^A1a.

Pearl: PsA affects approximately 0.1% of the general population and 30% of psoriasis patients; obesity, smoking, severe psoriasis, nail disease, and HLA-B27 are the strongest independent risk factors, with obesity being the most modifiable driver ^[76]^B2b^[90]^A1a^[52]^D5.

Clinical Presentation

▸PsA presents with peripheral arthritis (oligoarticular or polyarticular), enthesitis, dactylitis, axial involvement, and skin/nail psoriasis; the pattern guides treatment selection.
▸Enthesitis and dactylitis are hallmark features that distinguish PsA from rheumatoid arthritis and other inflammatory arthritides.
▸Axial PsA differs from ankylosing spondylitis in HLA-B27 frequency and radiographic appearance; BASDAI ≥4 indicates active axial disease.

HY High Yield: Always examine the nails (pitting, onycholysis) and entheses (Achilles, plantar fascia) in any patient with psoriasis and joint pain; these findings are specific to PsA and often precede arthritis.

The patient with psoriatic arthritis (PsA) typically presents with a combination of peripheral arthritis, enthesitis, dactylitis, axial pain, and skin or nail psoriasis, evolving over weeks to months. The onset is usually insidious, though acute flares can occur. Psoriasis precedes arthritis in 70-80% of cases, but in 15-20% the arthritis appears first, and in 5-10% the two begin simultaneously ^[36]^D5. The clinical heterogeneity reflects the underlying immunopathology: IL-23/IL-17-driven inflammation at entheses, synovium, and skin, with genetic predisposition (HLA-B27, IL23R variants) shaping the phenotype ^[37]^D5^[53]^D5.

Presenting Symptoms

Peripheral arthritis is the most common presenting symptom, affecting 80-95% of patients. It typically involves the lower extremities (knees, ankles) in an oligoarticular pattern (≤4 joints) early on, but can progress to a symmetric polyarthritis resembling rheumatoid arthritis ^[124]^A1c^[125]^A1c. Patients report morning stiffness lasting >30 minutes, joint swelling, and pain that improves with activity. Enthesitis, inflammation at tendon or ligament insertions, occurs in 30-50% of patients and is a hallmark of PsA ^[93]^A1a^[172]^D5. The most common sites are the Achilles tendon insertion and the plantar fascia. Dactylitis ("sausage digit") affects 30-40% of patients and results from flexor tenosynovitis, often involving a single finger or toe ^[93]^A1a^[182]^D5. Axial involvement (sacroiliitis and spondylitis) is present in 25-70% of patients, depending on the definition, and manifests as inflammatory back pain: insidious onset, morning stiffness >30 minutes, improvement with exercise but not rest, and nocturnal pain ^[127]^A1b^[174]^D5. Skin and nail disease are integral: plaque psoriasis (often scalp, extensor surfaces, umbilicus) and nail changes (pitting, onycholysis, hyperkeratosis) are found in 80-90% and 50-70% of patients, respectively ^[36]^D5^[93]^A1a.

Musculoskeletal Examination Findings

On inspection, look for joint swelling (especially DIP joints, which are characteristic), dactylitis, and psoriatic plaques. Palpation reveals synovitis (warm, boggy joints) and entheseal tenderness at the Achilles, plantar fascia, patellar tendon, and epicondyles. The Leeds Enthesitis Index (LEI) scores tenderness at six sites (bilateral lateral epicondyles, medial femoral condyles, Achilles insertions) and is validated for clinical trials ^[172]^D5. For axial disease, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥4 indicates active axial involvement ^[127]^A1b. Range of motion may be limited in the spine (Schober test <5 cm) and chest expansion <2.5 cm suggests costovertebral involvement. Nail examination: pitting, onycholysis, subungual hyperkeratosis. The Psoriasis Area and Severity Index (PASI) quantifies skin disease severity.

Phenotypic Variants

Variant	Key Features	Frequency
Oligoarticular	Asymmetric, ≤4 joints (knees, ankles, DIPs)	40-50% at onset
Polyarticular	Symmetric, ≥5 joints (MCPs, PIPs, wrists, MTPs)	30-40%
Axial predominant	Sacroiliitis, spondylitis; often HLA-B27+ (25% vs 75% in AS)	25-70%
DIP predominant	Isolated DIP joint involvement; associated with nail disease	5-10%
Arthritis mutilans	Severe osteolysis, telescoping digits, "pencil-in-cup" deformity	<5%

Adapted from ^[124]^A1c^[125]^A1c^[174]^D5^[182]^D5. The axial PsA phenotype differs from ankylosing spondylitis: less HLA-B27 association, more asymmetric sacroiliitis, and atypical syndesmophytes (chunky, non-marginal) ^[155]^B3b^[174]^D5.

Red Flags

Acute monoarthritis: rule out septic arthritis (especially in patients on biologics).
New-onset inflammatory back pain in a young adult: consider axial SpA; refer for MRI if X-rays are normal.
Uveitis: acute anterior uveitis occurs in 7-10% of PsA patients; requires urgent ophthalmology referral ^[93]^A1a^[188]^B2b.
Inflammatory bowel disease symptoms: diarrhea, abdominal pain; IBD is associated with PsA and may worsen with IL-17 inhibitors ^[153]^B2b.
Rapidly progressive joint destruction: suspect arthritis mutilans; early aggressive therapy needed.

Atypical Presentations

PsA can present without overt arthritis. Isolated enthesitis (e.g., , Achilles tendinitis) may be the first manifestation, especially in patients with psoriasis ^[51]^D5^[172]^D5. Tenosynovitis of the flexor tendons can mimic dactylitis but may occur without digital swelling. Nail psoriasis alone (pitting, onycholysis) can precede arthritis by years and is a risk factor for PsA development ^[76]^B2b^[148]^B2b. In some patients, axial disease dominates without peripheral arthritis, leading to misdiagnosis as ankylosing spondylitis ^[174]^D5. The CASPAR criteria (which require inflammatory articular disease plus ≥3 points from psoriasis, nail changes, dactylitis, negative RF, and radiographic juxta-articular new bone formation) help identify atypical cases ^[125]^A1c.

Pearl: PsA is a heterogeneous disease with five recognized clinical domains (peripheral arthritis, axial disease, enthesitis, dactylitis, skin/nail disease); a thorough examination of all domains is essential because treatment selection depends on the dominant phenotype ^[124]^A1c^[125]^A1c^[182]^D5.

Diagnosis & Workup: Serology, Imaging & Classification Criteria

▸CASPAR criteria (≥3 points) have 91.4% sensitivity and 98.7% specificity for diagnosing PsA and should be applied systematically in every patient with suspected inflammatory arthritis [248].
▸Rheumatoid factor and anti-CCP are typically negative; a positive result should prompt evaluation for rheumatoid arthritis or an overlap syndrome.
▸Ultrasound with power Doppler detects subclinical enthesitis and synovitis in psoriasis patients and can identify those at risk of progressing to PsA [223, 264].

Dx Diagnostic Essentials: **Gold-standard diagnostic test:** CASPAR classification criteria (≥3 points). Sensitivity 91.4%, specificity 98.7% [248].

HY High Yield: **Pitfall:** Rheumatoid factor negativity is a CASPAR criterion. A positive RF should prompt consideration of rheumatoid arthritis or an overlap syndrome, not PsA.

CASPAR criteria anchor the diagnosis of psoriatic arthritis, requiring at least 3 points from five weighted domains: current psoriasis (2 points), personal or family history of psoriasis (1 point), dactylitis (1 point), juxta-articular new bone formation on radiographs (1 point), rheumatoid factor negativity (1 point), and nail dystrophy (1 point) ^[248]^D5. Although developed for classification, the CASPAR criteria have been adopted as a diagnostic standard because of their high sensitivity (91.4%) and specificity (98.7%) in distinguishing PsA from other inflammatory arthritides ^[248]^D5. Diagnosis remains fundamentally clinical, but the criteria provide a structured framework that reduces diagnostic delay, which often exceeds one year ^[256]^B2b.

History and Physical

The diagnosis begins with a targeted history and examination. Ask about inflammatory joint pain (morning stiffness >30 minutes, improvement with activity), swelling of entire digits (dactylitis, or "sausage digit"), and pain at tendon or ligament insertions (enthesitis, most commonly at the Achilles tendon and plantar fascia). Elicit a history of psoriasis, which may be subtle or limited to the scalp, umbilicus, or intergluteal cleft. Nail changes, pitting, onycholysis, subungual hyperkeratosis, are present in up to 80% of patients with PsA and are a strong predictor of arthritis ^[226]^B3b.

On examination, palpate for synovitis in the hands, wrists, knees, and feet. Assess for dactylitis by comparing digit circumference. Enthesitis is detected by applying firm pressure to the Achilles insertion, plantar fascia origin, and medial femoral condyle. Axial involvement is suggested by reduced spinal mobility and sacroiliac joint tenderness. Red flags that mandate urgent evaluation include acute monoarthritis with fever (septic arthritis), rapidly progressive symmetric polyarthritis with positive rheumatoid factor (rheumatoid arthritis), and crystal-induced arthritis (gout or pseudogout).

Gold-Standard Test: CASPAR Classification Criteria

The CASPAR criteria are the single most validated diagnostic tool. They require a total of ≥3 points from the following domains:

Domain	Points
Current psoriasis (by rheumatologist or dermatologist)	2
Personal or family history of psoriasis (first- or second-degree relative)	1
Dactylitis (current or history by rheumatologist)	1
Juxta-articular new bone formation on hand or foot radiographs (excluding osteophytes)	1
Rheumatoid factor negativity (by any method)	1
Nail dystrophy (pitting, onycholysis, hyperkeratosis)	1

In the original derivation cohort, a threshold of ≥3 points yielded a sensitivity of 91.4% and specificity of 98.7% ^[248]^D5. These performance characteristics have been replicated in subsequent validation studies ^[222]^A1a. The criteria are most useful in patients with established psoriasis and inflammatory arthritis; they perform less well in the absence of skin disease (PsA sine psoriasis), where sensitivity drops to approximately 80% ^[248]^D5.

Laboratory Studies

No single serologic test confirms PsA. The diagnosis is one of exclusion, supported by the absence of autoantibodies typical of other rheumatic diseases.

Test	Finding	Clinical Implication
Rheumatoid factor (RF)	Negative	Required for CASPAR point; if positive, consider RA or overlap
Anti-cyclic citrullinated peptide (anti-CCP)	Negative	More specific than RF for RA; rarely positive in PsA
C-reactive protein (CRP)	May be elevated	Correlates with disease activity but normal in ~40% of patients
Erythrocyte sedimentation rate (ESR)	May be elevated	Less sensitive than CRP
Uric acid	Normal	Rule out gout in monoarticular presentation
HLA-B27	Positive in 25% of axial PsA	Not diagnostic; associated with younger age and more severe axial disease ^[155]^B3b

Novel biomarkers are under investigation. Serum levels of IL-17A, β-defensin-2, and IL-19 correlate with disease activity and may help differentiate PsA from psoriasis alone ^[195]^A1b^[105]^B3b. IgA anti-CD74 autoantibodies have been associated with treatment escalation in peripheral PsA ^[263]^B3b. However, none are yet incorporated into routine diagnostic algorithms.

Imaging

Imaging confirms synovitis, enthesitis, and structural damage, and can detect subclinical disease in patients with psoriasis who have arthralgia ^[264]^D5.

Radiography remains the first-line modality for assessing structural damage. Characteristic findings include erosions with adjacent new bone formation (pencil-in-cup deformity), juxta-articular periostitis, and ankylosis. The PsA-modified Sharp/van der Heijde score quantifies damage in clinical trials ^[198]^A1b. For axial disease, the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) and Psoriatic Arthritis Spondylitis Radiology Index (PASRI) are used, but sensitivity to change is limited ^[158]^C4.

Ultrasound with power Doppler is highly sensitive for detecting synovitis, tenosynovitis, and enthesitis. In a meta-analysis, the presence of power Doppler signal at entheses had a specificity of 92% for PsA compared to healthy controls ^[223]^A1a. Ultrasound can identify subclinical enthesitis in up to 40% of psoriasis patients without arthritis, and its presence predicts progression to PsA ^[87]^A1a^[264]^D5.

Magnetic resonance imaging (MRI) with short-tau inversion recovery (STIR) sequences detects bone marrow edema, a marker of active osteitis. Whole-body MRI can assess both peripheral and axial inflammation simultaneously ^[162]^C4^[215]^C4. MRI is particularly useful when radiographs are normal but clinical suspicion is high.

Advanced imaging remains investigational. 68Ga-FAPI PET/CT detects fibroblast activation in synovium and entheses, and may identify patients at risk of progression from psoriasis to PsA ^[121]^B2b^[218]^C4. High-resolution peripheral quantitative CT (HR-pQCT) can quantify erosion and enthesiophyte progression with high precision ^[196]^A1b.

Diagnostic Algorithm

A stepwise approach integrates clinical, serologic, and imaging data.

Step 1: Clinical suspicion. Identify inflammatory joint pain, morning stiffness, dactylitis, enthesitis, or axial symptoms in a patient with or without known psoriasis.

Step 2: Apply CASPAR criteria. Calculate the point score. A total ≥3 supports the diagnosis. If the patient has current psoriasis (2 points) plus any one other feature (e.g., dactylitis or nail dystrophy), the threshold is met.

Step 3: Exclude mimics. Order RF, anti-CCP, and uric acid. If RF or anti-CCP is positive, consider rheumatoid arthritis. If uric acid is elevated, consider gout. If acute monoarthritis with fever, perform arthrocentesis to rule out septic arthritis.

Step 4: Confirm with imaging. If CASPAR criteria are not met (e.g., no psoriasis history) or if clinical findings are equivocal, obtain radiographs of hands and feet. If still uncertain, perform ultrasound of symptomatic joints and entheses. MRI is reserved for cases where axial involvement is suspected or when ultrasound is inconclusive.

Step 5: Classify disease phenotype. Determine whether the predominant pattern is peripheral oligoarticular, polyarticular, axial, or entheseal. This guides treatment selection.

Step 6: Refer to rheumatology. Early diagnosis and referral improve outcomes; a treat-to-target strategy initiated within the first year reduces radiographic progression ^[209]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Should CASPAR criteria be used for diagnosis?	ACR/NPF: Yes, as a diagnostic aid ^[189]^A1c	EULAR: No, they are classification criteria, not diagnostic ^[243]^D5	Moderate	In practice, most rheumatologists use CASPAR to support diagnosis; caution is needed in atypical presentations
How to define axial PsA?	GRAPPA: Use modified New York criteria for sacroiliitis ^[251]^D5	EULAR: Axial PsA is a clinical diagnosis supported by MRI ^[174]^D5	Weak	Axial PsA may have less HLA-B27 association and more asymmetric sacroiliitis; no consensus definition exists ^[250]^D5
Role of ultrasound in screening psoriasis patients?	Some experts: Screen all psoriasis patients with US ^[264]^D5	ACR: Insufficient evidence for routine screening ^[189]^A1c	Weak	US can detect subclinical disease, but cost-effectiveness and impact on outcomes are unproven

Pearl: The CASPAR criteria (≥3 points) provide a rapid, validated diagnostic framework, but the diagnosis remains clinical; imaging, especially ultrasound with power Doppler, is essential for detecting subclinical enthesitis and synovitis, particularly in patients with psoriasis and arthralgia who do not yet meet CASPAR threshold ^[223]^A1a^[264]^D5.

Severity, Disease Activity & Risk Stratification

▸DAPSA (remission ≤4) and MDA (5 of 7 criteria) are the core composite measures guiding treat-to-target; MDA is the recommended target in EULAR and ACR/NPF guidelines [64, 92, 265].
▸Obesity, female sex, high CRP, and polyarticular involvement predict poor treatment response and should prompt early intensive therapy [147, 294, 37].
▸The CALLY index (cutoff 41.2) and the GLP-1 receptor agonist combination strategy (ixekizumab + tirzepatide) represent emerging tools for risk stratification and disease modification [259, 279].

HY High Yield: MDA is a more stringent target than DAPSA LDA and is the recommended treat-to-target goal in both EULAR 2023 and ACR/NPF 2018 guidelines [64, 265].

! Warning: Female sex is associated with higher baseline disease activity and lower odds of achieving MDA (OR 0.67); clinicians should be alert to the possibility of concomitant fibromyalgia masquerading as active PsA in women [147, 172].

No single gold-standard instrument captures the full heterogeneity of psoriatic arthritis (PsA). Instead, clinicians rely on a family of validated composite indices that each weight domains differently, peripheral arthritis, skin, enthesitis, dactylitis, axial disease, function, and patient-reported impact, and the choice of tool shapes both treat-to-target goals and trial eligibility ^[276]^D5^[272]^D5. The Disease Activity in Psoriatic Arthritis (DAPSA) score and the Minimal Disease Activity (MDA) criteria are the two most widely adopted composite measures in clinical practice, while the Psoriatic Arthritis Disease Activity Score (PASDAS) and Composite Psoriatic Disease Activity Index (CPDAI) appear more often in research ^[292]^A1a^[92]^A1a.

DAPSA: The Joint-Focused Composite

DAPSA sums the swollen joint count (66 joints), tender joint count (68 joints), patient global assessment (0-10 cm VAS), patient pain (0-10 VAS), and C-reactive protein (mg/dL). No skin or enthesitis domain is included. Cutoffs are: remission ≤4, low disease activity (LDA) >4 to ≤14, moderate disease activity >14 to ≤28, and high disease activity >28 ^[276]^D5^[92]^A1a. In a meta-analysis of 258 publications, DAPSA remission was achieved by 23% of patients (95% CI 18-29%) across trial cohorts, and DAPSA LDA by 40% (95% CI 33-47%) ^[92]^A1a. DAPSA change is responsive to treatment and correlates with radiographic progression ^[276]^D5. The TICOPA trial showed that a treat-to-target strategy aiming for MDA (which overlaps with DAPSA LDA) yielded superior ACR20 responses at 48 weeks compared with standard care (OR 1.91, 95% CI 1.23-2.97) ^[209]^A1b.

MDA: The Multi-Domain Target

MDA requires the patient to meet 5 of 7 criteria: tender joint count ≤1, swollen joint count ≤1, psoriasis body surface area ≤3% or PASI ≤1, patient pain VAS ≤15 mm, patient global VAS ≤20 mm, Health Assessment Questionnaire (HAQ) ≤0.5, and enthesitis count ≤1 ^[234]^B2b^[276]^D5. MDA is a more stringent target than DAPSA LDA and is the recommended treatment target in both EULAR 2023 and ACR/NPF 2018 guidelines ^[64]^A1c^[265]^A1c. In the meta-analysis, MDA was achieved by 33% (95% CI 28-38%) of patients; very low disease activity (VLDA), all 7 criteria met, by 14% (95% CI 10-18%) ^[92]^A1a. The STAMP trial (2025) directly compared an intensive biologic-first strategy (secukinumab) with standard step-up, both targeting MDA; the intensive arm achieved MDA more rapidly, with 53% vs 33% at week 24 (RR 1.59, 95% CI 1.22-2.06) ^[202]^A1b.

PASDAS and CPDAI: Research-Grade Instruments

PASDAS adds physician global, enthesitis, dactylitis, and the Short Form-36 physical component summary to the DAPSA components, giving a weighted score (0-100). It has excellent discriminant validity: pooled standardised mean difference between active drug and placebo = 0.63 (95% CI 0.46-0.80) in a network meta-analysis of 28 trials ^[292]^A1a. CPDAI assigns scores 0-3 in each of four domains (peripheral joints, skin, enthesitis/dactylitis, axial disease) and sums them; it discriminated better than DAPSA in the GRAPPA-OMERACT analysis (SMD 0.49 vs 0.69) ^[292]^A1a. The CRESPA trial showed that both PASDAS and CPDAI had superior longitudinal construct validity compared with DAS28-CRP in peripheral spondyloarthritis ^[275]^A1b.

Axial Disease Assessment

Axial PsA is assessed with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) . A BASDAI ≥4 defines active axial disease and was the entry criterion in the MAXIMISE trial, where secukinumab 300 mg achieved ASAS40 response in 63% vs 31% placebo at week 12 (OR 3.91, 95% CI 2.21-6.92) ^[127]^A1b. ASDAS-CRP is more sensitive to change and is preferred by EULAR for axial PsA, though no formal PsA-specific cutoff has been validated ^[64]^A1c.

Enthesitis and Dactylitis Scores

Leeds Enthesitis Index (LEI) , Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) , and Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index are the three validated tools. The DEUS study found that ultrasound-detected active enthesitis (using OMERACT definitions) was present in 42% of patients with normal physical examination, underscoring the role of imaging in risk stratification ^[99]^C4. For dactylitis, the Dactylitis Severity Score (DSS) counts digits and grades severity (0-3 per digit) ^[172]^D5.

Risk Stratification: Predictors of Severe Disease

Baseline predictors of rapid radiographic progression include polyarticular involvement (>5 swollen joints) , elevated CRP (>15 mg/L) , baseline erosions, and high DAPSA (>28) ^[37]^D5^[284]^D5. The CALLY index (CRP × albumin ÷ lymphocyte count) has been proposed as a novel biomarker: in a retrospective cohort of 150 PsA patients, lower CALLY values correlated with higher DAPSA (r = -0.41, p <0.001) and an optimal cutoff of 41.2 discriminated active from inactive disease (AUC 0.79, 95% CI 0.71-0.87) ^[259]^B3b. Obesity (BMI ≥30) is a modifiable risk factor that independently predicts lower odds of achieving MDA (OR 0.54, 95% CI 0.38-0.77) ^[294]^D5^[279]^A1b. The TOGETHER-PsA trial (2026) showed that combining ixekizumab with (a GLP-1 receptor agonist) achieved simultaneous ACR50 + ≥10% weight loss in 32% of patients vs 9% with ixekizumab alone (p<0.001), highlighting weight reduction as a disease-modifying intervention ^[279]^A1b.

Sex Differences in Disease Activity

A systematic review and meta-analysis of 51 RCTs found that female sex is associated with higher baseline disease activity (mean DAPSA 7.5 points higher vs males, 95% CI 4.8-10.2) and lower odds of achieving MDA at 6 months (OR 0.67, 95% CI 0.55-0.81) ^[147]^A1a. This disparity persists across all drug classes and may reflect differences in pain perception, concomitant , or true biological refractoriness ^[147]^A1a^[172]^D5.

Flare Definition and Monitoring

Flare is defined by the GRAPPA-OMERACT working group as a composite of ≥1 point increase in patient global, ≥1 swollen joint, and ≥1 tender joint, plus a decision to escalate therapy ^[88]^A1a. The incidence of flare over 12 months is 22-23% in cohort studies, and risk factors include prior biologic failure, high baseline DAPSA, and obesity ^[88]^A1a. Regular monitoring every 3-6 months with a composite score is recommended by EULAR to identify flare early and adjust therapy ^[64]^A1c.

Imaging in Risk Stratification

Whole-body MRI (WB-MRI) can detect subclinical inflammation: in the MOSAIC study, apremilast reduced WB-MRI inflammation scores by 34% (95% CI 22-46%) at week 24 ^[162]^C4. 68Ga-FAPI PET/CT shows higher positivity in peripheral joints (22%) than in entheses (12%) or axial joints (0%) in a prospective study of 16 patients, suggesting a role for fibroblast-activation imaging in refractory disease ^[218]^C4.

Pearl: DAPSA and MDA are the cornerstone composite measures for treat-to-target in PsA, with MDA as the preferred target in guidelines; obesity, female sex, and high baseline CRP stratify patients at risk of poor outcomes, and emerging biomarkers like the CALLY index may refine risk assessment ^[92]^A1a^[202]^A1b^[64]^A1c^[259]^B3b.

Comparison of Composite Disease Activity Measures in Psoriatic Arthritis

Measure	Domains Included	Cutoffs for Remission/LDA	Discriminant Validity (SMD vs placebo)	Key Reference
DAPSA	SJC66, TJC68, PtGA, pain VAS, CRP	≤4 remission; 4-14 LDA	0.63 (95% CI 0.46-0.80) ^[292]^A1a	^[276]^D5^[92]^A1a
MDA	TJC ≤1, SJC ≤1, BSA ≤3% or PASI ≤1, pain VAS ≤15, PtGA ≤20, HAQ ≤0.5, enthesitis ≤1	5 of 7 criteria met	, (target, not a continuous score)	^[234]^B2b^[276]^D5
PASDAS	DAPSA components + physician global, enthesitis, dactylitis, SF-36 PCS	<3.2 remission; 3.2-<5.4 LDA	0.63 (0.46-0.80) ^[292]^A1a	^[276]^D5
CPDAI	Peripheral joints, skin, enthesitis/dactylitis, axial (each 0-3)	≤4 remission; 5-8 LDA	0.49 (0.28-0.70) ^[292]^A1a	^[276]^D5
ASDAS-CRP	Back pain, PtGA, peripheral pain, morning stiffness, CRP	<1.3 remission; 1.3-<2.1 LDA (axial)	Not formally validated in PsA	^[64]^A1c

Acute Management: Flares & Organ-Threatening Disease

▸Flares occur in 10-27% of patients over 6 months; severity classification guides disposition and therapy.
▸Short-course systemic glucocorticoids (≤3 months) are acceptable for moderate-severe flares despite traditional avoidance.
▸Escalate to TNFi or IL-17i for severe flares; avoid IL-17i in active IBD due to paradoxical exacerbation.

! Warning: Do NOT initiate IL-17 inhibitors (secukinumab, ixekizumab) in patients with active inflammatory bowel disease; they can cause paradoxical disease exacerbation [310]. Prefer TNFi or IL-23i in this population.

HY High Yield: For ICI-induced PsA flare, apremilast or IL-17/23 inhibitors may control arthritis without compromising antitumor immunity [232,285,317].

Flares in psoriatic arthritis are common, with a 6-month incidence of 10-27% and a 12-month incidence of 22-23% ^[88]^A1a. The prevalence of current flare ranges from 7% to 50% across studies ^[88]^A1a. Prompt recognition and structured escalation prevent irreversible joint damage, loss of function, and rare but serious organ-threatening complications.

Step 1: Initial Assessment and Severity Classification

Classify flare severity using validated tools: the PsA FLARE Questionnaire (sensitivity 0.85, specificity 0.78) ^[336]^C4 or loss of Minimal Disease Activity (MDA) ^[321]^B2b. Define mild flare as ≤2 swollen/tender joints, no significant skin or axial involvement, and patient-reported pain ≤3/10. Moderate flare involves 3-5 joints, enthesitis, dactylitis, or psoriasis worsening by ≥1 PGA grade. Severe flare includes ≥6 joints, acute axial pain with morning stiffness >60 minutes, pustular or erythrodermic psoriasis, acute anterior uveitis, or new-onset inflammatory bowel disease (IBD) symptoms. Organ-threatening manifestations (severe uveitis, IBD flare, acute severe psoriasis) warrant urgent rheumatology consultation and hospitalization.

Step 2: First-Line Interventions

Mild flare: NSAIDs (e.g., naproxen 500 mg twice daily) or intra-articular corticosteroids (e.g., triamcinolone acetonide 40 mg for large joints) ^[297]^A1c.
Moderate flare: Short-course systemic glucocorticoids (e.g., 10-20 mg/day tapered over 2-4 weeks) may be used despite traditional caution; a systematic review found no consistent evidence of psoriatic flare with short-term use ^[305]^B2a. However, avoid prolonged use (>3 months) due to metabolic and cardiovascular risks ^[308]^B2b^[311]^B2b.
Severe/organ-threatening flare: Prednisone 0.5-1 mg/kg/day (max 60 mg/day) for acute uveitis or IBD flare, with rapid taper over 4-6 weeks. For acute severe psoriasis (pustular/erythrodermic), consider 3-5 mg/kg/day or 15-25 mg/week as bridging therapy ^[164]^A1a.

Step 3: Escalation of Disease-Modifying Therapy

If flare occurs despite optimized conventional synthetic DMARD (csDMARD) therapy (e.g., methotrexate 25 mg/week), escalate to a biologic or targeted synthetic DMARD per EULAR 2019 recommendations ^[297]^A1c. For severe flares, initiate TNF inhibitor (e.g., 40 mg every other week) or IL-17 inhibitor (e.g., secukinumab 150-300 mg weekly for 4 weeks, then monthly) ^[66]^A1b^[300]^C4. In patients with concomitant IBD, prefer TNFi or IL-23i over IL-17i, as IL-17 blockade can paradoxically exacerbate IBD ^[310]^D5. For ICI-induced PsA flare, consider apremilast 30 mg twice daily or IL-17/23 inhibitors, which may preserve antitumor immunity ^[232]^C4^[285]^C4^[317]^A1c.

Step 4: Monitoring and Titration

Assess response at 4 weeks (for biologics) or 12 weeks (for csDMARDs). Target MDA or DAPSA remission ^[321]^B2b. If inadequate response, switch within class (e.g., adalimumab to secukinumab) or to a different mechanism (e.g., TNFi to IL-23i) ^[331]^B3b. For patients on JAK inhibitors (tofacitinib, baricitinib), monitor for thrombosis, infection, and lipid changes ^[205]^A1b^[71]^A1b.

Step 5: Resolution and Transition

Once flare resolves, taper glucocorticoids over 2-4 weeks. Continue maintenance DMARD at the effective dose. In patients achieving sustained remission (≥12 months), consider cautious tapering of biologic dose or interval, but complete withdrawal is associated with high flare rates (22-84%) ^[306]^A1a^[307]^D5^[312]^B2b.

Drug / Modality Comparison Table

Intervention	Indication	Dose	Key Evidence	Outcome	Evidence Level
NSAIDs (naproxen)	Mild flare	500 mg BID	EULAR 2019 ^[297]^A1c	Symptom relief	1c
Intra-articular corticosteroids	Oligoarticular flare	Triamcinolone 40 mg (large joint)	EULAR 2019 ^[297]^A1c	Rapid local control	1c
Systemic glucocorticoids	Moderate-severe flare	Prednisone 10-60 mg/day, taper	Systematic review ^[305]^B2a	Rapid global control; caution with prolonged use	2a
Cyclosporine	Acute severe psoriasis	3-5 mg/kg/day	Cochrane NMA ^[164]^A1a	Rapid skin clearance	1a
TNFi (adalimumab)	Severe flare, IBD	40 mg every other week	RCT ^[300]^C4	ACR50 39% at 12 weeks	1b
IL-17i (secukinumab)	Severe flare, no IBD	150-300 mg weekly ×4, then monthly	Phase 3 ^[66]^A1b	ACR20 67% at 16 weeks	1b
Apremilast	ICI-induced flare	30 mg BID	Case series ^[232]^C4	Complete/partial response in 71%	4

Dosing Table

Drug	Starting dose	Target/max dose	Renal adjustment	Hepatic adjustment	Key monitoring
Prednisone	10-60 mg/day	Taper to 5 mg/day	None	None	Glucose, BP, infection
Cyclosporine	3 mg/kg/day	5 mg/kg/day	Reduce by 25% if CrCl <50	Avoid if severe	BP, Cr, K+, trough level
Adalimumab	40 mg SC every other week	40 mg every other week	None	None	Infection, injection site
Secukinumab	150-300 mg SC weekly ×4	150-300 mg monthly	None	None	Infection, IBD symptoms
Apremilast	10 mg AM, 10 mg PM ×1 day, then 10 mg AM, 20 mg PM ×1 day, then 20 mg BID	30 mg BID	CrCl <30: 30 mg daily	None	GI symptoms, weight loss

Treatment Failure Protocol

Inadequate response at 4-12 weeks: Confirm adherence, rule out infection. Switch to a different mechanism (e.g., TNFi → IL-17i or IL-23i).
Loss of response after initial benefit: Check drug levels (for TNFi) or consider immunogenicity. Add csDMARD (e.g., methotrexate) to biologic.
Organ-threatening progression despite high-dose corticosteroids: Escalate to IV pulse (1 g/day ×3 days) and consider or (off-label) for severe refractory uveitis or IBD.

What NOT to Do

Do NOT use systemic glucocorticoids as monotherapy for >3 months without a steroid-sparing DMARD; risk of diabetes, osteoporosis, and infection outweighs benefit ^[308]^B2b^[311]^B2b.
Do NOT initiate IL-17 inhibitors in patients with active IBD; they can cause paradoxical disease exacerbation ^[310]^D5.
Do NOT abruptly discontinue biologics without bridging; flare risk increases 2- to 4-fold ^[306]^A1a.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication for practice
Role of systemic glucocorticoids in PsA flare	Traditional teaching: Avoid due to risk of psoriatic flare and metabolic harm	Systematic review ^[305]^B2a: Short-term use (≤3 months) is common and not clearly associated with flare; may be acceptable for bridging	Moderate	Short courses (2-4 weeks) are reasonable for moderate-severe flares; avoid prolonged use
of ICI-induced PsA flare	Continue ICI + treat flare with NSAIDs/corticosteroids ^[317]^A1c	Switch to apremilast or IL-17/23i to preserve ICI efficacy ^[232]^C4^[285]^C4	Moderate	Shared decision-making with oncology; apremilast or targeted biologics may be preferred in severe flares

Pearl: For acute PsA flares, classify severity rapidly using validated tools; short-course glucocorticoids are acceptable for bridging, but prolonged use is harmful; escalate to biologics (TNFi or IL-17i) if csDMARDs fail, and avoid IL-17i in patients with active IBD ^[88]^A1a^[297]^A1c^[305]^B2a^[310]^D5.

Long-term Management: The DMARD Ladder & Treat-to-Target

▸Treat-to-target aiming for MDA or LDA is the cornerstone of PsA management, with disease activity assessed every 1-3 months during escalation.
▸csDMARDs (MTX preferred) are first-line for peripheral arthritis; inadequate response after 3-6 months warrants a bDMARD (TNFi, IL-17i, IL-23i, or IL-12/23i).
▸JAK inhibitors are reserved for second-line after bDMARD failure due to safety concerns (malignancy, MACE); tapering can be considered after sustained remission.

! Warning: JAK inhibitors (tofacitinib, upadacitinib) carry a boxed warning for serious infections, malignancy, and MACE. Reserve for patients who have failed at least one bDMARD, and screen for cardiovascular risk factors and age >65 years before initiation [64, 67].

The EULAR 2023 recommendations anchor the long-term of psoriatic arthritis (PsA) in a treat-to-target (T2T) strategy, with the explicit goal of achieving and maintaining minimal disease activity (MDA) or, at minimum, low disease activity (LDA) ^[64]^A1c (1c). The ACR/NPF 2018 guideline endorses the same principle, recommending that disease activity be assessed every 1-3 months during dose escalation and every 3-6 months once the target is reached ^[265]^A1c (1c). This section translates that framework into a stepwise DMARD ladder, with effect sizes from the pivotal trials that support each rung.

Step 1: First-Line Therapy, Conventional Synthetic DMARDs

For patients with active peripheral arthritis and no poor prognostic features, a conventional synthetic DMARD (csDMARD) is the recommended first step. (MTX) 15-25 mg orally or subcutaneously once weekly is the preferred agent, supported by a Cochrane review that found MTX superior to placebo for joint counts and physician global assessment, though the effect size is modest (ACR20 relative risk 1.33, 95% CI 1.04-1.70; NNT = 8) ^[286]^A1a (1a). Folic acid 5 mg weekly should be co-prescribed to reduce and hepatic toxicity ^[368]^D5 (5).

Alternatives include leflunomide 20 mg daily or sulfasalazine 2-3 g daily in divided doses. The COMPLETE-PsA trial (N=140) compared MTX monotherapy with MTX plus leflunomide and found no significant difference in DAS28 remission at 24 weeks (OR 1.32, 95% CI 0.62-2.82), indicating that combination csDMARD offers little advantage over MTX alone ^[109]^A1b (1b). Oral glucocorticoids are not recommended for long-term use; EULAR advises against them entirely, citing an unfavourable risk-benefit profile ^[64]^A1c (1c).

Step 2: Inadequate Response to csDMARD, Adding a Biologic DMARD

When the T2T target is not reached after 3-6 months of an adequate csDMARD trial, a biologic DMARD (bDMARD) should be initiated. The choice depends on the dominant clinical domain:

Domain	Preferred bDMARD class	Key trial	ACR20 at 24 weeks vs placebo	NNT
Peripheral arthritis	TNFi, IL-17i, IL-12/23i, IL-23i	FUTURE 5 (secukinumab 300 mg)	62.6% vs 27.4% ^[129]^A1b	3
Axial disease	IL-17i (secukinumab)	MAXIMISE (secukinumab 300 mg)	BASDAI50 63.3% vs 30.7% at week 12 ^[127]^A1b	4
Skin psoriasis	IL-17i, IL-23i	SPIRIT-H2H (ixekizumab vs )	ACR50+PASI100 36% vs 28% ^[194]^B2b	13
Enthesitis	IL-17i, TNFi	FUTURE 5 (secukinumab 300 mg)	Enthesitis resolution 55.2% vs 32.7% ^[129]^A1b	5
Dactylitis	IL-17i, TNFi	FUTURE 5 (secukinumab 300 mg)	Dactylitis resolution 68.4% vs 44.9% ^[129]^A1b	5

TNF inhibitors (adalimumab 40 mg every other week, 50 mg weekly, golimumab 50 mg monthly, certolizumab 200 mg every 2 weeks, 5 mg/kg IV every 8 weeks) remain the most extensively studied class. A Cochrane meta-analysis of 14 RCTs confirmed that TNFi significantly improve ACR20 (RR 2.15, 95% CI 1.82-2.54; NNT = 4) and inhibit radiographic progression (mean Δ modified Sharp/van der Heijde score -0.53, 95% CI -0.89 to -0.17) ^[287]^A1a (1a).

IL-17 inhibitors (secukinumab 150-300 mg every 4 weeks, ixekizumab 80 mg every 2-4 weeks, bimekizumab 160 mg every 4 weeks) offer rapid skin clearance and are particularly effective for axial disease. In the MAXIMISE trial, secukinumab 300 mg achieved BASDAI50 in 63.3% of patients with axial PsA at week 12 vs 30.7% for placebo (OR 3.89, 95% CI 2.52-6.00; NNT = 4) ^[127]^A1b (1b). Bimekizumab, which dual-neutralises IL-17A and IL-17F, showed ACR20 of 67.5% vs 33.3% for placebo in biologic-naïve patients (BE OPTIMAL; NNT = 3) ^[204]^A1b (1b).

IL-23 inhibitors (guselkumab 100 mg every 8 weeks, risankizumab 150 mg every 12 weeks) are effective for peripheral arthritis and skin disease but should not be used as first-line for axial PsA. In DISCOVER-2, guselkumab every 8 weeks achieved ACR20 in 64.1% vs 33.0% for placebo at week 24 (NNT = 4) ^[203]^A1b (1b). A post-hoc analysis of DISCOVER-2 showed that guselkumab improved axial outcomes (BASDAI spinal pain) but the effect was less robust than that of IL-17i ^[274]^A1b (1b). The EULAR 2023 task force recommends IL-23i primarily for patients with predominant peripheral arthritis and skin involvement ^[64]^A1c (1c).

IL-12/23 inhibitor (ustekinumab 45-90 mg every 12 weeks) is an alternative, with ACR20 of 42.4% vs 20.0% for placebo at week 24 (NNT = 5) ^[143]^A1b (1b). The MUST trial found that adding MTX to ustekinumab did not improve DAS28 at week 24 (mean difference 0.04, 95% CI -0.28 to 0.36), supporting monotherapy use ^[269]^A1b (1b).

Step 3: Inadequate Response to First bDMARD, Switching Mechanism

If the T2T target is not met after 3-6 months of an adequate bDMARD trial, switching to a bDMARD with a different mechanism of action is recommended. For patients who fail a TNFi, an IL-17i or IL-23i is appropriate. In SPIRIT-P2, ixekizumab 80 mg every 4 weeks achieved ACR20 in 48.0% of TNFi-IR patients vs 23.0% for placebo (NNT = 4) ^[142]^A1b (1b). Similarly, in BE COMPLETE, bimekizumab 160 mg every 4 weeks in TNFi-IR patients yielded ACR20 of 67.5% vs 33.3% for placebo (NNT = 3) ^[207]^A1b (1b).

JAK inhibitors (tofacitinib 5-10 mg twice daily, upadacitinib 15 mg once daily) are positioned as second-line after bDMARD failure, though they may be considered first-line in patients with contraindications to bDMARDs. In SELECT-PsA 2, upadacitinib 15 mg in bDMARD-IR patients achieved ACR20 of 56.9% vs 24.1% for placebo at week 12 (NNT = 4) ^[126]^A1b (1b). Tofacitinib 5 mg twice daily in TNFi-IR patients showed ACR20 of 50.0% vs 24.0% for placebo (NNT = 4) ^[211]^A1b (1b). However, JAKi carry a boxed warning for serious infections, malignancy, and major adverse cardiovascular events (MACE) based on the ORAL Surveillance trial in RA. A meta-analysis across indications found an increased malignancy risk vs TNFi (IRR 1.48, 95% CI 1.06-2.06) ^[67]^A1a (1a). EULAR recommends reserving JAKi for patients who have failed at least one bDMARD, and only after screening for cardiovascular risk factors and age >65 years ^[64]^A1c (1c).

Step 4: Tapering in Sustained Remission

Once MDA is maintained for ≥6 months, a gradual tapering of the bDMARD can be considered. The DRESS-PS trial randomised patients with stable LDA to TNFi dose reduction (50% dose interval prolongation) vs continuation and found non-inferiority for disease flare at 12 months (HR 0.87, 95% CI 0.63-1.20) ^[238]^B2b (2b). At 24 months, the tapering group had similar rates of sustained MDA (68% vs 71%) and lower drug costs. Complete withdrawal is not recommended because flare rates exceed 60% within 6 months ^[238]^B2b (2b).

Drug / Modality Comparison Table

Drug class	Starting dose	Target dose	Key monitoring
Methotrexate	7.5-15 mg PO/SC weekly	20-25 mg weekly	LFTs, Cr, CBC every 4-8 weeks
Leflunomide	10-20 mg PO daily	20 mg daily	LFTs, CBC, BP every 4-8 weeks
Adalimumab	40 mg SC every 2 weeks	40 mg every 2 weeks	TB screening, CBC, LFTs
Secukinumab	300 mg SC weekly ×4, then every 4 weeks	150-300 mg every 4 weeks	TB screening, CBC
Ixekizumab	160 mg SC, then 80 mg every 2-4 weeks	80 mg every 4 weeks	TB screening, CBC
Bimekizumab	160 mg SC every 4 weeks	160 mg every 4 weeks	TB screening, CBC
Guselkumab	100 mg SC at weeks 0, 4, then every 8 weeks	100 mg every 8 weeks	TB screening, CBC
Upadacitinib	15 mg PO daily	15 mg daily	CBC, LFTs, lipids, TB screening
Tofacitinib	5 mg PO twice daily	5-10 mg twice daily	CBC, LFTs, lipids, TB screening

Treatment Failure Protocol

Confirm adherence and rule out non-inflammatory causes of pain (e.g., , which affects 10-30% of PsA patients ^[11]^B2b (2b)).
Assess drug levels and anti-drug antibodies if available, particularly for TNFi.
Switch to a bDMARD with a different mechanism of action (e.g., TNFi → IL-17i, or IL-17i → IL-23i).
If two bDMARDs fail, consider a JAK inhibitor after .
If three bDMARDs fail, define as difficult-to-treat PsA (D2T-PsA) per GRAPPA criteria: failure of ≥2 b/tsDMARDs with different mechanisms, plus moderate-to-high disease activity ^[251]^D5 (5). Refer to a specialist centre for multidisciplinary evaluation.

What NOT to Do

Do not use oral glucocorticoids for long-term disease control; they are associated with weight gain, diabetes, and osteoporosis without evidence of disease modification ^[64]^A1c (1c).
Do not combine two bDMARDs (e.g., TNFi + IL-17i) due to increased infection risk without additive efficacy ^[64]^A1c (1c).
Do not use IL-23i as first-line for axial PsA; post-hoc analyses suggest some benefit, but the EULAR task force recommends IL-17i or TNFi for axial disease ^[64]^A1c (1c).

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength of disagreement	Implication for practice
First-line bDMARD after csDMARD failure	EULAR 2023, any bDMARD (TNFi, IL-17i, IL-12/23i, IL-23i) is acceptable; no hierarchy ^[64]^A1c	ACR/NPF 2018, strongly recommend TNFi over IL-17i for patients with active PsA and no contraindications ^[265]^A1c	Moderate (EULAR is more permissive; ACR favours TNFi based on longer safety data)	Clinicians may choose TNFi as first bDMARD in most patients, but IL-17i is a reasonable alternative, especially when skin disease is prominent.
Role of JAKi as first-line therapy	EULAR 2023, JAKi should be used after bDMARD failure, or as first-line only in patients with contraindications to bDMARDs ^[64]^A1c	ACR/NPF 2018, no recommendation for JAKi as first-line (guideline published before JAKi approval) ^[265]^A1c	Strong (EULAR explicitly restricts first-line use; ACR is silent)	JAKi should be reserved for second-line or later, with careful cardiovascular risk assessment.
IL-23i for axial PsA	EULAR 2023, recommends against IL-23i for axial disease ^[64]^A1c	Some experts, post-hoc data from DISCOVER-2 and real-world studies show improvement in spinal pain and BASDAI ^[358]^D5 (5)	Moderate (EULAR guideline vs emerging evidence)	IL-23i may be considered in axial PsA if IL-17i or TNFi are contraindicated, but the evidence is not yet strong enough to change guidelines.

Pearl: Treat-to-target with regular monitoring every 1-3 months and escalation until MDA is achieved is the standard of care; early use of bDMARDs after csDMARD failure improves outcomes, with NNTs of 3-5 for ACR20 across classes, and tapering can be attempted after sustained remission but complete withdrawal should be avoided ^[64]^A1c^[238]^B2b.

Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)

▸Uveitis occurs in ~25% of PsA patients; acute anterior uveitis requires urgent ophthalmology referral to prevent synechiae and vision loss.
▸Cardiovascular risk is increased by 40-50%; annual screening for hypertension, dyslipidemia, and diabetes is mandatory.
▸Interstitial lung disease prevalence is 5-10%; consider screening in smokers or those with respiratory symptoms.

HY High Yield: Acute anterior uveitis in PsA presents with red, painful eye and photophobia; delay in treatment can lead to synechiae and vision loss.

Extra-articular involvement in psoriatic arthritis extends beyond the musculoskeletal system to affect the eyes, tract, cardiovascular system, and lungs, each with distinct screening and implications. Recognition of these manifestations is essential for comprehensive care and guides therapy selection.

Eyes: Uveitis

Uveitis is the most common extra-articular manifestation in PsA, with a pooled prevalence of approximately 25% (95% CI 20-30%) ^[93]^A1a. It is typically acute anterior uveitis, unilateral, recurrent, and strongly associated with HLA-B27 positivity ^[69]^B2a. The incidence of uveitis in PsA is estimated at 10.2 per 1000 person-years, lower than in ankylosing spondylitis but higher than in the general population ^[384]^B2b. Presentation includes acute onset of red, painful eye with photophobia and blurred vision. Prompt ophthalmology referral is essential; treatment involves and cycloplegics. For refractory or recurrent cases, biologic DMARDs such as certolizumab pegol have shown effectiveness in controlling uveitis flares ^[395]^C4. TNF inhibitors (except ) are preferred; IL-17 inhibitors may be associated with paradoxical uveitis in some cases ^[387]^C4.

Gastrointestinal: Inflammatory Bowel Disease

The prevalence of IBD in PsA is approximately 6-8%, with Crohn's disease more common than ulcerative colitis ^[93]^A1a. The incidence of IBD in PsA is 2.3 per 1000 person-years ^[384]^B2b. Shared pathogenic pathways involving the IL-23/IL-17 axis underlie this association ^[161]^D5. Screening for gastrointestinal symptoms (chronic diarrhea, abdominal pain, weight loss) should be performed at diagnosis and periodically. Management of IBD in PsA requires coordination with gastroenterology; IL-12/23 inhibitors (ustekinumab) and IL-23 inhibitors (guselkumab, risankizumab) are effective for both joint and gut disease. TNF inhibitors are also effective but may rarely exacerbate IBD.

Cardiovascular System

PsA is associated with a 40-50% increased risk of cardiovascular events compared to the general population, driven by chronic inflammation and traditional risk factors ^[391]^A1a. prevalence is elevated (odds ratio 1.3-1.5) ^[391]^A1a. Endothelial progenitor cell dysfunction contributes to accelerated atherosclerosis ^[393]^D5. IL-17 mediates systemic effects on blood vessels, promoting endothelial activation and vascular inflammation ^[57]^D5. Screening: annual blood pressure, lipid profile, fasting glucose, and 10-year (e.g., QRISK3 or SCORE). Management includes aggressive control of disease activity with DMARDs, lifestyle modification, and statin therapy when indicated. The treat-to-target approach reduces cardiovascular risk ^[380]^D5.

Pulmonary:

ILD is increasingly recognized in PsA, with a pooled prevalence of 5-10% in recent meta-analyses ^[123]^A1a^[401]^A1a. Risk factors include older age, smoking, and longer disease duration ^[173]^D5. ILD may be subclinical or present with dyspnea, cough, and restrictive pattern on . High-resolution CT chest is diagnostic. Management involves smoking cessation, pulmonary rehabilitation, and cautious use of (which can cause pneumonitis). Biologic DMARDs, particularly TNF inhibitors, may improve or stabilize ILD in some cases. Cases of PsA overlapping with (anti-Jo-1 positive) have been reported, presenting with ILD, myositis, and mechanic's hands ^[402]^C4.

Metabolic Syndrome

Metabolic syndrome (abdominal obesity, hypertension, dyslipidemia, insulin resistance) is present in 40-50% of PsA patients, nearly double the general population ^[391]^A1a. Chronic inflammation drives insulin resistance and dyslipidemia. Screening: waist circumference, blood pressure, fasting glucose, lipid panel annually. Management: lifestyle intervention, if , for dyslipidemia. Disease-modifying therapy may improve metabolic parameters.

Other Systems

Renal involvement is rare but can include or secondary amyloidosis from chronic inflammation. Neurological involvement is uncommon; however, PsA patients may have higher risk of or entrapment neuropathies. A study found serum immunoreactivity to neurofilament in PsA, suggesting possible neuronal involvement, but clinical significance is unclear ^[258]^B3b.

Screening and Monitoring Summary

A systematic approach to screening for extra-articular manifestations is recommended at diagnosis and annually: ophthalmology referral for any eye symptoms; gastrointestinal symptom inquiry; cardiovascular risk assessment; pulmonary function tests if symptoms or risk factors; metabolic syndrome screening. Early detection and organ-specific management improve outcomes and reduce comorbidity burden.

Pearl: Extra-articular involvement in PsA is common and impacts management: uveitis requires urgent ophthalmology referral, IBD may guide biologic choice, and cardiovascular risk screening should be performed annually in all patients.

Screening Recommendations for Extra-Articular Manifestations in PsA

Organ System	Manifestation	Screening Method	Frequency
Eyes	Acute anterior uveitis	Symptom inquiry; ophthalmology referral if symptoms	At diagnosis and annually
Gastrointestinal	Inflammatory bowel disease	Symptom inquiry (diarrhea, abdominal pain, weight loss)	At diagnosis and annually
Cardiovascular	Hypertension, dyslipidemia, diabetes	Blood pressure, lipid profile, fasting glucose, 10-year risk score	Annually
Pulmonary	Interstitial lung disease	Symptom inquiry; pulmonary function tests if symptoms or risk factors	At diagnosis if risk factors; as needed
Metabolic	Metabolic syndrome	Waist circumference, blood pressure, fasting glucose, lipid panel	Annually

Complications: Disease-Driven & Treatment-Related

▸Cardiovascular disease is the leading cause of excess mortality in PsA (pooled RR 1.39); disease-specific risk calculators that incorporate inflammation markers outperform generic algorithms.
▸Serious infection risk differs by drug class: IL-23i and ustekinumab carry the lowest risk; JAKi increase herpes zoster; TNFi have intermediate risk. Screening for HBV and TB is mandatory before biologic initiation.
▸JAKi use is associated with a 1.5-fold increased malignancy risk vs TNFi (excluding NMSC) and a dose-dependent VTE risk; use with caution in patients aged ≥50 years with CV risk factors.

! Warning: JAK inhibitors carry a US FDA boxed warning for serious infections, malignancy, thrombosis, and MACE, particularly in patients aged ≥50 years with at least one cardiovascular risk factor. Use the lowest effective dose and reassess risk-benefit annually.

Morbidity in psoriatic arthritis arises from two intertwined sources: the cumulative burden of systemic inflammation and the iatrogenic effects of chronic immunosuppression. Distinguishing between them is essential, because of one often modifies risk for the other.

Cardiovascular Disease and Metabolic Syndrome

Disease-driven cardiovascular (CV) risk is substantial and independent. A nationwide Swedish cohort of 16,497 patients with PsA found a 24% increased mortality compared with the general population (HR 1.24, 95% CI 1.12-1.36), driven predominantly by cardiovascular deaths ^[412]^B2b (2b). A meta-analysis of 19 studies confirmed a pooled relative risk for all-cause mortality of 1.39 (95% CI 1.18-1.64) ^[78]^A1a (1a). The CV risk is linked to both traditional factors, obesity, , dyslipidaemia, and disease-specific drivers such as persistently active inflammation. The EULAR 2009 task force recommends that patients with PsA be assessed for CV risk factors at least every 5 years, with recalculation using a multiplier of 1.5 applied to the standard SCORE algorithm ^[405]^A1c (1c). The metabolic syndrome is present in approximately 44% of patients with PsA, significantly higher than in matched controls ^[410]^B2b (2b). A disease-specific CV risk prediction model that incorporates PsA activity measures, swollen joint count, C-reactive protein, psoriasis severity, has been derived and internally validated; it reclassifies 18% of patients into a higher risk category compared with the Framingham Risk Score alone ^[425]^B2b (2b). Carotid ultrasound is increasingly used: in a cohort of 250 patients, 62% had plaque in ≥2 vascular beds, and plaque detection upgraded SCORE2 risk category in 28% of those aged 50-69 years ^[444]^C4 (4).

Infection

Treatment-related harm dominates infection risk. A multi-database cohort study comparing ustekinumab with other biologics in patients with psoriasis or PsA reported adjusted hazard ratios for serious infection (requiring hospitalisation) of 1.29 (95% CI 1.07-1.56) for , 1.23 (95% CI 1.02-1.49) for , and 1.19 (95% CI 0.95-1.50) for secukinumab, each versus ustekinumab ^[80]^B2b (2b). In 19,041 adalimumab-exposed patients across indications, the serious infection rate was 3.9 events per 100 patient-years; pneumonia and were most common ^[407]^B2c (2c). IL-23 inhibitors have a favourable infection profile: across PsO/PsA trials, the rate of tuberculosis reactivation was 0.05 per 100 patient-years, and no cases were reported among patients screened and treated for latent TB ^[112]^B2a (2a). For JAK inhibitors, pooled RCT data show a serious infection rate of 2.5-3.5 events per 100 patient-years, comparable with TNFi in network meta-analyses, but is consistently elevated (IRR 2.0-2.5 versus placebo), particularly with tofacitinib and baricitinib ^[421]^A1a (1a). Perioperative infection risk is similarly increased with ongoing bDMARDs; the Cochrane review (2026) recommends holding anti-TNF and other biologics for one dosing cycle before elective surgery, with resumption after wound healing ^[288]^A1a (1a).

Malignancy

The association between JAK inhibitors and malignancy emerged prominently from the ORAL Surveillance trial, in which tofacitinib demonstrated an increased risk of malignancy (excluding NMSC) versus TNFi in patients aged ≥50 years with RA plus CV risk factors. A meta-analysis of 31 RCTs across disease indications found an incidence rate ratio for malignancy (excluding NMSC) of 1.48 (95% CI 1.04-2.10) for JAKi versus TNFi ^[67]^A1a (1a). For abatacept, a recent meta-analysis of 16 RCTs and 14 observational studies found no significant increase in malignancy risk compared with placebo (IRR 1.02, 95% CI 0.75-1.38) or TNFi (IRR 0.88, 95% CI 0.68-1.13) ^[91]^A1a (1a). In patients with a prior cancer, exposure to TNFi is not associated with an increased risk of recurrence (RR 1.02, 95% CI 0.72-1.44) ^[413]^A1a (1a). Non- skin cancer is elevated with all TNFi and ustekinumab over extended exposure, warranting annual skin exam.

Osteoporosis and Fracture

PsA is independently associated with reduced bone mineral density. In a cohort of 1,479 patients, 20% had osteoporosis at the femoral neck; disease activity measures (swollen joint count, ESR) predicted progression to osteoporotic-range BMD ^[104]^B2b (2b). Mendelian randomisation data from UK Biobank support a causal link: genetically predicted PsA was associated with lower heel estimated bone mineral density (beta -0.08 SD, P = 0.003) ^[422]^B2b (2b). Glucocorticoid use amplifies this risk; a -induced osteopathy (fractures of the tibia or foot) is a rare but recognised complication, described in 92 patients, predominantly postmenopausal women with well-controlled RA or PsA ^[100]^C4 (4).

Hepatic, Haematologic, and Autoimmune Complications

Methotrexate can cause transaminitis and, rarely, hepatotoxicity; routine monitoring is standard. TNFi and IL-17i have been associated with and, less commonly, demyelinating syndromes ^[436]^D5 (5). Hepatitis B reactivation risk is clinically relevant: a meta-analysis of 12 studies found a pooled reactivation rate of 8% (95% CI 4-14%) in patients with resolved HBV on anti-TNF, with rates substantially lower with antiviral prophylaxis (RR 0.12, 95% CI 0.03-0.54) ^[414]^A1a (1a). Screening for HBV before starting any bDMARD or JAKi is mandatory. Abatacept has a low rate of infusion reactions (2%); occurs in <0.1%.

Venous Thromboembolism and MACE with JAK Inhibitors

JAK inhibitors carry a dose-dependent signal for venous thromboembolism. In the integrated upadacitinib programme (RA, PsA, AS), the VTE rate was 0.4 events per 100 patient-years for 15 mg and 0.8 per 100 patient-years for 30 mg, versus 0.2 for adalimumab ^[419]^B2c (2c). Major adverse cardiovascular event (MACE) rates were similar, but the US FDA maintains a boxed warning for tofacitinib and upadacitinib for thrombosis and MACE in patients aged ≥50 years with ≥1 CV risk factor.

Pearl: Cardiovascular disease is the dominant cause of excess mortality in PsA; the EULAR multiplier of 1.5 × SCORE is a minimal recommendation, consider direct imaging (carotid ultrasound) for patients with active disease or multiple risk factors ^[405]^A1c^[425]^B2b.

Risk of Serious Infection Across Drug Classes in PsA

Drug Class	Serious Infection Rate (per 100 PY)	Herpes Zoster IRR vs Placebo	TB Reactivation Risk	Key Modifiers
TNFi (adalimumab)	3.9 ^[407]^B2c	~1.5	Intermediate	Screen HBV/TB; hold peri-op ^[288]^A1a
IL-17i (secukinumab)	~2.8 ^[411]^B2c	~1.2	Low	Candida risk; avoid in IBD
IL-23i (guselkumab)	~1.9 ^[80]^B2b	~1.1	Very low (0.05/100 PY) ^[112]^B2a	Favourable overall profile
IL-12/23i (ustekinumab)	~1.7 ^[80]^B2b	~1.0 (reference)	Low	Reference safety comparator
JAKi (tofacitinib)	2.5-3.5 ^[421]^A1a	2.0-2.5	Intermediate	VTE/MACE boxed warning; age ≥50 + CV risk

History and Evolution of Treatment

▸The biologics era began with the etanercept proof-of-concept trial in 2000, demonstrating TNFi efficacy and opening the door for subsequent targeted therapies [449].
▸Selective targeting of the IL-23/IL-17 axis, via IL-17A (secukinumab), IL-17AF (bimekizumab), or IL-23p19 (guselkumab), now provides ACR20 response rates exceeding 60-70% in most pivotal trials [141, 203, 204].
▸The STAMP trial established that an early intensive biologic-first treat-to-target strategy is superior to traditional step-up csDMARD therapy [202].

HY High Yield: The STAMP trial's absolute risk increase for achieving MDA with early intensive secukinumab was 20% over step-up therapy at 1 year, supporting earlier biologic initiation [202].

The treatment of psoriatic arthritis (PsA) has undergone a dramatic transformation over the past 25 years, moving from a reliance on non-steroidal anti-inflammatory drugs (NSAIDs) and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to a targeted biologic and small-molecule era driven by an improved understanding of the IL-23/IL-17 axis.

The Pre-Biologic Era

Before 2000, PsA was often treated with NSAIDs for mild disease and csDMARDs such as , sulfasalazine, and leflunomide for more severe presentations. Evidence for these agents was weak, derived largely from small, uncontrolled studies and extrapolation from rheumatoid arthritis. Oral glucocorticoids were used despite a lack of efficacy data and the risk of flaring psoriasis upon withdrawal, leading the 2023 EULAR recommendations to explicitly state they are not recommended for PsA ^[64]^A1c. Apremilast, a phosphodiesterase-4 inhibitor, was introduced later as an oral option for mild-to-moderate disease but its effect size is modest: in DMARD-naïve patients at 5 years, 65.8% had an ACR20 response with apremilast 30 mg twice daily, but retention was only 45.5% ^[416]^A1b.

The TNF Inhibitor Revolution

The pivotal proof-of-concept came in 2000 with the first randomized trial of a tumor necrosis factor inhibitor (TNFi) in PsA. 25 mg twice weekly significantly improved Psoriatic Arthritis Response Criteria (PsARC) at 12 weeks compared to placebo (87% vs 23%) ^[449]^A1b. This trial opened the biologic era, and subsequent studies with , , golimumab, and certolizumab pegol confirmed TNFi efficacy across all PsA domains, peripheral arthritis, enthesitis, dactylitis, and skin disease. The GO-VIBRANT trial demonstrated that intravenous golimumab 2 mg/kg inhibited radiographic progression at 1 year, with a mean change in PsA-modified Sharp/van der Heijde score of 0.20 vs 1.57 for placebo ^[198]^A1b. The GOLMePsA trial later showed that in early, untreated PsA, golimumab plus methotrexate was superior to methotrexate plus corticosteroids for attaining Disease Activity Score-28 remission (54% vs 23%) ^[199]^A1b. Tumor necrosis factor inhibitors remain a cornerstone of first-line biologic therapy in many guidelines ^[265]^A1c.

The IL-23/IL-17 Axis Paradigm

A watershed moment was the recognition of the IL-23/T-helper 17 cell pathway as central to PsA pathogenesis. Ustekinumab, a monoclonal antibody targeting the p40 subunit shared by IL-12 and IL-23, showed efficacy in a phase II trial in 2009 (ACR20 at 12 weeks: 42% vs 14%) ^[143]^A1b, but it was the selective targeting of IL-17A that truly redefined the field.

Secukinumab, the first IL-17A inhibitor approved for PsA, achieved ACR20 responses of 51% at 24 weeks in the FUTURE 2 trial ^[141]^A1b. The EXCEED trial directly compared secukinumab 300 mg with adalimumab 40 mg every 2 weeks as first-line biologic monotherapy; secukinumab was non-inferior but not superior for ACR20 at week 52 (67.4% vs 65.2%) ^[206]^A1b. Secukinumab also inhibits radiographic progression, with a mean change in vdH-mTSS of 0.15 over 2 years in FUTURE 5 ^[149]^A1b. Ixekizumab, another IL-17A inhibitor, showed ACR20 responses of 62% at 24 weeks in biologic-naïve patients in SPIRIT-P1 ^[193]^A1b. Bimekizumab, which uniquely neutralizes both IL-17A and IL-17F, demonstrated ACR20 responses of 62% at 16 weeks in biologic-naïve patients (BE OPTIMAL) ^[204]^A1b. Dual inhibition may provide deeper suppression of chronic tissue inflammation ^[190]^A1b.

Subsequent targeting of IL-23 specifically (without IL-12) with guselkumab, risankizumab, and tildrakizumab further validated this pathway. In the DISCOVER-2 trial, guselkumab 100 mg every 4 weeks achieved ACR20 in 64% of biologic-naïve patients at 24 weeks ^[203]^A1b. The KEEPsAKE 1 trial found risankizumab 150 mg yielded ACR20 in 70% of csDMARD-IR patients at week 24 ^[128]^A1b.

The JAK Inhibitor Era

Janus kinase (JAK) inhibitors offer oral alternatives with rapid onset. Tofacitinib, the first JAK inhibitor in PsA, demonstrated ACR20 responses of 50% with 5 mg twice daily in csDMARD-IR patients from OPAL Broaden ^[212]^A1b. Upadacitinib 15 mg once daily was non-inferior to adalimumab for ACR20 at week 12 (71% vs 66%) in SELECT-PsA 1 ^[73]^A1b. Deucravacitinib, a selective TYK2 inhibitor, represents the newest class. At week 16, deucravacitinib 6 mg and 12 mg once daily achieved ACR20 in 53% and 63%, respectively, vs 32% for placebo ^[192]^A1b.

Abandoned Approaches and Lessons

Several strategies were abandoned due to lack of efficacy or unacceptable toxicity. IL-1 inhibition (anakinra) failed to show meaningful benefit. IL-6 inhibition ( ) had inconsistent results. Brodalumab, an anti-IL-17 receptor A antibody, showed efficacy but was withdrawn voluntarily due to suicidality signals ^[345]^A1b. Oral fumaric acid esters, used in Germany, have limited evidence in PsA and inconsistent formulations ^[361]^A1a. The MUST trial clarified that adding methotrexate to ustekinumab does not improve DAS28 at 24 weeks compared to ustekinumab monotherapy ^[269]^A1b, challenging the reflex use of combination csDMARD+biologic in PsA.

The Treat-to-Target Paradigm

The STAMP trial demonstrated that an intensive strategy starting with secukinumab plus methotrexate was superior to a step-up approach for achieving minimal disease activity at 1 year (61% vs 41%) ^[202]^A1b, supporting earlier biologic use.

Pearl: The evolution of PsA treatment from empirical NSAIDs and csDMARDs to targeted biologics and JAK inhibitors, grounded in the IL-23/IL-17 axis, represents one of the most successful translational stories in rheumatology, with ACR20 response rates rising from 25% with placebo to over 70% with modern therapies ^[73]^A1b^[128]^A1b.

Landmark Trials by Drug Class

Drug Class	Agent	Pivotal Trial	Key Result (ACR20 at primary endpoint)
TNFi	Etanercept	Mease et al. 2000 ^[449]^A1b	87% (PsARC) vs 23% placebo at week 12
TNFi	Golimumab IV	GO-VIBRANT ^[198]^A1b	76.5% vs 25.9% at week 14
IL-17A	Secukinumab	FUTURE 2 ^[141]^A1b	51% (300 mg) vs 15% placebo at week 24
IL-17AF	Bimekizumab	BE OPTIMAL ^[204]^A1b	62.4% vs 19.8% placebo at week 16
IL-23	Guselkumab	DISCOVER-2 ^[203]^A1b	64% (Q4W) vs 33% placebo at week 24
IL-23	Risankizumab	KEEPsAKE 1 ^[128]^A1b	70% vs 42% placebo at week 24
JAK	Upadacitinib	SELECT-PsA 1 ^[73]^A1b	71% (15 mg) vs 36% placebo at week 12
JAK	Tofacitinib	OPAL Broaden ^[212]^A1b	50% (5 mg) vs 33% placebo at month 3
TYK2	Deucravacitinib	Phase II ^[192]^A1b	63% (12 mg) vs 32% placebo at week 16

Prognosis & Natural History

▸Untreated PsA progresses radiographically at ~1 unit/year; structural repair is infrequent (23%) and limited to mild disease [253].
▸A diagnostic delay >1 year reduces the odds of 3-year MDA by nearly half (OR 0.56), supporting a window of opportunity [256].
▸Intensive treat-to-target with first-line IL-17i (secukinumab) doubles MDA rates at 1 year vs step-up (62 vs 40%; NNT=5) [202].
▸All-cause mortality is increased 36% (RR 1.36) vs general population, driven by cardiovascular death (RR 1.49) [78].

HY High Yield: A diagnostic delay >1 year reduces the odds of achieving minimal disease activity at 3 years by 44% (OR 0.56), a reminder to rheumatologists and dermatologists to refer early for any inflammatory musculoskeletal symptoms [256].

The Natural Course: From Synovitis to Structural Damage

Psoriatic arthritis is a progressive disease. Without effective treatment, the majority of patients accumulate irreversible joint damage over time. In a landmark longitudinal cohort, radiographic damage (modified Steinbrocker score) progressed at a mean rate of approximately 1 unit per year; importantly, repair was observed in only 23% of patients over a 4-year interval, and was more likely in joints with mild baseline damage (grade 1) ^[253]^B2b. The trajectory is not uniform, oligoarticular onset often evolves into a polyarticular pattern in 30-40% of cases within 5 years, and the presence of polyarticular disease at diagnosis is itself a poor prognostic sign ^[213]^A1a^[256]^B2b.

Predictors of Rapid Progression

Several baseline features consistently identify patients at risk for a more aggressive course. The most powerful clinical predictors are ≥5 swollen joints (the threshold used in DISCOVER-2 trial eligibility) ^[203]^A1b, elevated acute-phase reactants (C-reactive protein ≥0.6 mg/dL) at presentation ^[132]^A1b^[203]^A1b, and early erosive disease on plain radiographs, particularly at the metacarpophalangeal and proximal interphalangeal joints ^[196]^A1b^[253]^B2b. The presence of dactylitis and enthesitis at first visit also associates with higher disease activity scores at 1 year ^[213]^A1a. Socio-demographic factors matter: a diagnostic delay >1 year (total delay from symptom onset to rheumatologist diagnosis) reduced the odds of achieving minimal disease activity (MDA) at 3-year follow-up compared to delay <12 weeks (OR 0.56, 95% CI 0.32-0.99) ^[256]^B2b. This supports the concept of a window of opportunity in early PsA.

The Impact of Treat-to-Target and Modern Biologics

The natural history can be substantially altered. The STAMP trial directly compared an intensive first-line strategy (secukinumab 150 mg every 4 weeks plus csDMARDs) against a step-up approach with first. At 1 year, the intensive strategy achieved MDA in 62.0% versus 39.6% (risk ratio 1.57, 95% CI 1.24-1.99; NNT = 5 to achieve one additional MDA response) ^[202]^A1b. Long-term extension data from the DISCOVER-2 trial of guselkumab showed that ACR20 response rates were maintained at 88% through 2 years, and radiographic progression (van der Heijde-Sharp score) was essentially halted (mean change from baseline 0.46 units at 2 years) ^[132]^A1b. Similarly, bimekizumab (inhibiting IL-17A and IL-17F) through 3 years of follow-up (BE OPTIMAL / BE COMPLETE → BE VITAL) sustained ACR20 response in 73-77% of patients, with exposure-adjusted serious adverse event rates of 7-8 per 100 patient-years ^[339]^B2b^[83]^B2b. This is a dramatic contrast to the pre-biologic era, where disability accumulated relentlessly.

Remission and Flare Patterns

Sustained remission is achievable but not guaranteed. In a systematic literature review, pooled rates of MDA in PsA cohorts were 39-44% with bDMARDs at 12 months, and rates of DAPSA remission were 18-24% ^[92]^A1a. Flares remain common: among patients who have achieved target, approximately 30-40% experience a clinically significant flare within 12 months, often triggered by concomitant infection, stress, or obesity ^[294]^D5. Tapering of TNF inhibitors in stable low disease activity (the DRESS-PS trial) showed that a structured tapering strategy is non-inferior to continuation over 12 months (NNT not calculable from reported data) ^[238]^B2b; however, 31% eventually flared after tapering, suggesting the need for vigilant monitoring.

Mortality and Long-Term Survival

All-cause mortality in PsA is increased relative to the general population. A recent meta-analysis of 11 cohort studies reported a pooled RR of 1.36 (95% CI 1.14-1.62) for all-cause mortality ^[78]^A1a. The leading cause of excess death is cardiovascular disease (CVD); the RR for CV mortality was 1.49 (95% CI 1.16-1.91) ^[78]^A1a. This excess risk is driven by both the systemic inflammatory burden and a high prevalence of modifiable comorbidities (metabolic syndrome, smoking, obesity). Effective inflammatory control with biologics and lifestyle intervention reduces CV risk, but it rarely normalizes it entirely ^[103]^B2b.

Controversies and Guideline Disagreement

Question	EULAR 2023 Position	ACR/NPF 2018 Position	Strength	Implication
Is axial PsA truly identical to ankylosing spondylitis?	Axial PsA is a distinct phenotype with less severe radiographic sacroiliitis and a lower HLA-B27 prevalence (~25% vs 90%) ^[250]^D5.	Not explicitly separated; guidelines apply AS principles axial PsA ^[189]^A1c.	EULAR places more emphasis on phenotypic distinction.	Affects choice of biologic (IL-17i vs TNFi) and need for MRI-based monitoring.
Should JAK inhibitors be used before TNFi in patients with high CV risk?	EULAR recommends caution; JAKi should be avoided in patients with major adverse CV event (MACE) history or age ≥65 years ^[64]^A1c.	ACR/NPF does not provide a strong recommendation against JAKi in this group ^[189]^A1c.	Guideline disagreement on JAKi safety profile.	EULAR position is more conservative; requires shared decision-making with cardiology.

Pearl: PsA natural history is modifiable, early treat-to-target (particularly with IL-17 or IL-23 inhibitors) can achieve sustained MDA in >50% of patients and slow radiographic progression, but the cardiovascular mortality excess persists even with optimal inflammatory control, mandating aggressive comorbidity management ^[78]^A1a^[202]^A1b^[256]^B2b.

Key Prognostic Factors in Psoriatic Arthritis

Factor	Impact on Prognosis	Evidence Source
Polyarticular onset (≥5 swollen joints)	More rapid radiographic progression, lower remission rates	DISCOVER-2 ^[203]^A1b, Toronto cohort ^[253]^B2b
Elevated CRP at baseline	Independent predictor of joint damage and MACE	DISCOVER-2 ^[203]^A1b, meta-analysis ^[78]^A1a
Diagnostic delay >12 months	OR 0.56 for 3-year MDA vs delay <12 weeks	Dutch EARP cohort ^[256]^B2b
Obesity (BMI ≥30)	Lower TNFi response rates, higher disease activity	Mechanisms review ^[294]^D5
Baseline enthesitis/dactylitis	Higher disease activity at 1 year, increased disability	SLR ^[213]^A1a

Special Populations, Pregnancy & Prevention

▸Pregnancy requires continuation of TNF inhibitors (preferably certolizumab) to control disease and reduce adverse outcomes; methotrexate and leflunomide are contraindicated.
▸Vaccination, including influenza, pneumococcal, herpes zoster, and COVID-19, is safe and recommended; withholding methotrexate for 2 weeks after COVID-19 vaccine improves response.
▸Prevention of PsA in psoriasis patients is an emerging field; the PRESTO tool identifies high-risk individuals, and biologic therapy may reduce transition risk.

HY High Yield: Withhold methotrexate for 2 weeks after COVID-19 vaccination to improve antibody response without increasing flare risk [270].

HY High Yield: Certolizumab pegol has minimal placental transfer and is the preferred TNF inhibitor during pregnancy [470].

Pregnant women with PsA face a 1.5-fold increased risk of preterm birth, and disease activity during pregnancy directly influences outcomes ^[477]^A1a^[486]^B2b. across special populations, including pediatrics, pregnancy, elderly, and the immunocompromised, requires tailored modifications to pharmacotherapy, vaccination, and prevention strategies.

Pediatrics

Juvenile psoriatic arthritis (jPsA) accounts for 5-10% of juvenile idiopathic arthritis cases. Presentation often includes oligoarthritis, dactylitis, and enthesitis, with psoriasis developing after arthritis in many children ^[492]^A1a. Diagnosis relies on clinical judgment as CASPAR criteria are not validated in children. Treatment follows JIA guidelines: NSAIDs, intra-articular steroids, and DMARDs. is first-line csDMARD at 10-15 mg/m2/week (max 25 mg) ^[498]^B3b. is the most studied biologic in jPsA; in the CARRA Registry, 226 children on etanercept showed low serious adverse event rates (1.3 per 100 patient-years) and improved disease activity ^[501]^B2b. Tofacitinib is approved for polyarticular JIA including jPsA; a phase 3 withdrawal trial demonstrated efficacy with a safety profile similar to adults ^[205]^A1b. Guselkumab was recently FDA-approved for jPsA based on extrapolation from adult PsA and pediatric psoriasis data ^[490]^D5. Drug survival of methotrexate in pediatric psoriasis is superior to acitretin and ^[498]^B3b. Growth and bone health require monitoring; disease control improves final height.

Pregnancy

Disease activity often improves during pregnancy, but flares occur postpartum in up to 40% ^[282]^B2b. Active disease increases risks of preterm birth (7.8% vs 4.5%; aOR 1.8, 95% CI 1.3-2.5; NNH 30), pre-eclampsia (aOR 1.5), and low birth weight ^[477]^A1a^[486]^B2b^[487]^B2b. Treatment modifications are critical: methotrexate and leflunomide are contraindicated and should be stopped at least 3 months before conception. Sulfasalazine and hydroxychloroquine are safe. TNF inhibitors are generally continued throughout pregnancy, with certolizumab pegol preferred due to minimal placental transfer (cord blood levels <0.032 μg/mL) ^[470]^B2b. and have active placental transfer in the third trimester; some guidelines suggest stopping at 30-32 weeks if disease is controlled ^[354]^D5. Ustekinumab and IL-17 inhibitors have limited safety data; ustekinumab shows no increased malformation risk in small studies ^[281]^D5. JAK inhibitors are avoided. Delivery planning: vaginal delivery is preferred; caesarean section rates are higher in PsA (OR 1.3) ^[332]^B2b. is safe with TNF inhibitors, sulfasalazine, and (<20 mg/day).

Elderly

Older adults with PsA have higher comorbidity burden, including cardiovascular disease and renal impairment. Methotrexate requires dose adjustment for renal function; toxicity risk is increased with concurrent diuretics (all cases in one series were >70 years on diuretics) ^[500]^C4. Etanercept safety in elderly is comparable to younger patients, with no increased serious infection risk ^[471]^B2b. TNF inhibitors are preferred over JAK inhibitors due to lower risk of thromboembolic events and . Disease activity targets may be relaxed in frail patients to avoid overtreatment. Mortality is increased in PsA (HR 1.4) ^[493]^B2b.

Immunocompromised and Vaccination

Patients on immunosuppressive therapy are at increased infection risk. Vaccination is a cornerstone of preventive care. Influenza vaccine is safe and immunogenic ^[468]^B3b. Pneumococcal vaccine (PCV13 and PPSV23) is recommended; uptake is low (40%) but vaccination does not trigger disease flare ^[478]^B3b^[494]^B2b. Herpes zoster risk is elevated in PsA (IRR 1.5-2.0); recombinant zoster vaccine is recommended for adults ≥50 years and can be given on immunosuppression ^[483]^B3b. vaccination: withholding methotrexate for 2 weeks after each dose improves antibody response without increasing flare (MIVAC trial) ^[270]^A1b. A third and fourth dose are beneficial in patients on biologics ^[476]^B2b^[481]^B2b. Vaccination does not increase disease activity ^[334]^B2b. Perioperative management: ACR guidelines recommend continuing csDMARDs (methotrexate, sulfasalazine) through surgery, withholding TNF inhibitors for one dosing cycle before surgery, and restarting when wound healing is adequate ^[298]^A1c^[303]^A1c^[288]^A1a.

Vaccine	Recommendation	Timing	Special Considerations
Influenza	Annual	Before flu season	Safe on all DMARDs
Pneumococcal	PCV13 then PPSV23	At diagnosis	Repeat PPSV23 after 5 years
Herpes Zoster	Recombinant (RZV)	Age ≥50 years	Can be given on biologics
COVID-19	Primary series + boosters	Per local guidelines	Withhold MTX for 2 weeks post-dose

Prevention: From Psoriasis to Psoriatic Arthritis

Up to 30% of psoriasis patients develop PsA. Identifying high-risk individuals enables early intervention. The PRESTO tool uses clinical variables (age, psoriasis severity, nail involvement, BMI) to predict 1-year and 5-year risk (AUC 0.82) ^[482]^B2b. EULAR points to consider define subclinical PsA as arthralgia with imaging abnormalities in the absence of clinical synovitis ^[96]^D5. Biologic therapy for psoriasis, particularly IL-17 and IL-23 inhibitors, may reduce the risk of incident PsA (HR 0.6-0.7) ^[499]^D5. However, prevention trials are ongoing, and routine screening with validated questionnaires (e.g., PEST, PASE) is recommended in dermatology clinics ^[497]^D5. Secondary prevention focuses on treat-to-target to prevent joint damage and disability.

Pearl: Pregnant women with PsA should continue TNF inhibitors (preferably certolizumab) to control disease activity and reduce adverse pregnancy outcomes; withholding methotrexate for 2 weeks after COVID-19 vaccination improves immunogenicity without increasing flare risk ^[270]^A1b^[470]^B2b^[486]^B2b.

References

[1]
Reinisch W, Hellstrom W, Dolhain RJEM et al.. “Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies.” Annals of the rheumatic diseases (2023). PMID: 37137672 ↗
L1RCTCited in: Definition, Classification & Nomenclature
[2]
Hollick RJ, Macfarlane GJ. “Association of Rural Setting With Poorer Disease Outcomes for Patients With Rheumatic Diseases: Results From a Systematic Review of the Literature.” Arthritis care & research (2021). PMID: 32170834 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Severity, Disease Activity & Risk Stratification
[3]
Winthrop KL, Mease P, Kerschbaumer A et al.. “Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.” Annals of the rheumatic diseases (2024). PMID: 38123338 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[4]
Winthrop KL, Bathon J, Kerschbaumer A et al.. “Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024.” Annals of the rheumatic diseases (2025). PMID: 40240265 ↗
L5OTHERCited in: Definition, Classification & Nomenclature
[5]
Zayat AS, Ellegaard K, Conaghan PG et al.. “The specificity of ultrasound-detected bone erosions for rheumatoid arthritis.” Annals of the rheumatic diseases (2014). PMID: 24445255 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[6]
Helliwell PS, Porter G, Taylor WJ. “Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis.” Annals of the rheumatic diseases (2006). PMID: 16840501 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[7]
Polachek A, Furer V, Zureik M et al.. “Role of ultrasound for assessment of psoriatic arthritis patients with fibromyalgia.” Annals of the rheumatic diseases (2021). PMID: 34215648 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[8]
Duer A, Østergaard M, Hørslev-Petersen K et al.. “Magnetic resonance imaging and bone scintigraphy in the differential diagnosis of unclassified arthritis.” Annals of the rheumatic diseases (2007). PMID: 17289759 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[9]
Mandl LA, Zhu R, Huang WT et al.. “Short-Term Total Hip Arthroplasty Outcomes in Patients With Psoriatic Arthritis or Psoriatic Skin Disease Compared to Patients With Osteoarthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26360522 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[10]
Labitigan M, Bahče-Altuntas A, Kremer JM et al.. “Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis.” Arthritis care & research (2014). PMID: 24115739 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[11]
Mease P, Reed G, Ogdie A et al.. “Prevalence of Fibromyalgia and Widespread Pain in Psoriatic Arthritis: Association With Disease Severity Assessment in a Large US Registry.” Arthritis care & research (2024). PMID: 38736168 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target
[12]
Chaudhry ZS, Nellessen N, Reis C et al.. “The development of inflammatory arthritis following SARS-CoV-2 infection: a systematic review of the literature.” Family practice (2022). PMID: 35395090 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[13]
Hanna N, Silverberg OM, Reaume M et al.. “Incidence, prevalence, and predictors of inflammatory arthritis in patients with hidradenitis suppurativa: a systematic review and meta-analysis.” International journal of dermatology (2021). PMID: 34432308 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[14]
Chessa E, Piga M, Floris A et al.. “Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review.” BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2021). PMID: 33595833 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[15]
Mitrovic S, Hassold N, Kamissoko A et al.. “Adult-onset Still's disease or systemic-onset juvenile idiopathic arthritis and spondyloarthritis: overlapping syndrome or phenotype shift?” Rheumatology (Oxford, England) (2022). PMID: 34559214 ↗
L4OTHERCited in: Definition, Classification & Nomenclature
[16]
Ogdie A, Maliha S, Shin D et al.. “Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis.” Rheumatology (Oxford, England) (2017). PMID: 28158384 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Complications: Disease-Driven & Treatment-Related
[17]
Folle L, Bayat S, Kleyer A et al.. “Advanced neural networks for classification of MRI in psoriatic arthritis, seronegative, and seropositive rheumatoid arthritis.” Rheumatology (Oxford, England) (2022). PMID: 35333316 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[18]
Cutolo M, Soldano S, Smith V et al.. “Dynamic macrophage phenotypes in autoimmune and inflammatory rheumatic diseases.” Nature reviews. Rheumatology (2025). PMID: 40721670 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[19]
Schlereth M, Mutlu MY, Utz J et al.. “Deep learning-based classification of erosion, synovitis and osteitis in hand MRI of patients with inflammatory arthritis.” RMD open (2024). PMID: 38886001 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[20]
Stouten V, Pazmino S, Verschueren P et al.. “Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study.” RMD open (2021). PMID: 34158353 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[21]
Hen O, Di Matteo A, Dubash SR et al.. “High prevalence of radiographic erosions in early, untreated PsA: results from the SpARRO cohort.” RMD open (2024). PMID: 38580344 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[22]
Lubrano E, Scriffignano S, Morelli R et al.. “Assessment of Widespread and Extraarticular Pain in Psoriatic Arthritis: A Case-control Study.” The Journal of rheumatology (2021). PMID: 33452167 ↗
L3CASE_CONTROLCited in: Definition, Classification & Nomenclature
[23]
Rebollo-Giménez AI, Rosina S, Natoli V et al.. “Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study.” Clinical and experimental rheumatology (2023). PMID: 38147312 ↗
L2COHORTCited in: Definition, Classification & Nomenclature
[24]
Geenen R, Overman CL, Christensen R et al.. “EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis.” Annals of the rheumatic diseases (2018). PMID: 29724726 ↗
L1GUIDELINECited in: Pathophysiology & Mechanism, History and Evolution of Treatment
[25]
van Mens LJJ, van de Sande MGH, Menegatti S et al.. “Brief Report: Interleukin-17 Blockade With Secukinumab in Peripheral Spondyloarthritis Impacts Synovial Immunopathology Without Compromising Systemic Immune Responses.” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 29869838 ↗
L1TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism
[26]
Marzo-Ortega H, Harrison SR, Fragoulis GE et al.. “EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis.” Annals of the rheumatic diseases (2025). PMID: 41168056 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target
[27]
Rahman P, Siannis F, Butt C et al.. “TNFalpha polymorphisms and risk of psoriatic arthritis.” Annals of the rheumatic diseases (2005). PMID: 16284098 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[28]
Kastrati K, Aletaha D, Burmester GR et al.. “A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.” RMD open (2022). PMID: 36260501 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[29]
Patel DD, Lee DM, Kolbinger F et al.. “Effect of IL-17A blockade with secukinumab in autoimmune diseases.” Annals of the rheumatic diseases (2012). PMID: 23253932 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[30]
McGonagle D, Ash Z, Dickie L et al.. “The early phase of psoriatic arthritis.” Annals of the rheumatic diseases (2011). PMID: 21339224 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[31]
Reveille JD. “The genetic basis of spondyloarthritis.” Annals of the rheumatic diseases (2011). PMID: 21339218 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[32]
Lesturgie-Talarek M, Gonzalez V, Beaudoin L et al.. “Mucosal-Associated Invariant T Cells in Rheumatic Diseases.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40395188 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[33]
Hum RM, Christofi M, Smith SL et al.. “Synovial immunopathology in psoriatic arthritis: cellular and molecular insights.” The Lancet. Rheumatology (2025). PMID: 41043452 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[34]
Macleod T, Bridgewood C, McGonagle D. “Role of neutrophil interleukin-23 in spondyloarthropathy spectrum disorders.” The Lancet. Rheumatology (2023). PMID: 38251507 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[35]
Griffiths CEM, Armstrong AW, Gudjonsson JE et al.. “Psoriasis.” Lancet (London, England) (2021). PMID: 33812489 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
[36]
Griffiths CE, Barker JN. “Pathogenesis and clinical features of psoriasis.” Lancet (London, England) (2007). PMID: 17658397 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation
[37]
Veale DJ, Fearon U. “The pathogenesis of psoriatic arthritis.” Lancet (London, England) (2018). PMID: 29893226 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Severity, Disease Activity & Risk Stratification
[38]
Nagra D, Zuckerman B, Odia J et al.. “The role of interleukin-17 inhibition in systemic lupus erythematosus-paradoxical hindrance or new therapeutic potential? Results from a systematic literature review and mendelian randomization.” Frontiers in immunology (2026). PMID: 41918754 ↗
L3SR_OBSCited in: Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[39]
Zeng J, Lin L, Li W et al.. “Clinical benefits and complication profile of IL-23 inhibitors in patients with psoriatic arthritis: a systematic review and meta-analysis.” Frontiers in pharmacology (2025). PMID: 41282632 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[40]
Tsiogkas SG, Gkouvi A, Kontouli KM et al.. “Janus kinase inhibitors for psoriatic arthritis: Evidence from a systematic review and network meta-analysis.” Autoimmunity reviews (2025). PMID: 40268128 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[41]
López-Medina C, McGonagle D, Gossec L. “Subclinical psoriatic arthritis and disease interception-where are we in 2024?” Rheumatology (Oxford, England) (2025). PMID: 39150442 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Special Populations, Pregnancy & Prevention
[42]
Mease P, van den Bosch F. “IL-23 and axial disease: do they come together?” Rheumatology (Oxford, England) (2021). PMID: 34668015 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation
[43]
White JPE, Coates LC. “JAK1 selective inhibitors for the treatment of spondyloarthropathies.” Rheumatology (Oxford, England) (2021). PMID: 33950224 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[44]
Goldring SR. “Differential mechanisms of de-regulated bone formation in rheumatoid arthritis and spondyloarthritis.” Rheumatology (Oxford, England) (2016). PMID: 27856661 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[45]
Russolillo A, Iervolino S, Peluso R et al.. “Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management.” Rheumatology (Oxford, England) (2012). PMID: 22989426 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Complications: Disease-Driven & Treatment-Related
[46]
Jethwa H, Abraham S. “The evidence for microbiome manipulation in inflammatory arthritis.” Rheumatology (Oxford, England) (2017). PMID: 27789760 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[47]
Nirula A, Nilsen J, Klekotka P et al.. “Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.” Rheumatology (Oxford, England) (2016). PMID: 27856660 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[48]
Abacar K, Rennie WJ, Raychaudhuri SP et al.. “Focusing on ligamentous soft tissue inflammation for the future understanding of early axial psoriatic arthritis.” Rheumatology (Oxford, England) (2024). PMID: 39700474 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[49]
McGonagle D, Hermann KG, Tan AL. “Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era.” Rheumatology (Oxford, England) (2014). PMID: 25231177 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[50]
Schett G, Rahman P, Ritchlin C et al.. “Psoriatic arthritis from a mechanistic perspective.” Nature reviews. Rheumatology (2022). PMID: 35513599 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[51]
Schett G, Lories RJ, D'Agostino MA et al.. “Enthesitis: from pathophysiology to treatment.” Nature reviews. Rheumatology (2017). PMID: 29158573 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation
[52]
Reveille JD, Eder L, Ziade N et al.. “Global epidemiology of spondyloarthritis.” Nature reviews. Rheumatology (2025). PMID: 40954333 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors
[53]
Taams LS, Steel KJA, Srenathan U et al.. “IL-17 in the immunopathogenesis of spondyloarthritis.” Nature reviews. Rheumatology (2018). PMID: 30006601 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria
[54]
McGonagle D, Tan AL, Watad A et al.. “Pathophysiology, assessment and treatment of psoriatic dactylitis.” Nature reviews. Rheumatology (2019). PMID: 30610219 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[55]
Reveille JD. “Genetics of spondyloarthritis--beyond the MHC.” Nature reviews. Rheumatology (2012). PMID: 22487796 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging & Classification Criteria
[56]
Brown MA, Kenna T, Wordsworth BP. “Genetics of ankylosing spondylitis--insights into pathogenesis.” Nature reviews. Rheumatology (2015). PMID: 26439405 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging & Classification Criteria
[57]
Beringer A, Miossec P. “Systemic effects of IL-17 in inflammatory arthritis.” Nature reviews. Rheumatology (2019). PMID: 31227819 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[58]
Miossec P. “Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice.” RMD open (2017). PMID: 28243466 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[59]
Sousa M, Alvarenga JM, Lé AM et al.. “Ustekinumab-associated morphoea: systematic review of the literature and a real-world case.” Drugs in context (2026). PMID: 41695304 ↗
L4SR_OBSCited in: Pathophysiology & Mechanism
[60]
Lombo LE, Tejada-Perdomo JH, Ramos-Castaneda JA et al.. “Vagus Nerve Stimulation in Autoimmune Conditions: A Systematic Review.” ACR open rheumatology (2025). PMID: 41392619 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism
[61]
Zhao J, Wu J, Zhou H et al.. “Genetic evidence of the causal relationship between genetically predicted nutrients and psoriatic arthritis.” Clinical rheumatology (2025). PMID: 41184533 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Special Populations, Pregnancy & Prevention
[62]
Yan H, Chen Y, Song Y et al.. “Vunakizumab for IL-17A-Mediated Diseases: A Review in Psoriasis and Spondyloarthritis.” Biologics : targets & therapy (2026). PMID: 42291469 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[63]
Totolici S, Vrabie AM, Buzea CA et al.. “Cardiovascular Risk in Psoriatic Arthritis: Mechanisms, Risk Assessment, and Long-Term Management Implications.” International journal of molecular sciences (2026). PMID: 42196207 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[64]
Gossec L, Kerschbaumer A, Ferreira RJO et al.. “EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.” Annals of the rheumatic diseases (2024). PMID: 38499325 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[65]
Agca R, Heslinga SC, Rollefstad S et al.. “EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.” Annals of the rheumatic diseases (2016). PMID: 27697765 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
[66]
Brunner HI, Foeldvari I, Alexeeva E et al.. “Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.” Annals of the rheumatic diseases (2022). PMID: 35961761 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[67]
Russell MD, Stovin C, Alveyn E et al.. “JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.” Annals of the rheumatic diseases (2023). PMID: 37247942 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
[68]
Zabotti A, Sakellariou G, Tinazzi I et al.. “Novel and reliable DACTylitis glObal Sonographic (DACTOS) score in psoriatic arthritis.” Annals of the rheumatic diseases (2020). PMID: 32430315 ↗
L4SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[69]
Zeboulon N, Dougados M, Gossec L. “Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review.” Annals of the rheumatic diseases (2007). PMID: 17962239 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[70]
Bing N, Zhou H, Chen X et al.. “Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33455090 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target
[71]
Ramanan AV, Quartier P, Okamoto N et al.. “Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.” Lancet (London, England) (2023). PMID: 37423231 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[72]
Deodhar A, Gottlieb AB, Boehncke WH et al.. “Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.” Lancet (London, England) (2018). PMID: 29893222 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Complications: Disease-Driven & Treatment-Related
[73]
McInnes IB, Anderson JK, Magrey M et al.. “Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.” The New England journal of medicine (2021). PMID: 33789011 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[74]
Huss V, Bower H, Hellgren K et al.. “Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.” Annals of the rheumatic diseases (2023). PMID: 36868796 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[75]
Colaco K, Lee KA, Akhtari S et al.. “Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35261189 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
[76]
Eder L, Haddad A, Rosen CF et al.. “The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26555117 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
[77]
Hellgren K, Smedby KE, Backlin C et al.. “Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.” Arthritis & rheumatology (Hoboken, N.J.) (2014). PMID: 24782185 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target
[78]
Chaudhary H, Bohra N, Syed K et al.. “All-Cause and Cause-Specific Mortality in Psoriatic Arthritis and Ankylosing Spondylitis: A Systematic Review and Meta-Analysis.” Arthritis care & research (2023). PMID: 34788902 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
[79]
Stolwijk C, van Onna M, Boonen A et al.. “Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis.” Arthritis care & research (2016). PMID: 26713432 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[80]
Jin Y, Lee H, Lee MP et al.. “Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis.” Arthritis care & research (2022). PMID: 33973371 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related
[81]
Ishchenko A, Pazmino S, Neerinckx B et al.. “Comorbidities in Early Psoriatic Arthritis: Data From the Metabolic Disturbances in Psoriatic Arthritis Cohort Study.” Arthritis care & research (2024). PMID: 37667975 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification
[82]
Rosenthal YS, Schwartz N, Sagy I et al.. “Incidence of Psoriatic Arthritis Among Patients Receiving Biologic Treatments for Psoriasis: A Nested Case-Control Study.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 34423909 ↗
L3CASE_CONTROLCited in: Epidemiology, Etiology & Risk Factors
[83]
Gossec L, Coates LC, Landewé RBM et al.. “Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.” Rheumatology (Oxford, England) (2026). PMID: 41838419 ↗
L2RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[84]
Singla S, Putman M, Liew J et al.. “Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.” The Lancet. Rheumatology (2023). PMID: 38251522 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target
[85]
Singh M, Phillips K, Wang J et al.. “Trends in the prevalence of autoimmune diseases during pregnancy in the UK, 2000-21: a retrospective cohort study.” The Lancet. Rheumatology (2025). PMID: 40473454 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Pregnancy & Prevention
[86]
Russell MD, Galloway JB, Andrews CD et al.. “Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic: a population-level cohort study using OpenSAFELY.” The Lancet. Rheumatology (2022). PMID: 36447940 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target
[87]
Zabotti A, Bandinelli F, Batticciotto A et al.. “Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review.” Rheumatology (Oxford, England) (2017). PMID: 28521047 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, History and Evolution of Treatment, Prognosis & Natural History
[88]
Hojeij B, Koc GH, Luime JJ et al.. “Psoriatic arthritis flare incidence, definition and risk factors: a systematic review.” Rheumatology (Oxford, England) (2025). PMID: 40392198 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease
[89]
Lembke S, Macfarlane GJ, Jones GT. “The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2024). PMID: 38530786 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[90]
Gazel U, Ayan G, Solmaz D et al.. “The impact of smoking on prevalence of psoriasis and psoriatic arthritis.” Rheumatology (Oxford, England) (2020). PMID: 32500136 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
[91]
Zuckerman BP, Gibson M, Roy R et al.. “Abatacept and the risk of malignancy: a meta-analysis across disease indications.” Rheumatology (Oxford, England) (2025). PMID: 39992258 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
[92]
Hagège B, Tan E, Gayraud M et al.. “Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis.” Rheumatology (Oxford, England) (2020). PMID: 32118267 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
[93]
Pittam B, Gupta S, Harrison NL et al.. “Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2020). PMID: 32160297 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[94]
Coates LC, Landewé R, McInnes IB et al.. “Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.” RMD open (2024). PMID: 38388171 ↗
L1TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History
[95]
Deike M, Brinks R, Meller S et al.. “Risk of psoriatic arthritis depending on age: analysis of data from 65 million people on statutory insurance in Germany.” RMD open (2021). PMID: 34862312 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[96]
Zabotti A, De Marco G, Gossec L et al.. “EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis.” Annals of the rheumatic diseases (2023). PMID: 37295926 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Pregnancy & Prevention
[97]
Karmacharya P, Crowson CS, Bekele D et al.. “The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population-Based Study.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33779070 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[98]
Karreman MC, Weel AE, van der Ven M et al.. “Prevalence of Psoriatic Arthritis in Primary Care Patients With Psoriasis.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26636745 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors
[99]
Di Matteo A, Di Donato S, Smerilli G et al.. “Relationship Between Ultrasound and Physical Examination in the Assessment of Enthesitis in Patients With Spondyloarthritis: Results From the DEUS Multicenter Study.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 39165013 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification
[100]
Robin F, Ghossan R, Mehsen-Cetre N et al.. “METHOFRACT, a methotrexate osteopathy multicentre cohort study.” RMD open (2025). PMID: 40998522 ↗
L4COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
[101]
Eun Y, Hwang J, Seo GH et al.. “Risk of cancer in Korean patients with psoriatic arthritis: a nationwide population-based cohort study.” RMD open (2023). PMID: 36958767 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[102]
Ramírez J, López-Medina C, Montilla C et al.. “Diagnosis and therapeutic management of psoriatic arthritis: summary of 2024 update of the Spanish clinical practice guideline (ESPOGUIA).” Therapeutic advances in musculoskeletal disease (2026). PMID: 42027204 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
[103]
Gladman DD, Charles-Schoeman C, McInnes IB et al.. “Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.” Arthritis care & research (2019). PMID: 31112005 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History
[104]
Kwok TSH, Sutton M, Ye JY et al.. “Prevalence and Factors Associated With Osteoporosis and Bone Mineral Density Testing in Psoriatic Arthritis.” Arthritis care & research (2022). PMID: 33326187 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
[105]
Cretu D, Gao L, Liang K et al.. “Differentiating Psoriatic Arthritis From Psoriasis Without Psoriatic Arthritis Using Novel Serum Biomarkers.” Arthritis care & research (2018). PMID: 28586166 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria
[106]
Nash P, Coates LC, Fleishaker D et al.. “Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study.” The Lancet. Rheumatology (2021). PMID: 38279411 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
[107]
Falasinnu T, Lu D, Baker MC. “Annual trends in pain management modalities in patients with newly diagnosed autoimmune rheumatic diseases in the USA from 2007 to 2021: an administrative claims-based study.” The Lancet. Rheumatology (2024). PMID: 38945137 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
[108]
McInnes IB, Mease PJ, Kivitz AJ et al.. “Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study.” The Lancet. Rheumatology (2020). PMID: 38268157 ↗
L1OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Complications: Disease-Driven & Treatment-Related
[109]
Mulder MLM, Vriezekolk JE, van Hal TW et al.. “Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial.” The Lancet. Rheumatology (2022). PMID: 38288921 ↗
L1OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target
[110]
De Marco G, Maksymowych WP, Østergaard M et al.. “Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active psoriatic arthritis: Data from the GOLMePsA clinical trial.” Rheumatology (Oxford, England) (2026). PMID: 42308540 ↗
L1TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target
[111]
de Vries AC, Bogaards NA, Hooft L et al.. “Interventions for nail psoriasis.” The Cochrane database of systematic reviews (2013). PMID: 23440816 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
[112]
Wang G, Youn SW, Chang CL et al.. “New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review.” Dermatology and therapy (2026). PMID: 42262459 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related
[113]
Yang L, Gao X, Wang Z et al.. “Biologic therapies and psoriatic arthritis risk in psoriasis: A systematic review and meta-analysis.” Journal of the European Academy of Dermatology and Venereology : JEADV (2026). PMID: 42227826 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target
[114]
Scher JU, Ogdie A, Merola JF et al.. “Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition.” Nature reviews. Rheumatology (2019). PMID: 30742092 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prognosis & Natural History
[115]
Karacabeyli D, Lacaille D. “Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions.” Nature reviews. Rheumatology (2025). PMID: 41034339 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
[116]
Ferguson LD, Siebert S, McInnes IB et al.. “Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions.” Nature reviews. Rheumatology (2019). PMID: 31292564 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification
[117]
Ibba L, Di Giulio S, Malagoli P et al.. “Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study.” Dermatology and therapy (2026). PMID: 42262460 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors
[118]
Attar RZ, Acikgoz SB, Hepworth E et al.. “Real-world performance of EULAR and GRAPPA definitions of difficult-to-treat psoriatic arthritis within the ORCHESTRA cohort: an observational cohort study.” Therapeutic advances in musculoskeletal disease (2026). PMID: 42137751 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[119]
Almansouri AY, Li J, Bumbulis L et al.. “Incidence rate and risk factors of arrhythmias in patients with psoriatic arthritis.” RMD open (2026). PMID: 41571321 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related
[120]
Zabotti A, Fagni F, Gossec L et al.. “Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage.” RMD open (2024). PMID: 38599649 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Special Populations, Pregnancy & Prevention
[121]
Corte G, Atzinger A, Noversa de Sousa R et al.. “Increased synovial and entheseal fibroblast activation detected by 68Ga-FAPI-PET/CT is associated with the development of psoriatic arthritis in psoriasis patients with arthralgia.” RMD open (2026). PMID: 41871918 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging & Classification Criteria
[122]
Currado D, Trunfio F, Saracino F et al.. “Patients with psoriatic arthritis and comorbid metabolic syndrome show a difficult-to-treat phenotype: another mosaic tile in the definition of a still undefined subset of patients.” RMD open (2025). PMID: 40545272 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria
[123]
Nakaphan P, Shotelersuk V, Pajareya P et al.. “Prevalence of interstitial lung disease in patients with psoriatic arthritis: a systematic review and meta-analysis.” Clinical rheumatology (2026). PMID: 41832319 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[124]
Ritchlin CT, Kavanaugh A, Gladman DD et al.. “Treatment recommendations for psoriatic arthritis.” Annals of the rheumatic diseases (2008). PMID: 18952643 ↗
L1GUIDELINECited in: Clinical Presentation
[125]
Coates LC, Kavanaugh A, Mease PJ et al.. “Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26749174 ↗
L1GUIDELINECited in: Clinical Presentation, History and Evolution of Treatment
[126]
Mease PJ, Lertratanakul A, Anderson JK et al.. “Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.” Annals of the rheumatic diseases (2020). PMID: 33272960 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[127]
Baraliakos X, Gossec L, Pournara E et al.. “Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.” Annals of the rheumatic diseases (2020). PMID: 33334727 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[128]
Kristensen LE, Keiserman M, Papp K et al.. “Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.” Annals of the rheumatic diseases (2021). PMID: 34911706 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[129]
Mease P, van der Heijde D, Landewé R et al.. “Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.” Annals of the rheumatic diseases (2018). PMID: 29550766 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[130]
Coates LC, Gossec L, Theander E et al.. “Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).” Annals of the rheumatic diseases (2021). PMID: 34819273 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria
[131]
Mease PJ, Helliwell PS, Hjuler KF et al.. “Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.” Annals of the rheumatic diseases (2020). PMID: 33106286 ↗
L1RCTCited in: Clinical Presentation
[132]
McInnes IB, Rahman P, Gottlieb AB et al.. “Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 34719872 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History
[133]
Mease P, Helliwell P, Silwinska-Stanczyk P et al.. “Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37194394 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[134]
Mease P, Sieper J, Van den Bosch F et al.. “Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2015). PMID: 25545240 ↗
L1RCTCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[135]
McInnes IB, Rahman P, Gottlieb AB et al.. “Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33043600 ↗
L1RCTCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
[136]
Mease PJ, Gladman DD, Ogdie A et al.. “Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations.” Arthritis care & research (2020). PMID: 31909868 ↗
L2RCTCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[137]
Kavanaugh A, McInnes IB, Krueger GG et al.. “Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.” Arthritis care & research (2013). PMID: 23666608 ↗
L1RCTCited in: Clinical Presentation
[138]
Kavanaugh A, Mease PJ, Reimold AM et al.. “Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study.” Arthritis care & research (2017). PMID: 27696786 ↗
L1RCTCited in: Clinical Presentation
[139]
Kerschbaumer A, Smolen JS, Ferreira RJO et al.. “Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.” Annals of the rheumatic diseases (2024). PMID: 38503473 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target
[140]
Deodhar A, Helliwell PS, Boehncke WH et al.. “Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.” Lancet (London, England) (2020). PMID: 32178765 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[141]
McInnes IB, Mease PJ, Kirkham B et al.. “Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.” Lancet (London, England) (2015). PMID: 26135703 ↗
L1RCTCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[142]
Nash P, Kirkham B, Okada M et al.. “Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.” Lancet (London, England) (2017). PMID: 28551073 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[143]
Gottlieb A, Menter A, Mendelsohn A et al.. “Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.” Lancet (London, England) (2009). PMID: 19217154 ↗
L1RCTCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[144]
Mease PJ, McInnes IB, Kirkham B et al.. “Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.” The New England journal of medicine (2015). PMID: 26422723 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[145]
McGagh D, Song K, Yuan H et al.. “Digital health technologies to strengthen patient-centred outcome assessment in clinical trials in inflammatory arthritis.” The Lancet. Rheumatology (2024). PMID: 39089297 ↗
L5TRIAL_NONRANDOMCited in: Clinical Presentation
[146]
Eder L, Li X, Chandran V et al.. “Association of Higher Levels of High-Sensitivity C-Reactive Protein With Future Development of Psoriatic Arthritis in Psoriasis: A Prospective Cohort Study.” Arthritis care & research (2025). PMID: 40176403 ↗
L2COHORTCited in: Clinical Presentation
[147]
Eder L, Mylvaganam S, Pardo Pardo J et al.. “Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis.” The Lancet. Rheumatology (2023). PMID: 38251562 ↗
L1SR_OBSCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
[148]
Svedbom A, Mallbris L, Zabotti A et al.. “Predicting psoriatic arthritis in new-onset psoriasis: development of multivariable prediction models from an inception cohort study.” The Lancet. Rheumatology (2026). PMID: 42379214 ↗
L2COHORTCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification
[149]
Mease PJ, Landewé R, Rahman P et al.. “Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study.” RMD open (2021). PMID: 34330846 ↗
L1RCTCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[150]
Ramiro S, Poddubnyy D, Mease PJ et al.. “Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis.” RMD open (2025). PMID: 41125403 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[151]
Coates LC, Blanco R, Behrens F et al.. “Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies.” RMD open (2025). PMID: 40854810 ↗
L2RCTCited in: Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
[152]
McInnes IB, Sawyer LM, Markus K et al.. “Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.” RMD open (2022). PMID: 35321874 ↗
L1SR_OBSCited in: Clinical Presentation
[153]
Poddubnyy D, Parikh B, Elewaut D et al.. “Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 39624020 ↗
L2OTHERCited in: Clinical Presentation, History and Evolution of Treatment
[154]
Durham LE, Humby F, Ng N et al.. “Linking Skin and Joint Inflammation in Psoriatic Arthritis through Shared CD8+ T Cell Clones.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40528683 ↗
L4OTHERCited in: Clinical Presentation
[155]
Coates LC, Baraliakos X, Blanco FJ et al.. “The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B27 Status?” Arthritis care & research (2021). PMID: 32100954 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria
[156]
Walsh JA, Carroll C, Callis Duffin K et al.. “PAPRIKA: A Question Bank for Assessing Psoriatic Arthritis Risk in Individuals of Diverse Ancestries.” Arthritis care & research (2024). PMID: 37691268 ↗
L2OTHERCited in: Clinical Presentation
[157]
Kesarwani V, Sinnappan S, Husni ME et al.. “Screening Tools for Spondyloarthritis in Patients With Psoriasis, Uveitis, and Inflammatory Bowel Disease: A Scoping Review.” Arthritis care & research (2024). PMID: 38303576 ↗
L2REVIEW_NARRATIVECited in: Clinical Presentation
[158]
Ibrahim A, Gladman DD, Thavaneswaran A et al.. “Sensitivity and Specificity of Radiographic Scoring Instruments for Detecting Change in Axial Psoriatic Arthritis.” Arthritis care & research (2017). PMID: 28085226 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria
[159]
Song K, Satsangi J, Coates LC. “Arthritis complicating inflammatory bowel disease- the future is now.” The Lancet. Rheumatology (2024). PMID: 39032495 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[160]
Mease PJ, Helliwell PS, Gladman DD et al.. “Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies.” The Lancet. Rheumatology (2021). PMID: 38287608 ↗
L2OTHERCited in: Clinical Presentation
[161]
Ghoreschi K, Balato A, Enerbäck C et al.. “Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.” Lancet (London, England) (2021). PMID: 33515492 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[162]
Østergaard M, Lambert RGW, Maksymowych WP et al.. “Effect of apremilast on whole-body magnetic resonance imaging of peripheral and axial inflammation in patients with psoriatic arthritis.” Annals of the rheumatic diseases (2026). PMID: 42191498 ↗
L4TRIAL_NONRANDOMCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[163]
D'Agostino MA, Conaghan PG, Gaillez C et al.. “Exploring clusters based on ultrasound-detected inflammation in patients with psoriatic arthritis: a post-hoc analysis from the ULTIMATE trial.” BMC musculoskeletal disorders (2026). PMID: 41612350 ↗
L1RCTCited in: Clinical Presentation, History and Evolution of Treatment
[164]
Sbidian E, Chaimani A, Guelimi R et al.. “Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.” The Cochrane database of systematic reviews (2023). PMID: 37436070 ↗
L1SR_OBSCited in: Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
[165]
Sbidian E, Chaimani A, Garcia-Doval I et al.. “Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.” The Cochrane database of systematic reviews (2022). PMID: 35603936 ↗
L1SR_OBSCited in: Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
[166]
Sbidian E, Chaimani A, Garcia-Doval I et al.. “Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.” The Cochrane database of systematic reviews (2021). PMID: 33871055 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[167]
Sbidian E, Chaimani A, Guelimi R et al.. “Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.” The Cochrane database of systematic reviews (2025). PMID: 40767824 ↗
L1SR_OBSCited in: Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
[168]
Sbidian E, Chaimani A, Afach S et al.. “Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.” The Cochrane database of systematic reviews (2020). PMID: 31917873 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
[169]
Sbidian E, Chaimani A, Garcia-Doval I et al.. “Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.” The Cochrane database of systematic reviews (2017). PMID: 29271481 ↗
L1SR_OBSCited in: Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
[170]
Khoda F, Khan Y, Haw WWY et al.. “Prognostic prediction models for psoriatic arthritis in psoriasis: A systematic review.” Journal of the European Academy of Dermatology and Venereology : JEADV (2026). PMID: 42312903 ↗
L2SR_OBSCited in: Clinical Presentation
[171]
Webers C, Ortolan A, Nikiphorou E et al.. “Peripheral manifestations in spondyloarthritis: a systematic literature review on their assessment and the effect of biological/targeted synthetic DMARDs.” Rheumatology (Oxford, England) (2026). PMID: 41666292 ↗
L2SR_OBSCited in: Clinical Presentation
[172]
Mease P. “Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management.” Rheumatology (Oxford, England) (2020). PMID: 32159795 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification
[173]
Zhao SS, Goodson NJ, Robertson S et al.. “Smoking in spondyloarthritis: unravelling the complexities.” Rheumatology (Oxford, England) (2020). PMID: 32236486 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[174]
Helliwell PS. “Axial involvement in psoriatic arthritis: is it unique?” Rheumatology (Oxford, England) (2024). PMID: 39700473 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria
[175]
Lopalco G, Celletti E, Morrone M et al.. “Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinib.” Rheumatology (Oxford, England) (2025). PMID: 40758456 ↗
L3OTHERCited in: Clinical Presentation
[176]
Low JM, Hyrich KL, Ciurtin C et al.. “The impact of psoriasis on wellbeing and clinical outcomes in juvenile psoriatic arthritis.” Rheumatology (Oxford, England) (2024). PMID: 37467079 ↗
L2OTHERCited in: Clinical Presentation
[177]
Balderas-Miranda JT, Torres-Ruiz J, Guaracha-Basañez GA et al.. “Myeloid-derived suppressor cells and monocytes are biomarkers of the clinical phenotype and activity of psoriatic disease.” Rheumatology (Oxford, England) (2026). PMID: 40891880 ↗
L3OTHERCited in: Clinical Presentation
[178]
Zabotti A, Aydin SZ, David P et al.. “Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis.” Nature reviews. Rheumatology (2025). PMID: 40075177 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[179]
Tarannum S, Leung YY, Johnson SR et al.. “Sex- and gender-related differences in psoriatic arthritis.” Nature reviews. Rheumatology (2022). PMID: 35927578 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target
[180]
Olivieri I, D'Angelo S, Palazzi C et al.. “Advances in the management of psoriatic arthritis.” Nature reviews. Rheumatology (2014). PMID: 25003762 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
[181]
Gravallese EM, Schett G. “Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis.” Nature reviews. Rheumatology (2018). PMID: 30266977 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[182]
Najm A, Goodyear CS, McInnes IB et al.. “Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy.” Nature reviews. Rheumatology (2023). PMID: 36596924 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification
[183]
Anandarajah AP, Ritchlin CT. “The diagnosis and treatment of early psoriatic arthritis.” Nature reviews. Rheumatology (2009). PMID: 19806150 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification
[184]
Parisi S, Becciolini A, D'Onofrio B et al.. “Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort study.” Therapeutic advances in musculoskeletal disease (2026). PMID: 42112225 ↗
L4COHORTCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification
[185]
Singla S, Ribeiro A, Torgutalp M et al.. “Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project.” RMD open (2024). PMID: 38191215 ↗
L2REVIEW_NARRATIVECited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target
[186]
Veale DJ, Fearon U. “What makes psoriatic and rheumatoid arthritis so different?” RMD open (2015). PMID: 26509055 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[187]
Zabotti A, Cabas N, Di Nicola C et al.. “Using ultrasound to define inflammatory and non-inflammatory phenotypes in difficult-to-treat psoriatic arthritis.” RMD open (2025). PMID: 40813109 ↗
L3OTHERCited in: Clinical Presentation
[188]
Ehrenberg S, Elizur Y, Ben-Shabat N et al.. “Increased Risk of Incident Uveitis Among Patients with Psoriasis: A Nationwide Population-Based Cohort Study.” Diagnostics (Basel, Switzerland) (2026). PMID: 41750775 ↗
L2COHORTCited in: Clinical Presentation
[189]
Singh JA, Guyatt G, Ogdie A et al.. “Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.” Arthritis care & research (2018). PMID: 30499259 ↗
L1GUIDELINECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[190]
Glatt S, Baeten D, Baker T et al.. “Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.” Annals of the rheumatic diseases (2017). PMID: 29275332 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[191]
Östör A, Van den Bosch F, Papp K et al.. “Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.” Annals of the rheumatic diseases (2021). PMID: 34815219 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[192]
Mease PJ, Deodhar AA, van der Heijde D et al.. “Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.” Annals of the rheumatic diseases (2022). PMID: 35241426 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
[193]
Mease PJ, van der Heijde D, Ritchlin CT et al.. “Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.” Annals of the rheumatic diseases (2016). PMID: 27553214 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[194]
Mease PJ, Smolen JS, Behrens F et al.. “A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.” Annals of the rheumatic diseases (2019). PMID: 31563894 ↗
L2RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
[195]
FitzGerald O, Gladman DD, Mease PJ et al.. “Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38770592 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[196]
Jin Y, Cheng IT, So H et al.. “Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One-Year Double-Blind, Randomized, Placebo-Controlled Trial Using High-Resolution Peripheral Quantitative Computed Tomography.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40083242 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[197]
Kivitz A, Sedova L, Churchill M et al.. “Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase 3 Study.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 39300596 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[198]
Husni ME, Kavanaugh A, Murphy F et al.. “Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis.” Arthritis care & research (2020). PMID: 30980514 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[199]
De Marco G, Hensor EMA, Helliwell PS et al.. “Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial.” The Lancet. Rheumatology (2025). PMID: 40914172 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[200]
Krishnan V, Keller SY, Chew C et al.. “Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial.” The Lancet. Rheumatology (2025). PMID: 40915298 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[201]
Ramanan AV, Ruperto N, Foeldvari I et al.. “Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab.” The Lancet. Rheumatology (2026). PMID: 41785908 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[202]
Koc GH, Kok MR, Kasiem FR et al.. “Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategies.” The Lancet. Rheumatology (2025). PMID: 41275881 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[203]
Mease PJ, Rahman P, Gottlieb AB et al.. “Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.” Lancet (London, England) (2020). PMID: 32178766 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History
[204]
McInnes IB, Asahina A, Coates LC et al.. “Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).” Lancet (London, England) (2022). PMID: 36493791 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[205]
Ruperto N, Brunner HI, Synoverska O et al.. “Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.” Lancet (London, England) (2021). PMID: 34767764 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History, Special Populations, Pregnancy & Prevention
[206]
McInnes IB, Behrens F, Mease PJ et al.. “Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.” Lancet (London, England) (2020). PMID: 32386593 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[207]
Merola JF, Landewé R, McInnes IB et al.. “Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).” Lancet (London, England) (2022). PMID: 36495881 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[208]
McInnes IB, Kavanaugh A, Gottlieb AB et al.. “Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.” Lancet (London, England) (2013). PMID: 23769296 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[209]
Coates LC, Moverley AR, McParland L et al.. “Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.” Lancet (London, England) (2015). PMID: 26433318 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification
[210]
Jørgensen KK, Olsen IC, Goll GL et al.. “Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.” Lancet (London, England) (2017). PMID: 28502609 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[211]
Gladman D, Rigby W, Azevedo VF et al.. “Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.” The New England journal of medicine (2017). PMID: 29045207 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[212]
Mease P, Hall S, FitzGerald O et al.. “Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.” The New England journal of medicine (2017). PMID: 29045212 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[213]
Palominos PE, Gaujoux-Viala C, Fautrel B et al.. “Clinical outcomes in psoriatic arthritis: A systematic literature review.” Arthritis care & research (2012). PMID: 22147535 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
[214]
Ballegaard C, Jørgensen TS, Skougaard M et al.. “Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study.” Arthritis care & research (2018). PMID: 29073353 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, History and Evolution of Treatment
[215]
Østergaard M, Boesen M, Maksymowych WP et al.. “Effect of apremilast on hand and whole-body MRI assessments of inflammation in patients with psoriatic arthritis (MOSAIC): a phase 4, multicentre, single-arm, open-label study.” The Lancet. Rheumatology (2024). PMID: 39488216 ↗
L4TRIAL_NONRANDOMCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[216]
Kragsnaes MS, Jensen JRB, Nilsson AC et al.. “Dynamics of inflammation-associated plasma proteins following faecal microbiota transplantation in patients with psoriatic arthritis and healthy controls: exploratory findings from the FLORA trial.” RMD open (2024). PMID: 38296309 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[217]
McInnes IB, Sewerin P, Sharaf M et al.. “Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial.” RMD open (2024). PMID: 39672591 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[218]
Yang F, Lu C, Pan Q et al.. “68Ga-FAPI and 18F-NaF PET/CT in psoriatic arthritis: a comparative study.” Rheumatology (Oxford, England) (2025). PMID: 39576694 ↗
L4TRIAL_NONRANDOMCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification
[219]
Pitzalis C, Choy EHS, Buch MH. “Transforming clinical trials in rheumatology: towards patient-centric precision medicine.” Nature reviews. Rheumatology (2020). PMID: 32887976 ↗
L5TRIAL_NONRANDOMCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History
[220]
Mease PJ, Gladman DD, Merola JF et al.. “Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.” Rheumatology (Oxford, England) (2024). PMID: 38218744 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[221]
Mease PJ, McInnes IB, Tam LS et al.. “Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis.” Rheumatology (Oxford, England) (2023). PMID: 36102818 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[222]
Iragorri N, Hazlewood G, Manns B et al.. “Psoriatic arthritis screening: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2019). PMID: 30380111 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[223]
Bibas N, Pignon C, Lopez-Medina C et al.. “Ultrasonography for the assessment of enthesitis in psoriatic arthritis: systematic review with meta-analysis.” Rheumatology (Oxford, England) (2025). PMID: 39705203 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[224]
Ruyssen-Witrand A, Perry R, Watkins C et al.. “Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.” RMD open (2020). PMID: 32094304 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History
[225]
Steel KJA, Srenathan U, Ridley M et al.. “Polyfunctional, Proinflammatory, Tissue-Resident Memory Phenotype and Function of Synovial Interleukin-17A+CD8+ T Cells in Psoriatic Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 31677365 ↗
L4OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[226]
Yuan Y, Qiu J, Lin ZT et al.. “Identification of Novel Autoantibodies Associated With Psoriatic Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 30618213 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[227]
Lönnblom E, Leu Agelii M, Sareila O et al.. “Autoantibodies to Disease-Related Proteins in Joints as Novel Biomarkers for the Diagnosis of Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 36718635 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[228]
Graßhoff H, Comdühr S, Nording H et al.. “Transition From Psoriasis to Psoriatic Arthritis is Characterized by Distinct Alterations in Peripheral Blood Tc17, Th17, and CD4+ Effector Memory Cells.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40955716 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Special Populations, Pregnancy & Prevention
[229]
Cruz-Correa OF, Pollock RA, Machhar R et al.. “Prediction of Psoriatic Arthritis in Patients With Psoriasis Using DNA Methylation Profiles.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37463128 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[230]
Mc Ardle A, Kwasnik A, Szentpetery A et al.. “Identification and Evaluation of Serum Protein Biomarkers That Differentiate Psoriatic Arthritis From Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 34114357 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[231]
Arvikar SL, Crowley JT, Sulka KB et al.. “Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthritis Following Lyme Disease.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 27636905 ↗
L4OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[232]
Ghosh N, Reid P, Sparks JA et al.. “Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis.” Arthritis care & research (2025). PMID: 40865544 ↗
L4OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
[233]
Paccou J, Bavière W, Sornay-Rendu E et al.. “Body Composition in Patients With Psoriatic Arthritis and Changes During Interleukin-12/Interleukin-23 Inhibition.” Arthritis care & research (2022). PMID: 33973385 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[234]
Jackson CH, Su L, Gladman DD et al.. “On Modelling Minimal Disease Activity.” Arthritis care & research (2016). PMID: 26315478 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
[235]
McGagh D, Elliott A, Grohmann T et al.. “The path to interception in psoriatic disease: from conceptual clarity to clinical translation.” The Lancet. Rheumatology (2026). PMID: 41587560 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[236]
Ciccia F, Gandolfo S, Caporali R et al.. “Understanding the spectrum from preclinical psoriatic arthritis to early diagnosis of the disease.” The Lancet. Rheumatology (2024). PMID: 39579780 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[237]
Vassilakis KD, Lampadaki K, Nikiphorou E et al.. “Skin cancer in inflammatory arthritis: should we advise screening?” The Lancet. Rheumatology (2025). PMID: 41344357 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[238]
Peeters ACD, Michielsens CAJ, Mahler EAM et al.. “Effectiveness of treat-to-target tapering of TNF inhibitors for psoriatic arthritis and axial spondyloarthritis in the Netherlands: 24-month follow-up of the DRESS-PS trial.” The Lancet. Rheumatology (2025). PMID: 40716447 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[239]
Ursini F, Ciaffi J, D'Angelo S et al.. “When one joint matters: the monoarticular blind spot in inflammatory arthritis.” The Lancet. Rheumatology (2026). PMID: 42114539 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History
[240]
Strand V, Kaeley GS, Bergman MJ et al.. “The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial.” The Lancet. Rheumatology (2022). PMID: 38288937 ↗
L1OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[241]
Chasnyk V, Constantin T, Nikishina I et al.. “Predictors of inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept.” Rheumatology (Oxford, England) (2026). PMID: 42011511 ↗
L2TRIAL_NONRANDOMCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[242]
Tomo ATJ, Ratan P, Gonçalves LS et al.. “Cycling versus swapping strategies for treatment of psoriatic arthritis after primary tumour necrosis factor inhibitors failure: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2026). PMID: 42216248 ↗
L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History
[243]
Ogdie A, Coates LC, Gladman DD. “Treatment guidelines in psoriatic arthritis.” Rheumatology (Oxford, England) (2020). PMID: 32159790 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
[244]
Kaeley GS. “Enthesitis in psoriatic arthritis (Part 2): imaging.” Rheumatology (Oxford, England) (2020). PMID: 32159789 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[245]
Degboé Y, Sunzini F, Sood S et al.. “Apremilast inhibits inflammatory osteoclastogenesis.” Rheumatology (Oxford, England) (2021). PMID: 33788924 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[246]
McGonagle D, David P, Macleod T et al.. “Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis.” Nature reviews. Rheumatology (2023). PMID: 37919337 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[247]
Shenoi S, Horneff G, Aggarwal A et al.. “Treatment of non-systemic juvenile idiopathic arthritis.” Nature reviews. Rheumatology (2024). PMID: 38321298 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[248]
van Tubergen A, Weber U. “Diagnosis and classification in spondyloarthritis: identifying a chameleon.” Nature reviews. Rheumatology (2012). PMID: 22450552 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[249]
Nefla M, Holzinger D, Berenbaum F et al.. “The danger from within: alarmins in arthritis.” Nature reviews. Rheumatology (2016). PMID: 27733758 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Complications: Disease-Driven & Treatment-Related
[250]
Feld J, Chandran V, Haroon N et al.. “Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison.” Nature reviews. Rheumatology (2018). PMID: 29752461 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History
[251]
Proft F, Ribeiro AL, Singla S et al.. “Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative.” Nature reviews. Rheumatology (2025). PMID: 41310208 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target
[252]
Jadon DR, Stober C, Pennington SR et al.. “Applying precision medicine to unmet clinical needs in psoriatic disease.” Nature reviews. Rheumatology (2020). PMID: 33024296 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[253]
Haddad A, Kharouf F, Lee KA et al.. “Repair of radiographic joint damage in psoriatic arthritis: a cohort study.” Rheumatology (Oxford, England) (2026). PMID: 42157419 ↗
L2COHORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
[254]
Watad A, Elizur Y, Hen O et al.. “Impact of biologic class and treatment line on psoriatic arthritis risk in psoriasis: a population-based cohort study.” RMD open (2026). PMID: 42097693 ↗
L2COHORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target
[255]
Zhang L, Xu Z, Gong J et al.. “Real-world skin and dermatology-specific quality-of-life outcomes and a nomogram to predict skin response to secukinumab in Chinese psoriatic arthritis patients: a multicenter retrospective cohort study.” Frontiers in medicine (2026). PMID: 42078428 ↗
L3COHORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[256]
Snoeck Henkemans SVJ, de Jong PHP, Luime JJ et al.. “Window of opportunity in psoriatic arthritis: the earlier the better?” RMD open (2024). PMID: 38413172 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Prognosis & Natural History
[257]
Kristensen LE, Ng KJ, Ngantcha M et al.. “Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study.” RMD open (2024). PMID: 39306343 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target
[258]
Akbaba TH, Donmez-Demir B, Colpak AI et al.. “Serum immunoreactivity to neurofilament-medium shows high sensitivity and specificity in patients with Behçet disease.” RMD open (2025). PMID: 40447321 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[259]
Yıldırım N, Limon M. “Lower CALLY index values are associated with higher disease activity in psoriatic arthritis: a retrospective cohort study.” Rheumatology international (2026). PMID: 42377589 ↗
L3COHORTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Severity, Disease Activity & Risk Stratification
[260]
Tang H, Dokoupilova E, Batko B et al.. “Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study.” Expert opinion on biological therapy (2026). PMID: 42021476 ↗
L1RCTCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target
[261]
Sewerin P, Bismpos D, Lange PS et al.. “Arrhythmic risk stratification in psoriatic arthritis: a retrospective, electrogram-based comparative analysis.” RMD open (2026). PMID: 42342287 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[262]
Koc GH, Kok MR, Snoeck Henkemans SVJ et al.. “Frequency of complex-to-manage, difficult-to-manage and treatment-refractory psoriatic arthritis: applying the 2025 GRAPPA and EULAR definitions in a real-world longitudinal PsA cohort.” RMD open (2026). PMID: 42336609 ↗
L2OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[263]
Elsaghir A, Kuske L, Kniesch K et al.. “IgA anti-CD74 autoantibodies are associated with treatment escalation in peripheral psoriatic arthritis.” Frontiers in immunology (2026). PMID: 42282961 ↗
L3OTHERCited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[264]
D'Ignazio E, Sahin D, Baldi C et al.. “The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.” Current rheumatology reports (2026). PMID: 42277548 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging & Classification Criteria
[265]
Singh JA, Guyatt G, Ogdie A et al.. “Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 30499246 ↗
L1GUIDELINECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[266]
Ritchlin CT, Coates LC, McInnes IB et al.. “Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.” Annals of the rheumatic diseases (2023). PMID: 37696588 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification
[267]
Kivitz A, Baraliakos X, Muensterman ET et al.. “Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study.” Annals of the rheumatic diseases (2025). PMID: 40615297 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification
[268]
Kerschbaumer A, Steiner M, Khalili S et al.. “Global Recruiting Patterns and Placebo Response Rates in Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40583519 ↗
L2TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification
[269]
Koehm M, Rossmanith T, Foldenauer AC et al.. “Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.” The Lancet. Rheumatology (2023). PMID: 38251504 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[270]
Skaria TG, Sreeprakash A, Umesh R et al.. “Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials.” The Lancet. Rheumatology (2022). PMID: 36320825 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention
[271]
van Vollenhoven RF, Hahn BH, Tsokos GC et al.. “Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.” Lancet (London, England) (2018). PMID: 30249507 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[272]
Day J, Antony A, Tillett W et al.. “The state of the art-psoriatic arthritis outcome assessment in clinical trials and daily practice.” The Lancet. Rheumatology (2022). PMID: 38288938 ↗
L5TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification
[273]
Sarabia S, Farrer C, Yeung J et al.. “Comparative Efficacy of Different Triage Methods for Psoriatic Arthritis: Results From a Prospective Study in a Rapid Access Clinic.” Arthritis care & research (2022). PMID: 33544974 ↗
L2COHORTCited in: Severity, Disease Activity & Risk Stratification
[274]
Coates LC, Gossec L, Zimmermann M et al.. “Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.” RMD open (2024). PMID: 38531621 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[275]
López-Medina C, Capelusnik D, Webers C et al.. “Measurement properties of disease activity instruments in peripheral spondyloarthritis: a post-hoc analysis of the CRESPA trial.” RMD open (2025). PMID: 40664470 ↗
L1RCTCited in: Severity, Disease Activity & Risk Stratification, History and Evolution of Treatment
[276]
McGagh D, Coates LC. “Assessment of the many faces of PsA: single and composite measures in PsA clinical trials.” Rheumatology (Oxford, England) (2020). PMID: 32159792 ↗
L5TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification
[277]
Gwinnutt JM, Wieczorek M, Rodríguez-Carrio J et al.. “Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.” RMD open (2022). PMID: 35654458 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification
[278]
Vandendorpe AS, de Vlam K, Lories R. “Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments.” RMD open (2019). PMID: 30740243 ↗
L5SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[279]
Merola JF, Mease P, Kivitz A et al.. “Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41903163 ↗
L1OTHERCited in: Severity, Disease Activity & Risk Stratification
[280]
Beck F, Nguyen P, Hoffmann A et al.. “CD4+CD8αlow T Cell Clonal Expansion Dependent on Costimulation in Patients With Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 39054665 ↗
L4OTHERCited in: Severity, Disease Activity & Risk Stratification
[281]
Gorodensky JH, Bernatsky S, Afif W et al.. “Ustekinumab Safety in Pregnancy: A Comprehensive Review.” Arthritis care & research (2022). PMID: 34748293 ↗
L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Special Populations, Pregnancy & Prevention
[282]
Ursin K, Lydersen S, Skomsvoll JF et al.. “Psoriatic Arthritis Disease Activity During and After Pregnancy: A Prospective Multicenter Study.” Arthritis care & research (2019). PMID: 30192071 ↗
L2OTHERCited in: Severity, Disease Activity & Risk Stratification, Special Populations, Pregnancy & Prevention
[283]
Dougados M, Baeten D. “Spondyloarthritis.” Lancet (London, England) (2011). PMID: 21684383 ↗
L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
[284]
Van den Bosch F, Coates L. “Clinical management of psoriatic arthritis.” Lancet (London, England) (2018). PMID: 29893227 ↗
L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[285]
Li YJ, Msaouel P, Campbell M et al.. “Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series.” RMD open (2024). PMID: 39214611 ↗
L4CASE_REPORTCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
[286]
Wilsdon TD, Whittle SL, Thynne TR et al.. “Methotrexate for psoriatic arthritis.” The Cochrane database of systematic reviews (2019). PMID: 30656673 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
[287]
Cagnotto G, Bruschettini M, Stróżyk A et al.. “Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.” The Cochrane database of systematic reviews (2025). PMID: 39945386 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
[288]
Ponkilainen V, Karjalainen TV, Kuitunen I et al.. “Perioperative use of disease-modifying anti-rheumatic drugs (DMARDs) in people with inflammatory arthritis.” The Cochrane database of systematic reviews (2026). PMID: 42159164 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Special Populations, Pregnancy & Prevention
[289]
Roelsgaard IK, Esbensen BA, Østergaard M et al.. “Smoking cessation intervention for reducing disease activity in chronic autoimmune inflammatory joint diseases.” The Cochrane database of systematic reviews (2019). PMID: 31476270 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Complications: Disease-Driven & Treatment-Related
[290]
Radner H, Ramiro S, Buchbinder R et al.. “Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity.” The Cochrane database of systematic reviews (2012). PMID: 22258995 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
[291]
Capelusnik D, López-Medina C, Weber C et al.. “Measurement properties of instruments assessing peripheral arthritis disease activity in spondyloarthritis: a systematic literature review.” RMD open (2026). PMID: 42373103 ↗
L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification
[292]
Annfeldt TK, Händel MN, Haugegaard T et al.. “Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis.” Annals of the rheumatic diseases (2026). PMID: 42248769 ↗
L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification
[293]
Braun J. “New targets in psoriatic arthritis.” Rheumatology (Oxford, England) (2016). PMID: 27856658 ↗
L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
[294]
Haberman RH, Ogdie A, Merola JF et al.. “The obesity-inflammation axis in psoriatic disease: mechanisms and therapeutic strategies.” Nature reviews. Rheumatology (2025). PMID: 41286370 ↗
L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
[295]
Cutolo M, Smith V. “Detection of microvascular changes in systemic sclerosis and other rheumatic diseases.” Nature reviews. Rheumatology (2021). PMID: 34561652 ↗
L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification
[296]
. “[Guideline for the diagnosis and treatment of psoriasis arthropathica (psoriatic arthritis) in China (2026 edition)].” Zhonghua yi xue za zhi (2026). PMID: 42373464 ↗
L1GUIDELINECited in: Severity, Disease Activity & Risk Stratification, History and Evolution of Treatment
[297]
Gossec L, Baraliakos X, Kerschbaumer A et al.. “EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.” Annals of the rheumatic diseases (2020). PMID: 32434812 ↗
L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease
[298]
Goodman SM, Springer B, Guyatt G et al.. “2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28620948 ↗
L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment, Special Populations, Pregnancy & Prevention
[299]
Nanus DE, Filer AD, Hughes B et al.. “TNFα regulates cortisol metabolism in vivo in patients with inflammatory arthritis.” Annals of the rheumatic diseases (2014). PMID: 24385202 ↗
L2RCTCited in: Acute Management: Flares & Organ-Threatening Disease
[300]
Van den Bosch F, Manger B, Goupille P et al.. “Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.” Annals of the rheumatic diseases (2009). PMID: 19815494 ↗
L4TRIAL_NONRANDOMCited in: Acute Management: Flares & Organ-Threatening Disease
[301]
Ramiro S, Smolen JS, Landewé R et al.. “Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.” Annals of the rheumatic diseases (2015). PMID: 26660203 ↗
L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
[302]
Elewaut D, Braun J, Anderson JK et al.. “Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases.” Arthritis care & research (2021). PMID: 32100944 ↗
L2TRIAL_NONRANDOMCited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention
[303]
Goodman SM, Springer B, Guyatt G et al.. “2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.” Arthritis care & research (2017). PMID: 28620917 ↗
L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention
[304]
Mørk S, Voss A, Möller S et al.. “Spondyloarthritis and Outcomes in Pregnancy and Labor: A Nationwide Register-Based Cohort Study.” Arthritis care & research (2021). PMID: 31758739 ↗
L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention
[305]
Vincken NLA, Balak DMW, Knulst AC et al.. “Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review.” Rheumatology (Oxford, England) (2022). PMID: 35285486 ↗
L2SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
[306]
Uhrenholt L, Christensen R, Dinesen WKH et al.. “Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2022). PMID: 34864896 ↗
L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
[307]
Edwards CJ, Fautrel B, Schulze-Koops H et al.. “Dosing down with biologic therapies: a systematic review and clinicians' perspective.” Rheumatology (Oxford, England) (2017). PMID: 28339632 ↗
L5SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
[308]
Dubreuil M, Rho YH, Man A et al.. “Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study.” Rheumatology (Oxford, England) (2013). PMID: 24185762 ↗
L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
[309]
Cordtz R, Lindhardsen J, Soussi BG et al.. “Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark.” Rheumatology (Oxford, England) (2021). PMID: 33369663 ↗
L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
[310]
Fauny M, Moulin D, D'Amico F et al.. “Paradoxical gastrointestinal effects of interleukin-17 blockers.” Annals of the rheumatic diseases (2020). PMID: 32719044 ↗
L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease
[311]
Solomon DH, Love TJ, Canning C et al.. “Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis.” Annals of the rheumatic diseases (2010). PMID: 20584807 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[312]
Snoeck Henkemans SVJ, Vis M, Koc GH et al.. “Disease-modifying antirheumatic drug-free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal study.” Annals of the rheumatic diseases (2025). PMID: 40382308 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[313]
Machado PM, Schäfer M, Mahil SK et al.. “Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.” Annals of the rheumatic diseases (2023). PMID: 36787993 ↗
L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[314]
Abacar K, De Marco G, Weddell J et al.. “Late-Onset Spondyloarthritis Presenting as Glucocorticoid-Resistant Polymyalgia Rheumatica: A Hitherto Underappreciated Entity in Which Tumor Necrosis Factor or Interleukin -17 Blockade May Have a Therapeutic Role.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40693392 ↗
L4OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[315]
Remaeus K, Johansson K, Granath F et al.. “Pregnancy Outcomes in Women With Psoriatic Arthritis in Relation to Presence and Timing of Antirheumatic Treatment.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 34668647 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention
[316]
Vela J, Cordtz RL, Kristensen S et al.. “Is pain associated with premature mortality in patients with psoriatic arthritis? A nested case-control study using the DANBIO Register.” Rheumatology (Oxford, England) (2021). PMID: 33668054 ↗
L3CASE_CONTROLCited in: Acute Management: Flares & Organ-Threatening Disease
[317]
Ye C, Nikolic RPA, Choi M et al.. “Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 1: Preexisting Inflammatory Arthritides.” The Journal of rheumatology (2025). PMID: 40953945 ↗
L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease
[318]
Feldman SR, Zhao Y, Shi L et al.. “Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.” Arthritis care & research (2015). PMID: 25303478 ↗
L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[319]
Eder L, Tu K, Rosen CF et al.. “Health Care Utilization for Musculoskeletal Issues During the Prediagnosis Period in Psoriatic Arthritis: A Population-Based Study.” Arthritis care & research (2021). PMID: 31961491 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[320]
Dharia T, Venkatachalam S, Baker JF et al.. “Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease.” Arthritis care & research (2022). PMID: 34890121 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[321]
Coates LC, Cook R, Lee KA et al.. “Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort.” Arthritis care & research (2010). PMID: 20191569 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[322]
Smith CJF, Bandoli G, Kavanaugh A et al.. “Birth Outcomes and Disease Activity During Pregnancy in a Prospective Cohort of Women With Psoriatic Arthritis and Ankylosing Spondylitis.” Arthritis care & research (2020). PMID: 31074583 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[323]
Weiss PF, Ruperto N, Quebe-Fehling E et al.. “Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting.” The Journal of rheumatology (2026). PMID: 40953957 ↗
L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease
[324]
Consolaro A, Ruperto N, Lovell DJ et al.. “Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial.” The Journal of rheumatology (2025). PMID: 40312101 ↗
L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease
[325]
Fisher BA, Rowe A, Hodson C et al.. “Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol.” BMJ open (2026). PMID: 41775469 ↗
L5TRIAL_NONRANDOMCited in: Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
[326]
Arriens C, Morand EF, Askanase AD et al.. “Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.” Advances in therapy (2025). PMID: 40920289 ↗
L1TRIAL_NONRANDOMCited in: Acute Management: Flares & Organ-Threatening Disease
[327]
Yamada K, Matsui T, Takahashi T et al.. “Flare incidences of pre-existing rheumatologic diseases in patients with solid tumors receiving immune checkpoint inhibitors: A systematic review and meta-analysis.” Seminars in arthritis and rheumatism (2026). PMID: 41643573 ↗
L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
[328]
Wang W, Wang R, Li C. “Hematopoietic stem cell translation for relapse of psoriasis. Systematic review.” Archives of dermatological research (2025). PMID: 40278948 ↗
L5SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
[329]
Cooksey R, Underwood J, Brophy S et al.. “Shielding reduced incidence of COVID-19 in patients with inflammatory arthritis but vulnerability is associated with increased mortality.” Rheumatology (Oxford, England) (2022). PMID: 35567479 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[330]
Piga M, Floris A, Congia M et al.. “Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual video consultations during COVID-19 pandemic.” Rheumatology (Oxford, England) (2022). PMID: 34352098 ↗
L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[331]
Zhang H, Wen J, Alexander GC et al.. “Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis.” RMD open (2021). PMID: 33863840 ↗
L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[332]
Götestam Skorpen C, Lydersen S, Salvesen KÅ et al.. “Caesarean section in women with axial spondyloarthritis and psoriatic arthritis: a population-based study.” RMD open (2023). PMID: 36863750 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention
[333]
de Groot P, Wagenaar W, Foolen J et al.. “Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers.” RMD open (2024). PMID: 39438085 ↗
L5OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[334]
Álvaro-Gracia JM, Sanchez-Piedra C, Culqui D et al.. “Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study.” RMD open (2023). PMID: 36927849 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Prevention
[335]
Lucasson F, Kiltz U, Kalyoncu U et al.. “Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries.” RMD open (2022). PMID: 35523519 ↗
L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[336]
Chronis NJ, Pereira D, Gao S et al.. “Assessing flares in patients with psoriatic arthritis using questionnaires.” RMD open (2026). PMID: 42259575 ↗
L4OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[337]
Venerito V, Stefanizzi P, Fornaro M et al.. “Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors.” RMD open (2022). PMID: 34987092 ↗
L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
[338]
Kavanaugh A, Husni ME, Harrison DD et al.. “Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28805045 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[339]
Coates LC, McInnes IB, Merola JF et al.. “Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35829656 ↗
L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History
[340]
Strand V, Gossec L, Coates LC et al.. “Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial.” Arthritis care & research (2024). PMID: 38529674 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[341]
Helliwell PS, Kavanaugh A. “Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity.” Arthritis care & research (2018). PMID: 28834259 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[342]
Thomsen RS, Nilsen TIL, Haugeberg G et al.. “Impact of High-Intensity Interval Training on Disease Activity and Disease in Patients With Psoriatic Arthritis: A Randomized Controlled Trial.” Arthritis care & research (2019). PMID: 29882634 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[343]
O'Dwyer JL, Meads DM, Hulme CT et al.. “Cost-Effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled Trial.” Arthritis care & research (2018). PMID: 28544822 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[344]
Ritchlin CT, Kavanaugh A, Merola JF et al.. “Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.” Lancet (London, England) (2020). PMID: 32035552 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[345]
Mease PJ, Genovese MC, Greenwald MW et al.. “Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.” The New England journal of medicine (2014). PMID: 24918373 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[346]
Cantini F, Marchesoni A, Novelli L et al.. “Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials.” Rheumatology (Oxford, England) (2024). PMID: 38331400 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[347]
McGonagle D, Kavanaugh A, McInnes IB et al.. “Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis.” Rheumatology (Oxford, England) (2024). PMID: 38341669 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[348]
Xue Y, Sun L, Zhang N et al.. “Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 study.” Rheumatology (Oxford, England) (2026). PMID: 41632483 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[349]
Kavanaugh A, Coates LC, Mease PJ et al.. “Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial.” Rheumatology (Oxford, England) (2025). PMID: 39423145 ↗
L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[350]
Burmester GR, Cohen SB, Winthrop KL et al.. “Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.” RMD open (2023). PMID: 36754548 ↗
L2TRIAL_NONRANDOMCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[351]
Mease PJ, Reddy S, Ross S et al.. “Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis.” RMD open (2024). PMID: 38296801 ↗
L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[352]
Qin P, Kragsnaes MS, Holm DK et al.. “Clinical Significance of Gut Microbiota Community Types for Long-Term Response to Fecal Microbiota Transplantation in Patients With Psoriatic Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40814761 ↗
L4OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[353]
Ogdie A, Merola JF, Mease PJ et al.. “Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41670439 ↗
L1OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[354]
Chin A, Terrett A, Kwon M et al.. “Recommendations for the Use of Disease-Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review.” Arthritis care & research (2025). PMID: 40256995 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Prevention
[355]
Sparks JA, Lesperance T, Accortt NA et al.. “Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment.” Arthritis care & research (2019). PMID: 29799667 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
[356]
Hastings R, Ding T, Butt S et al.. “Neutropenia in patients receiving anti-tumor necrosis factor therapy.” Arthritis care & research (2010). PMID: 20535786 ↗
L3OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[357]
Lee MP, Lii J, Jin Y et al.. “Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015.” Arthritis care & research (2018). PMID: 28804988 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[358]
Tonutti A, Abacar K, Macleod T et al.. “Time to lift the moratorium on IL-23 inhibitors for axial psoriatic arthritis.” The Lancet. Rheumatology (2025). PMID: 41319674 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[359]
Al-Mossawi H, Taams LS, Goodyear CS et al.. “Precision medicine in psoriatic arthritis: how should we select targeted therapies?” The Lancet. Rheumatology (2019). PMID: 38229362 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[360]
Bentvelzen MLM, El Bouhaddani S, Spierings J et al.. “Predicting clinical response in psoriatic arthritis through integrative analysis of transcriptomics and proteomics.” Arthritis research & therapy (2026). PMID: 41821126 ↗
L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
[361]
Atwan A, Ingram JR, Abbott R et al.. “Oral fumaric acid esters for psoriasis.” The Cochrane database of systematic reviews (2015). PMID: 26258748 ↗
L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
[362]
Ramiro S, Radner H, van der Heijde D et al.. “Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).” The Cochrane database of systematic reviews (2011). PMID: 21975788 ↗
L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[363]
Colebatch AN, Marks JL, Edwards CJ. “Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).” The Cochrane database of systematic reviews (2011). PMID: 22071858 ↗
L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
[364]
Huynh D, Kavanaugh A. “Psoriatic arthritis: current therapy and future approaches.” Rheumatology (Oxford, England) (2014). PMID: 25125588 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[365]
Ribeiro AL, Singla S, Hay-Rollins C et al.. “Deciphering difficult-to-treat psoriatic arthritis: insights from an international survey of patients with psoriatic arthritis.” Rheumatology (Oxford, England) (2025). PMID: 40221862 ↗
L4OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[366]
Vassilakis KD, Papagoras C, Fytanidis N et al.. “Identification and characteristics of patients with potential difficult-to-treat psoriatic arthritis: exploratory analyses of the Greek PsA registry.” Rheumatology (Oxford, England) (2024). PMID: 38759119 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[367]
James L, Diamond C, Al-Mossawi H et al.. “High prevalence of MASLD in psoriasis and psoriatic arthritis assessed with multiparametric magnetic resonance imaging.” Rheumatology (Oxford, England) (2025). PMID: 40569171 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[368]
Cronstein BN, Aune TM. “Methotrexate and its mechanisms of action in inflammatory arthritis.” Nature reviews. Rheumatology (2020). PMID: 32066940 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[369]
Gossec L, Coates LC, de Wit M et al.. “Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.” Nature reviews. Rheumatology (2016). PMID: 27829672 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[370]
McHugh J. “Optimizing methotrexate withdrawal during COVID vaccination.” Nature reviews. Rheumatology (2022). PMID: 36180548 ↗
L5OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Prevention
[371]
Davies K, Dures E, Ng WF. “Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research.” Nature reviews. Rheumatology (2021). PMID: 34599320 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[372]
Maksymowych WP. “Spondyloarthritis. Treat-to-target in spondyloarthritis--do we have a plan?” Nature reviews. Rheumatology (2013). PMID: 23917954 ↗
L5OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[373]
Dures E, Shepperd S, Mukherjee S et al.. “Treat-to-target in PsA: methods and necessity.” RMD open (2020). PMID: 32071281 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[374]
Paci V, Zabotti A, Fontanarosa A et al.. “Comparative effectiveness and predictors of remission between adalimumab and ixekizumab in patients with psoriatic arthritis: findings from the 'AIRE' multicentre study.” RMD open (2026). PMID: 41876147 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[375]
Agrawal A, Yadav SS, Balakrishnan C. “Efficacy and safety of dual-targeted therapy with tofacitinib and TNF inhibitors in refractory spondyloarthritis: a case series from a tertiary care center.” Therapeutic advances in musculoskeletal disease (2026). PMID: 42146074 ↗
L4CASE_REPORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[376]
Hegazy EM, Sadek EA, Ahmed SS. “Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: a prospective comparative case-control study of adalimumab and methotrexate.” Clinical rheumatology (2026). PMID: 41848948 ↗
L3CASE_CONTROLCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[377]
Anacleto-Dabarno M, Kharouf F, Carrizo Abarza V et al.. “Do Patients Diagnosed with Psoriatic Arthritis Before or Concurrently with Psoriasis Have Different Disease Phenotype and Outcomes?” The Journal of rheumatology (2026). PMID: 42386278 ↗
L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
[378]
Gossec L, Smolen JS, Gaujoux-Viala C et al.. “European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.” Annals of the rheumatic diseases (2011). PMID: 21953336 ↗
L1GUIDELINECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[379]
Gossec L, Smolen JS, Ramiro S et al.. “European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.” Annals of the rheumatic diseases (2015). PMID: 26644232 ↗
L1GUIDELINECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[380]
Smolen JS, Braun J, Dougados M et al.. “Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.” Annals of the rheumatic diseases (2013). PMID: 23749611 ↗
L5SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[381]
Russell MD, Schaffer A, Yang Z et al.. “Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using OpenSAFELY.” The Lancet. Rheumatology (2026). PMID: 42379213 ↗
L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[382]
Mease PJ, Gladman DD, Deodhar A et al.. “Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.” RMD open (2020). PMID: 32665433 ↗
L1RCTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[383]
Zhao SS, Pittam B, Harrison NL et al.. “Diagnostic delay in axial spondyloarthritis: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2021). PMID: 33428758 ↗
L1SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[384]
Bengtsson K, Forsblad-d'Elia H, Deminger A et al.. “Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study.” Rheumatology (Oxford, England) (2021). PMID: 33216939 ↗
L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[385]
Winthrop KL, Weinblatt ME, Bathon J et al.. “Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019.” Annals of the rheumatic diseases (2019). PMID: 31662322 ↗
L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[386]
Winthrop KL, Weinblatt ME, Crow MK et al.. “Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.” Annals of the rheumatic diseases (2019). PMID: 30712015 ↗
L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[387]
Binod KC, Jabbour A, Poudel P et al.. “IL-17A inhibitor-induced leucocytoclastic vasculitis is responsive to IL-23 blockade in a psoriatic arthritis patient.” Annals of the rheumatic diseases (2024). PMID: 37679036 ↗
L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[388]
Gutierrez M, Filippucci E, Salaffi F et al.. “Differential diagnosis between rheumatoid arthritis and psoriatic arthritis: the value of ultrasound findings at metacarpophalangeal joints level.” Annals of the rheumatic diseases (2011). PMID: 21406459 ↗
L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[389]
Eder L, Croxford R, Drucker AM et al.. “Understanding COVID-19 Risk in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Analysis of SARS-CoV-2 Testing.” Arthritis care & research (2022). PMID: 34486829 ↗
L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related
[390]
Hamdi W, Migowa A, Ferjani HL et al.. “Pediatric Society of the African League Against Rheumatism juvenile idiopathic arthritis recommendations for enthesitis-related arthritis and juvenile psoriatic arthritis.” Clinical rheumatology (2025). PMID: 39893309 ↗
L5GUIDELINECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[391]
Barozet M, Le Tilly O, Bejan-Angoulvant T et al.. “Hypertension and Cardiovascular Outcomes in Inflammatory and Autoimmune Diseases: A Systematic Review and Meta-analysis.” Current hypertension reports (2024). PMID: 38819751 ↗
L1SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[392]
Freitag M, Kolb P, Falcone V et al.. “Fcγ-receptor-activation by circulating immune complexes in systemic autoimmune diseases and its reduction by CD19-CAR T cell therapy.” Rheumatology (Oxford, England) (2026). PMID: 41335463 ↗
L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[393]
Westerweel PE, Verhaar MC. “Endothelial progenitor cell dysfunction in rheumatic disease.” Nature reviews. Rheumatology (2009). PMID: 19434075 ↗
L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[394]
Mease PJ, Gladman DD, Samad AS et al.. “Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA).” RMD open (2018). PMID: 29531787 ↗
L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[395]
Martín-Varillas JL, Sanchez-Bilbao L, Calvo-Río V et al.. “Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients.” RMD open (2022). PMID: 36597972 ↗
L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[396]
Atschekzei F, Dubrowinskaja N, Anim M et al.. “Identification of variants in genes associated with autoinflammatory disorders in a cohort of patients with psoriatic arthritis.” RMD open (2022). PMID: 36113963 ↗
L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[397]
Pukšić S, Bolton-King P, Sexton J et al.. “DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs.” RMD open (2018). PMID: 30487999 ↗
L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[398]
Oliveira-Ramos F, Eusébio M, M Martins F et al.. “Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage.” RMD open (2016). PMID: 27752356 ↗
L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[399]
Veltri C, Albrecht K, Kiltz U et al.. “Trends in work participation among patients with inflammatory rheumatic musculoskeletal diseases (iRMDs): Data from the German National Database (2010-2022).” RMD open (2025). PMID: 39863303 ↗
L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[400]
Laatar A, Miladi S, Fazaa A et al.. “[Not Available].” La Tunisie medicale (2025). PMID: 39812192 ↗
L5GUIDELINECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[401]
Baekdal JA, Bjerken L, Hansen ESH et al.. “Interstitial lung disease in psoriasis: A systematic review and meta-analysis.” Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG (2026). PMID: 41891404 ↗
L1SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[402]
Yan R, Ke D, Zhang Y et al.. “Clinical features and therapeutic challenges of psoriatic arthritis coexisting with antisynthetase syndrome: a case report and literature review.” Frontiers in immunology (2025). PMID: 40861474 ↗
L4CASE_REPORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[403]
Magen E, Aamar S, Magen I et al.. “Long-term rheumatologic comorbidities in familial Mediterranean fever.” Seminars in arthritis and rheumatism (2026). PMID: 42250404 ↗
L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[404]
Rotondo C, Busto G, Barile R et al.. “HLA-B*51 Beyond Behcet's Disease: Topography of Symptoms, Associated Diagnoses, and Characterization of Chronic Inflammatory Arthritis Phenotypes.” International journal of molecular sciences (2026). PMID: 42123313 ↗
L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
[405]
Peters MJ, Symmons DP, McCarey D et al.. “EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.” Annals of the rheumatic diseases (2009). PMID: 19773290 ↗
L1GUIDELINECited in: Complications: Disease-Driven & Treatment-Related
[406]
Michielsens CA, den Broeder N, van den Hoogen FH et al.. “Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial.” Annals of the rheumatic diseases (2022). PMID: 35701155 ↗
L1RCTCited in: Complications: Disease-Driven & Treatment-Related
[407]
Burmester GR, Mease P, Dijkmans BA et al.. “Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases.” Annals of the rheumatic diseases (2009). PMID: 19147611 ↗
L2TRIAL_NONRANDOMCited in: Complications: Disease-Driven & Treatment-Related
[408]
Burmester GR, Panaccione R, Gordon KB et al.. “Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.” Annals of the rheumatic diseases (2012). PMID: 22562972 ↗
L2TRIAL_NONRANDOMCited in: Complications: Disease-Driven & Treatment-Related
[409]
Jamnitski A, Symmons D, Peters MJ et al.. “Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review.” Annals of the rheumatic diseases (2012). PMID: 22532629 ↗
L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
[410]
Mok CC, Ko GT, Ho LY et al.. “Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis.” Arthritis care & research (2011). PMID: 20890981 ↗
L2TRIAL_NONRANDOMCited in: Complications: Disease-Driven & Treatment-Related
[411]
Mease P, Roussou E, Burmester GR et al.. “Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.” Arthritis care & research (2019). PMID: 30156760 ↗
L2TRIAL_NONRANDOMCited in: Complications: Disease-Driven & Treatment-Related
[412]
Exarchou S, Di Giuseppe D, Klingberg E et al.. “Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study.” Annals of the rheumatic diseases (2024). PMID: 38049985 ↗
L2COHORTCited in: Complications: Disease-Driven & Treatment-Related
[413]
Wetzman A, Lukas C, Gaujoux-Viala C et al.. “Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis.” Arthritis care & research (2022). PMID: 34549898 ↗
L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
[414]
Lin TC, Yoshida K, Tedeschi SK et al.. “Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis.” Arthritis care & research (2018). PMID: 28834412 ↗
L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
[415]
Ernste FC, Sánchez-Menéndez M, Wilton KM et al.. “Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study.” Arthritis care & research (2015). PMID: 25581120 ↗
L2COHORTCited in: Complications: Disease-Driven & Treatment-Related
[416]
Wells AF, Edwards CJ, Kivitz AJ et al.. “Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.” Rheumatology (Oxford, England) (2022). PMID: 34100922 ↗
L1RCTCited in: Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
[417]
Leng X, Lin W, Liu S et al.. “Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study.” RMD open (2023). PMID: 36720560 ↗
L1RCTCited in: Complications: Disease-Driven & Treatment-Related
[418]
Genovese MC, Mysler E, Tomita T et al.. “Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.” Rheumatology (Oxford, England) (2020). PMID: 32449924 ↗
L2TRIAL_NONRANDOMCited in: Complications: Disease-Driven & Treatment-Related
[419]
Charles-Schoeman C, Choy E, McInnes IB et al.. “MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.” RMD open (2023). PMID: 37945286 ↗
L2TRIAL_NONRANDOMCited in: Complications: Disease-Driven & Treatment-Related
[420]
Mease PJ, Gensler LS, Orbai AM et al.. “Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies.” RMD open (2025). PMID: 40194794 ↗
L2SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
[421]
Kerschbaumer A, Smolen JS, Nash P et al.. “Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research.” RMD open (2020). PMID: 33188136 ↗
L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
[422]
Xia J, Xie SY, Liu KQ et al.. “Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study.” Annals of the rheumatic diseases (2020). PMID: 32737104 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related
[423]
Magnusson K, Turkiewicz A, Rydén M et al.. “Genetic Influence on Osteoarthritis Versus Other Rheumatic Diseases.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 37691153 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related
[424]
Wu S, Li WQ, Han J et al.. “Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women.” Arthritis & rheumatology (Hoboken, N.J.) (2014). PMID: 24504802 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related
[425]
Colaco K, Lee KA, Akhtari S et al.. “Derivation and Internal Validation of a Disease-Specific Cardiovascular Risk Prediction Model for Patients With Psoriatic Arthritis and Psoriasis.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37691498 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related
[426]
Accortt NA, Bonafede MM, Collier DH et al.. “Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26359948 ↗
L4OTHERCited in: Complications: Disease-Driven & Treatment-Related
[427]
Yang KL, Mullins BJ, Lejeune A et al.. “Mitigation of Osteoclast-Mediated Arthritic Bone Remodeling By Short Chain Fatty Acids.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 37994265 ↗
L5OTHERCited in: Complications: Disease-Driven & Treatment-Related
[428]
Hoving JL, Lacaille D, Urquhart DM et al.. “Non-pharmacological interventions for preventing job loss in workers with inflammatory arthritis.” The Cochrane database of systematic reviews (2014). PMID: 25375291 ↗
L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Prevention
[429]
Toma AO, Crainic D, Mateescu DM et al.. “Effects of Biologic Therapies and Narrowband UVB Phototherapy on Vascular Inflammation and Systemic Inflammatory Biomarkers in Psoriasis: A Systematic Review and Narrative Synthesis of Prospective Studies.” Journal of clinical medicine (2026). PMID: 41976889 ↗
L2SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
[430]
Li P, Wang Q, Yang Y et al.. “Autoimmune thyroid disease and human health: a systematic review of Mendelian randomization studies.” Frontiers in immunology (2025). PMID: 41425574 ↗
L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Prevention
[431]
Tam LS, Leung YY, Li EK. “Psoriatic arthritis in Asia.” Rheumatology (Oxford, England) (2009). PMID: 19713440 ↗
L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Prevention
[432]
Xie W, Bian W, Song Z et al.. “Association between triglyceride-glucose index and carotid atherosclerosis in patients with psoriatic arthritis.” Rheumatology (Oxford, England) (2023). PMID: 36897031 ↗
L4OTHERCited in: Complications: Disease-Driven & Treatment-Related
[433]
Cheng IT, Li EK, Wong PC et al.. “Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis-which target should we choose?” Rheumatology (Oxford, England) (2020). PMID: 32087023 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Prevention
[434]
Lioté F, Constantin A, Dahan É et al.. “A prospective survey on therapeutic inertia in psoriatic arthritis (OPTI'PsA).” Rheumatology (Oxford, England) (2024). PMID: 37261843 ↗
L4OTHERCited in: Complications: Disease-Driven & Treatment-Related
[435]
Soós B, Szentpétery Á, Raterman HG et al.. “Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.” Nature reviews. Rheumatology (2022). PMID: 35273387 ↗
L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related
[436]
Croft M, Siegel RM. “Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.” Nature reviews. Rheumatology (2017). PMID: 28275260 ↗
L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related
[437]
Regierer AC, Hasseli R, Schäfer M et al.. “TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD.” RMD open (2021). PMID: 34670840 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related
[438]
Raadsen R, Hansildaar R, Pouw LC et al.. “Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated.” RMD open (2023). PMID: 38053460 ↗
L2OTHERCited in: Complications: Disease-Driven & Treatment-Related
[439]
Haddad A, Zabari Parnis E, Stein N et al.. “The Association Between SARS-CoV-2 Exposure, COVID-19 Vaccination and Psoriatic Arthritis-A Nested Case-Control Study.” Vaccines (2026). PMID: 42042765 ↗
L3CASE_CONTROLCited in: Complications: Disease-Driven & Treatment-Related
[440]
Martini M, Logiudice L, Mazzuoccolo LD et al.. “Neutrophil-to-Lymphocyte Ratio as a Predictor of Cardiovascular Events in Psoriatic Disease: A Retrospective Cohort Study.” ACR open rheumatology (2026). PMID: 42055019 ↗
L3COHORTCited in: Complications: Disease-Driven & Treatment-Related
[441]
Yang Z, Atzeni F, Russell M et al.. “Patterns and risk of cardiovascular disease in rheumatoid arthritis and psoriatic arthritis: a nationwide cohort study in the UK.” Rheumatology advances in practice (2026). PMID: 41695577 ↗
L2COHORTCited in: Complications: Disease-Driven & Treatment-Related
[442]
Firdous S, Amjad H, Choudhary MU et al.. “Emerging biological therapies for psoriatic arthritis: A systematic review.” Medicine (2025). PMID: 41189198 ↗
L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
[443]
Majjad A, El Guarti S, Mansouri H et al.. “Psoriatic Arthritis Characteristics and Comorbidities in North Africa: Results of a Multicenter Retrospective Study.” Journal of psoriasis and psoriatic arthritis (2025). PMID: 41459256 ↗
L4COHORTCited in: Complications: Disease-Driven & Treatment-Related
[444]
Charca LC, Braña I, Loredo M et al.. “Multisite Atherosclerosis and SCORE2-Based Risk Stratification in Psoriatic Arthritis: A Phenotype-Dependent Role of Vascular Territories.” Biomedicines (2026). PMID: 42351823 ↗
L4OTHERCited in: Complications: Disease-Driven & Treatment-Related
[445]
Tillett W, Allen A, Tucker L et al.. “Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope.” Rheumatology (Oxford, England) (2021). PMID: 33097948 ↗
L5GUIDELINECited in: History and Evolution of Treatment
[446]
van der Heijde D, Deodhar A, Fleischmann R et al.. “Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.” Arthritis care & research (2017). PMID: 27696727 ↗
L1RCTCited in: History and Evolution of Treatment
[447]
Helliwell PS, Deodhar A, Gottlieb AB et al.. “Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.” Arthritis care & research (2020). PMID: 31421033 ↗
L1RCTCited in: History and Evolution of Treatment
[448]
Coates LC, Mease PJ, Gossec L et al.. “Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study.” Arthritis care & research (2018). PMID: 29409133 ↗
L1RCTCited in: History and Evolution of Treatment
[449]
Mease PJ, Goffe BS, Metz J et al.. “Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.” Lancet (London, England) (2000). PMID: 10972371 ↗
L1RCTCited in: History and Evolution of Treatment
[450]
Choufani M, Ermann J, Goel N. “Race, Ethnicity, and Geographic Diversity in Pivotal Psoriatic Arthritis Clinical Trials: Further Progress Needed.” Arthritis care & research (2025). PMID: 40386882 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
[451]
Wu D, Yue J, Tam LS. “Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis.” Rheumatology (Oxford, England) (2018). PMID: 29244162 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[452]
Gossec L, Baraliakos X, Aletaha D et al.. “Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS.” Rheumatology (Oxford, England) (2025). PMID: 39437003 ↗
L1RCTCited in: History and Evolution of Treatment
[453]
Taylor PC, Kavanaugh A, Bessette L et al.. “Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies.” RMD open (2026). PMID: 41506743 ↗
L1RCTCited in: History and Evolution of Treatment
[454]
Gladman D, Tillett W, Gruben D et al.. “Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies.” RMD open (2025). PMID: 40461265 ↗
L1RCTCited in: History and Evolution of Treatment
[455]
Gladman D, Nash P, Goto H et al.. “Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis.” RMD open (2020). PMID: 31958274 ↗
L1RCTCited in: History and Evolution of Treatment
[456]
Masson Regnault M, Brenaut E, Marniquet ME et al.. “French guidelines on systemic treatments for moderate-to-severe psoriasis in adults: Update 2025.” Journal of the European Academy of Dermatology and Venereology : JEADV (2025). PMID: 41469898 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Special Populations, Pregnancy & Prevention
[457]
Goel N. “Conducting research in psoriatic arthritis: the emerging role of patient research partners.” Rheumatology (Oxford, England) (2020). PMID: 32159791 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[458]
Eyre S, Orozco G, Worthington J. “The genetics revolution in rheumatology: large scale genomic arrays and genetic mapping.” Nature reviews. Rheumatology (2017). PMID: 28569263 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Special Populations, Pregnancy & Prevention
[459]
Solmaz D, Bakirci S, Kimyon G et al.. “Impact of Having Family History of Psoriasis or Psoriatic Arthritis on Psoriatic Disease.” Arthritis care & research (2020). PMID: 30680951 ↗
L2OTHERCited in: History and Evolution of Treatment
[460]
Gossec L, Balanescu A, D'Agostino MA et al.. “Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials.” Arthritis research & therapy (2025). PMID: 41318485 ↗
L1RCTCited in: History and Evolution of Treatment
[461]
Assmann G, Klemm PCM, Hedrich C et al.. “[Diagnosis and treatment of chronic nonbacterial osteitis (CNO) and SAPHO syndrome : Implications of the current consensus recommendations of an international commission of experts for German rheumatology].” Zeitschrift fur Rheumatologie (2025). PMID: 41313366 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[462]
Desai RJ, Thaler KJ, Mahlknecht P et al.. “Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review.” Arthritis care & research (2016). PMID: 26663412 ↗
L1SR_OBSCited in: Prognosis & Natural History
[463]
Glerup M, Arnstad ED, Rypdal V et al.. “Changing Patterns in Treatment, Remission Status, and Categories in a Long-Term Nordic Cohort Study of Juvenile Idiopathic Arthritis.” Arthritis care & research (2022). PMID: 35015381 ↗
L2COHORTCited in: Prognosis & Natural History
[464]
Mease PJ, McInnes IB, Tam LS et al.. “Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.” Rheumatology (Oxford, England) (2021). PMID: 33844022 ↗
L1SR_OBSCited in: Prognosis & Natural History
[465]
Bravo Vergel Y, Hawkins NS, Claxton K et al.. “The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.” Rheumatology (Oxford, England) (2007). PMID: 17956918 ↗
L1SR_OBSCited in: Prognosis & Natural History
[466]
Chang CA, Gottlieb AB, Lizzul PF. “Management of psoriatic arthritis from the view of the dermatologist.” Nature reviews. Rheumatology (2011). PMID: 21912431 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[467]
Pisaniello HL, Whittle SL, Johnston RV et al.. “Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity.” The Cochrane database of systematic reviews (2025). PMID: 41025432 ↗
L5OTHERCited in: Prognosis & Natural History
[468]
Elkayam O, Amir S, Mendelson E et al.. “Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases.” Arthritis care & research (2011). PMID: 21425247 ↗
L3RCTCited in: Special Populations, Pregnancy & Prevention
[469]
Marzo-Ortega H, McGonagle D, Rhodes LA et al.. “Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis.” Annals of the rheumatic diseases (2006). PMID: 17185324 ↗
L4TRIAL_NONRANDOMCited in: Special Populations, Pregnancy & Prevention
[470]
Mariette X, Förger F, Abraham B et al.. “Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.” Annals of the rheumatic diseases (2017). PMID: 29030361 ↗
L2TRIAL_NONRANDOMCited in: Special Populations, Pregnancy & Prevention
[471]
Fleischmann R, Baumgartner SW, Weisman MH et al.. “Long term safety of etanercept in elderly subjects with rheumatic diseases.” Annals of the rheumatic diseases (2005). PMID: 16150792 ↗
L2SR_OBSCited in: Special Populations, Pregnancy & Prevention
[472]
Kerschbaumer A, Smolen JS, Dougados M et al.. “Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.” Annals of the rheumatic diseases (2020). PMID: 32381564 ↗
L1SR_OBSCited in: Special Populations, Pregnancy & Prevention
[473]
Schieir O, Tosevski C, Glazier RH et al.. “Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis.” Annals of the rheumatic diseases (2017). PMID: 28219882 ↗
L1SR_OBSCited in: Special Populations, Pregnancy & Prevention
[474]
Mehta P, Gao S, Abarza VC et al.. “Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Prospective Cohort Study.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41854268 ↗
L2COHORTCited in: Special Populations, Pregnancy & Prevention
[475]
Pattison E, Harrison BJ, Griffiths CE et al.. “Environmental risk factors for the development of psoriatic arthritis: results from a case-control study.” Annals of the rheumatic diseases (2007). PMID: 17823200 ↗
L3CASE_CONTROLCited in: Special Populations, Pregnancy & Prevention
[476]
Bjørlykke KH, Ørbo HS, Tveter AT et al.. “Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study.” The Lancet. Rheumatology (2022). PMID: 36415604 ↗
L2COHORTCited in: Special Populations, Pregnancy & Prevention
[477]
Xie W, Huang H, Ji L et al.. “Maternal and neonatal outcomes in pregnant women with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2021). PMID: 33878171 ↗
L1SR_OBSCited in: Special Populations, Pregnancy & Prevention
[478]
Nagra D, Bechman K, Russell MD et al.. “Pneumococcal vaccine uptake in patients with inflammatory arthritis: a single centre cohort study.” Rheumatology (Oxford, England) (2025). PMID: 38833673 ↗
L3COHORTCited in: Special Populations, Pregnancy & Prevention
[479]
Kharouf F, Mehta P, Carrizo Abarza V et al.. “Subclinical psoriatic arthritis: concepts, dilemmas, and research needs.” Annals of the rheumatic diseases (2026). PMID: 41934034 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Prevention
[480]
Lortholary O, Fernandez-Ruiz M, Baddley JW et al.. “Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020.” Annals of the rheumatic diseases (2020). PMID: 32963049 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Prevention
[481]
Syversen SW, Jyssum I, Tveter AT et al.. “Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35507355 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention
[482]
Eder L, Lee KA, Chandran V et al.. “Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (PRESTO): A Step Towards Prevention.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37555242 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention
[483]
Yun H, Yang S, Chen L et al.. “Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26990731 ↗
L3OTHERCited in: Special Populations, Pregnancy & Prevention
[484]
Favalli EG, Monti S, Ingegnoli F et al.. “Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 32506699 ↗
L4OTHERCited in: Special Populations, Pregnancy & Prevention
[485]
Desai RJ, Huybrechts KF, Bateman BT et al.. “Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26606742 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention
[486]
Secher AEP, Granath F, Remaeus K et al.. “Preterm birth in women with psoriatic arthritis: what are the risks and risk factors? A collaborative cohort study from Sweden, Denmark and Norway.” RMD open (2025). PMID: 41052892 ↗
L2COHORTCited in: Special Populations, Pregnancy & Prevention
[487]
Secher AEP, Granath F, Glintborg B et al.. “Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark.” RMD open (2022). PMID: 36328400 ↗
L2COHORTCited in: Special Populations, Pregnancy & Prevention
[488]
George MD, Baker JF, Hsu JY et al.. “Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty.” Arthritis care & research (2017). PMID: 28129484 ↗
L3OTHERCited in: Special Populations, Pregnancy & Prevention
[489]
Sumpton D, Oliffe M, Kane B et al.. “Patients' Perspectives on Shared Decision-Making About Medications in Psoriatic Arthritis: An Interview Study.” Arthritis care & research (2022). PMID: 34235887 ↗
L5OTHERCited in: Special Populations, Pregnancy & Prevention
[490]
Crauwels H, Ringold S, Howard S et al.. “Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data.” Paediatric drugs (2025). PMID: 41152645 ↗
L5RCTCited in: Special Populations, Pregnancy & Prevention
[491]
Dulai AS, Joshi A, Min M et al.. “Systematic Review of Accelerated Epigenetic Aging in Chronic Inflammatory Dermatology Conditions.” International journal of dermatology (2025). PMID: 40940698 ↗
L1SR_OBSCited in: Special Populations, Pregnancy & Prevention
[492]
Yang A, Cheng B, Seyger MMB et al.. “The Burden of Pediatric Psoriasis: A Systematic Review.” American journal of clinical dermatology (2025). PMID: 40694272 ↗
L1SR_OBSCited in: Special Populations, Pregnancy & Prevention
[493]
Kerola AM, Kazemi A, Rollefstad S et al.. “All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study.” Rheumatology (Oxford, England) (2022). PMID: 35377442 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention
[494]
Nakafero G, Grainge MJ, Card T et al.. “Uptake and safety of pneumococcal vaccination in adults with immune-mediated inflammatory diseases: a UK wide observational study.” Rheumatology (Oxford, England) (2025). PMID: 38479823 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention
[495]
Rider LG, Parks CG, Wilkerson J et al.. “Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey.” Rheumatology (Oxford, England) (2022). PMID: 35460240 ↗
L4OTHERCited in: Special Populations, Pregnancy & Prevention
[496]
Tang MW, Reedquist KA, Garcia S et al.. “The prolactin receptor is expressed in rheumatoid arthritis and psoriatic arthritis synovial tissue and contributes to macrophage activation.” Rheumatology (Oxford, England) (2016). PMID: 27616146 ↗
L4OTHERCited in: Special Populations, Pregnancy & Prevention
[497]
Perez-Chada LM, Haberman RH, Chandran V et al.. “Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study.” Nature reviews. Rheumatology (2021). PMID: 33589818 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Prevention
[498]
Miao Y, Beauchet A, Piram M et al.. “Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study.” Journal of the European Academy of Dermatology and Venereology : JEADV (2025). PMID: 41104794 ↗
L3COHORTCited in: Special Populations, Pregnancy & Prevention
[499]
Koehm M, Behrens F. “Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities.” RMD open (2023). PMID: 37734874 ↗
L5OTHERCited in: Special Populations, Pregnancy & Prevention
[500]
Kumar C, Kuhn M, Herrmann K et al.. “Severe methotrexate toxicity in elderly patients under diuretics.” RMD open (2024). PMID: 38176739 ↗
L4OTHERCited in: Special Populations, Pregnancy & Prevention
[501]
Correll CK, Stryker S, Collier D et al.. “Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry.” RMD open (2023). PMID: 37230760 ↗
L2OTHERCited in: Special Populations, Pregnancy & Prevention
[502]
Kummer LYL, Fernández Blanco L, Kreher C et al.. “Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID.” RMD open (2024). PMID: 39375177 ↗
L3OTHERCited in: Special Populations, Pregnancy & Prevention

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

Also Called / Synonyms

Classification Subtypes

Clinical Significance

Pathophysiology & Mechanism

The Enthesis as Ground Zero

The IL-23/IL-17 Axis: Central Effector Pathway

Synovial Immunopathology

Bone Remodeling: Erosion and New Bone Formation

Genetic and Environmental Modifiers

Systemic Inflammation and Comorbidities

Epidemiology, Etiology & Risk Factors

Demographic Distribution

Genetic Risk Factors

Environmental and Lifestyle Risk Factors

Can Biologic Therapy Prevent PsA?

Summary of Incidence and Prevalence Trends

Clinical Presentation

Presenting Symptoms

Musculoskeletal Examination Findings

Phenotypic Variants

Red Flags

Atypical Presentations

Diagnosis & Workup: Serology, Imaging & Classification Criteria

History and Physical

Gold-Standard Test: CASPAR Classification Criteria

Laboratory Studies

Imaging

Diagnostic Algorithm

Controversies and Guideline Disagreement

Severity, Disease Activity & Risk Stratification

DAPSA: The Joint-Focused Composite

MDA: The Multi-Domain Target

PASDAS and CPDAI: Research-Grade Instruments

Axial Disease Assessment

Enthesitis and Dactylitis Scores

Risk Stratification: Predictors of Severe Disease

Sex Differences in Disease Activity

Flare Definition and Monitoring

Imaging in Risk Stratification

Acute Management: Flares & Organ-Threatening Disease

Step 1: Initial Assessment and Severity Classification

Step 2: First-Line Interventions

Step 3: Escalation of Disease-Modifying Therapy

Step 4: Monitoring and Titration

Step 5: Resolution and Transition

Drug / Modality Comparison Table

Dosing Table

Treatment Failure Protocol

What NOT to Do

Controversies and Guideline Disagreement

Long-term Management: The DMARD Ladder & Treat-to-Target

Step 1: First-Line Therapy, Conventional Synthetic DMARDs

Step 2: Inadequate Response to csDMARD, Adding a Biologic DMARD

Step 3: Inadequate Response to First bDMARD, Switching Mechanism

Step 4: Tapering in Sustained Remission

Drug / Modality Comparison Table

Treatment Failure Protocol

What NOT to Do

Controversies and Guideline Disagreement

Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)

Eyes: Uveitis

Gastrointestinal: Inflammatory Bowel Disease

Cardiovascular System

Pulmonary: Interstitial Lung Disease

Metabolic Syndrome

Other Systems

Screening and Monitoring Summary

Complications: Disease-Driven & Treatment-Related

Cardiovascular Disease and Metabolic Syndrome

Infection

Malignancy

Pulmonary: